Francesco Montorsi

Pubblicazioni Scientifiche

Per vedere tutte le pubblicazioni scientifiche clicca qui

 

External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer.

Dell’Oglio P, Bandini M, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, Fossati N, Moschini M, Gandaglia G, Capitanio U, Briganti A, Graefen M, Montorsi F, Saad F, Karakiewicz PI.

Urol Oncol. 2018 Feb 6. pii: S1078-1439(18)30004-8. doi: 10.1016/j.urolonc.2018.01.004. [Epub ahead of print]

PMID:
29426698
2.

You Can Trust a Crystal Ball About as Far as You Can Throw It.

Capitanio U, Larcher A, Montorsi F, Karakiewicz P.

Eur Urol. 2018 Feb 5. pii: S0302-2838(18)30073-3. doi: 10.1016/j.eururo.2018.01.019. [Epub ahead of print] No abstract available.

PMID:
29422370
3.

Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.

Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, Cindolo L, Abdollah F, Tilki D, Briganti A, Montorsi F, Shariat SF, Schips L, Karakiewicz PI.

Eur Urol Focus. 2018 Feb 2. pii: S2405-4569(18)30008-7. doi: 10.1016/j.euf.2018.01.007. [Epub ahead of print]

PMID:
29398456
5.

Risk-based surveillance after surgical treatment of renal cell carcinoma.

Capogrosso P, Larcher A, Sjoberg DD, Vertosick EA, Cianflone F, Dell’Oglio P, Carenzi C, Salonia A, Vickers AJ, Montorsi F, Bertini R, Capitanio U.

J Urol. 2018 Jan 22. pii: S0022-5347(18)30111-3. doi: 10.1016/j.juro.2018.01.072. [Epub ahead of print]

PMID:
29371091
6.

Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy.

Moschini M, Mattei A, Cornelius J, Shariat SF, Dell’Oglio P, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.

World J Urol. 2018 Jan 24. doi: 10.1007/s00345-018-2190-1. [Epub ahead of print]

PMID:
29368231
7.

Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.

Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, Abdollah F, Shariat SF, Montorsi F, Saad F, Tilki D, Briganti A, Karakiewicz PI.

Eur Urol Focus. 2018 Jan 20. pii: S2405-4569(18)30010-5. doi: 10.1016/j.euf.2018.01.009. [Epub ahead of print]

PMID:
29366856
8.

Neoadjuvant and adjuvant treatment in high-risk prostate cancer.

Bandini M, Fossati N, Gandaglia G, Preisser F, Dell’Oglio P, Zaffuto E, Stabile A, Gallina A, Suardi N, Shariat SF, Montorsi F, Karakiewicz PI, Briganti A.

Expert Rev Clin Pharmacol. 2018 Jan 25:1-14. doi: 10.1080/17512433.2018.1429265. [Epub ahead of print]

PMID:
29355037
9.

The Impact of Lymph Node Metastases Burden at Radical Prostatectomy.

Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Pompe RS, Montorsi F, Saad F, Abdollah F, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2018 Jan 3. pii: S2405-4569(17)30296-1. doi: 10.1016/j.euf.2017.12.009. [Epub ahead of print]

PMID:
29306731
10.

Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection.

Brembilla G, Dell’Oglio P, Stabile A, Ambrosi A, Cristel G, Brunetti L, Damascelli A, Freschi M, Esposito A, Briganti A, Montorsi F, Del Maschio A, De Cobelli F.

Eur Radiol. 2017 Dec 21. doi: 10.1007/s00330-017-5229-6. [Epub ahead of print]

PMID:
29270644
11.

History and evolution of the use of oral mucosa for urethral reconstruction.

Barbagli G, Balò S, Montorsi F, Sansalone S, Lazzeri M.

Asian J Urol. 2017 Apr;4(2):96-101. doi: 10.1016/j.ajur.2016.05.006. Epub 2016 Jun 26. Review.

12.

A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals.

Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Shariat SF, Montorsi F, Saad F, Briganti A, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2017 Dec 14. pii: S2405-4569(17)30269-9. doi: 10.1016/j.euf.2017.11.013. [Epub ahead of print]

PMID:
29249688
13.

Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D’Amico lymph node invasion risk stratification.

Leyh-Bannurah SR, Budäus L, Zaffuto E, Pompe RS, Bandini M, Briganti A, Montorsi F, Schiffmann J, Shariat SF, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI.

Urol Oncol. 2018 Feb;36(2):81.e17-81.e24. doi: 10.1016/j.urolonc.2017.10.022. Epub 2017 Dec 14.

PMID:
29248430
14.

Anti-Mullerian Hormone-to-Testosterone Ratio is Predictive of Positive Sperm Retrieval in Men with Idiopathic Non-Obstructive Azoospermia.

Alfano M, Ventimiglia E, Locatelli I, Capogrosso P, Cazzaniga W, Pederzoli F, Frego N, Matloob R, Saccà A, Pagliardini L, Viganò P, Zerbi P, Nebuloni M, Pontillo M, Montorsi F, Salonia A.

Sci Rep. 2017 Dec 15;7(1):17638. doi: 10.1038/s41598-017-17420-z.

15.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2017 Dec 8. pii: S0302-2838(17)31005-9. doi: 10.1016/j.eururo.2017.11.020. [Epub ahead of print]

PMID:
29229176
16.

Radical Nephrectomy With or Without Lymph Node Dissection for High-Risk Non-Metastatic Renal Cell Carcinoma: A Multi-Institutional Analysis.

Gershman B, Thompson RH, Boorjian SA, Larcher A, Capitanio U, Montorsi F, Carenzi C, Bertini R, Briganti A, Lohse CM, Cheville JC, Leibovich BC.

J Urol. 2017 Dec 7. pii: S0022-5347(17)78034-2. doi: 10.1016/j.juro.2017.11.114. [Epub ahead of print]

PMID:
29225056
17.

Oncological and functional outcomes of elderly men treated with HIFU vs. minimally invasive radical prostatectomy: A propensity score analysis.

Capogrosso P, Barret E, Sanchez-Salas R, Nunes-Silva I, Rozet F, Galiano M, Ventimiglia E, Briganti A, Salonia A, Montorsi F, Cathelineau X.

Eur J Surg Oncol. 2018 Jan;44(1):185-191. doi: 10.1016/j.ejso.2017.11.008. Epub 2017 Dec 1.

PMID:
29223469
18.

Does Calculated Free Testosterone Overcome Total Testosterone in Protecting From Sexual Symptom Impairment? Findings of a Cross-Sectional Study.

Boeri L, Capogrosso P, Ventimiglia E, Cazzaniga W, Pederzoli F, Moretti D, Dehò F, Montanari E, Montorsi F, Salonia A.

J Sex Med. 2017 Dec;14(12):1549-1557. doi: 10.1016/j.jsxm.2017.10.070.

PMID:
29198510
19.

Long-term penile morphometric alterations in patients treated with robot-assisted versus open radical prostatectomy.

Capogrosso P, Ventimiglia E, Cazzaniga W, Stabile A, Pederzoli F, Boeri L, Gandaglia G, Dehò F, Briganti A, Montorsi F, Salonia A.

Andrology. 2018 Jan;6(1):136-141. doi: 10.1111/andr.12446. Epub 2017 Dec 1.

PMID:
29195014
20.

Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions.

Gandaglia G, Tilki D, Zaffuto E, Fossati N, Pompe RS, Dell’Oglio P, Graefen M, Montorsi F, Briganti A.

Eur Urol Focus. 2017 Nov 16. pii: S2405-4569(17)30253-5. doi: 10.1016/j.euf.2017.10.013. [Epub ahead of print]

PMID:
29153885
21.

Development of the First Model of Radical Prostatectomy in the Mouse: A Feasibility Study.

Di Trapani E, Nini A, Locatelli I, Buono R, Russo A, Dell’Oglio P, Castiglione F, La Croce G, Benigni F, Montorsi F, Salonia A, Cavarretta I, Briganti A.

Eur Urol. 2017 Nov 14. pii: S0302-2838(17)30970-3. doi: 10.1016/j.eururo.2017.10.031. [Epub ahead of print] No abstract available.

PMID:
29150358
22.

Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.

Mari A, Campi R, Tellini R, Gandaglia G, Albisinni S, Abufaraj M, Hatzichristodoulou G, Montorsi F, van Velthoven R, Carini M, Minervini A, Shariat SF.

World J Urol. 2018 Feb;36(2):157-170. doi: 10.1007/s00345-017-2115-4. Epub 2017 Nov 16. Review.

PMID:
29147759
23.

Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45.

Lavorgna G, Montorsi F, Salonia A.

Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30973-9. doi: 10.1016/j.eururo.2017.10.034. [Epub ahead of print] No abstract available.

PMID:
29129399
24.

Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall’Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30975-2. doi: 10.1016/j.eururo.2017.10.036. [Epub ahead of print] Review.

PMID:
29129398
25.

Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP.

Urol Oncol. 2018 Feb;36(2):79.e11-79.e17. doi: 10.1016/j.urolonc.2017.10.008. Epub 2017 Nov 10.

PMID:
29129353
26.

Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.

Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F, Karakiewicz PI.

Int Urol Nephrol. 2018 Jan;50(1):71-78. doi: 10.1007/s11255-017-1744-2. Epub 2017 Nov 11.

PMID:
29129028
27.

First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy.

Bandini M, Marchioni M, Pompe RS, Tian Z, Gandaglia G, Fossati N, Abdollah F, Graefen M, Montorsi F, Saad F, Shariat SF, Briganti A, Karakiewicz PI.

BJU Int. 2017 Nov 10. doi: 10.1111/bju.14074. [Epub ahead of print]

PMID:
29124911
28.

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone.

Boeri L, Capogrosso P, Ventimiglia E, Cazzaniga W, Pederzoli F, Moretti D, Dehò F, Montanari E, Montorsi F, Salonia A.

Sci Rep. 2017 Nov 9;7(1):15179. doi: 10.1038/s41598-017-15435-0.

29.

Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy.

Nocera L, Sood A, Dalela D, Gild P, Rogers CG, Peabody JO, Montorsi F, Menon M, Briganti A, Abdollah F.

Clin Genitourin Cancer. 2017 Oct 16. pii: S1558-7673(17)30309-9. doi: 10.1016/j.clgc.2017.10.003. [Epub ahead of print]

PMID:
29113771
30.

Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion.

Montironi R, Cimadamore A, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M.

Arch Pathol Lab Med. 2017 Nov;141(11):1460-1461. doi: 10.5858/arpa.2017-0198-LE. No abstract available.

PMID:
29072947
31.

Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.

Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Mazzone E, Dell’Oglio P, Stabile A, Freschi M, Montorsi F, Briganti A.

BJU Int. 2017 Oct 24. doi: 10.1111/bju.14066. [Epub ahead of print]

PMID:
29063734
32.

Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.

Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, Shariat SF, Briganti A, Saad F, Karakiewicz PI.

World J Urol. 2018 Jan;36(1):7-13. doi: 10.1007/s00345-017-2102-9. Epub 2017 Oct 23.

PMID:
29063268
33.

Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.

Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, Gandaglia G, Eastham JA, Scardino PT, Vickers A, Cozzarini C, Montorsi F, Briganti A.

Eur Urol. 2017 Oct 16. pii: S0302-2838(17)30828-X. doi: 10.1016/j.eururo.2017.09.027. [Epub ahead of print]

PMID:
29042125
34.

Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy.

Bandini M, Smith A, Zaffuto E, Pompe RS, Marchioni M, Capitanio U, Chun FK, Kapoor AB, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI.

World J Urol. 2018 Jan;36(1):51-57. doi: 10.1007/s00345-017-2093-6. Epub 2017 Oct 11.

PMID:
29022072
35.

Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion.

Capogrosso P, Montorsi F.

Eur Urol. 2018 Jan;73(1):38-39. doi: 10.1016/j.eururo.2017.08.033. Epub 2017 Sep 27. No abstract available.

PMID:
28958826
36.

Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.

Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, Shariat SF; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration group.

BJU Int. 2018 Feb;121(2):252-259. doi: 10.1111/bju.14020. Epub 2017 Oct 12.

PMID:
28940605
37.

Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium.

Nini A, Capitanio U, Larcher A, Dell’Oglio P, Dehò F, Suardi N, Muttin F, Carenzi C, Freschi M, Lucianò R, La Croce G, Briganti A, Colombo R, Salonia A, Castiglioni A, Rigatti P, Montorsi F, Bertini R.

Eur Urol. 2017 Sep 13. pii: S0302-2838(17)30712-1. doi: 10.1016/j.eururo.2017.08.019. [Epub ahead of print]

PMID:
28917595
39.

When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging: Indications for Preoperative Bone Scintigraphy.

Larcher A, Muttin F, Fossati N, Dell’Oglio P, Di Trapani E, Stabile A, Ripa F, Trevisani F, Carenzi C, Picchio M, Briganti A, Salonia A, Mottrie A, Bertini R, Montorsi F, Capitanio U.

Urology. 2017 Dec;110:114-120. doi: 10.1016/j.urology.2017.08.043. Epub 2017 Sep 7.

PMID:
28890151
40.

Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy.

Moschini M, Shariat SF, Abufaraj M, Foerster B, D Andrea D, Soria F, Dell Oglio P, Mattei A, Montorsi F, Colombo R, Briganti A, Gallina A.

Urol Oncol. 2017 Dec;35(12):672.e1-672.e6. doi: 10.1016/j.urolonc.2017.08.013. Epub 2017 Sep 5.

PMID:
28887096
41.

Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery.

Ventimiglia E, Folkvaljon Y, Carlsson S, Bratt O, Montorsi F, Volz D, Akre O, Johansson E, Stattin P.

J Surg Oncol. 2017 Sep 6. doi: 10.1002/jso.24816. [Epub ahead of print]

PMID:
28876467
42.

Depressive Symptoms and Low Sexual Desire after Radical Prostatectomy: Early and Long-Term Outcomes in a Real-Life Setting.

Boeri L, Capogrosso P, Ventimiglia E, Cazzaniga W, Pederzoli F, Gandaglia G, Finocchio N, Dehò F, Briganti A, Montanari E, Montorsi F, Salonia A.

J Urol. 2018 Feb;199(2):474-480. doi: 10.1016/j.juro.2017.08.104. Epub 2017 Sep 1.

PMID:
28867561
43.

New surgical approaches for clinically high-risk or metastatic prostate cancer.

Dell’Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Karakiewicz PI, Shariat SF, Montorsi F, Briganti A.

Expert Rev Anticancer Ther. 2017 Nov;17(11):1013-1031. doi: 10.1080/14737140.2017.1374858. Epub 2017 Sep 11. Review.

PMID:
28862047
44.

Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy.

Moschini M, Soria F, Susani M, Korn S, Briganti A, Roupret M, Seitz C, Gust K, Haitel A, Montorsi F, Wirth G, Robinson BD, Karakiewicz PI, Özsoy M, Rink M, Shariat SF.

Bladder Cancer. 2017 Jul 27;3(3):161-169. doi: 10.3233/BLC-160086.

45.

Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution.

Villa L, Haddad M, Capitanio U, Somani BK, Cloutier J, Doizi S, Salonia A, Briganti A, Montorsi F, Traxer O.

J Urol. 2018 Jan;199(1):66-73. doi: 10.1016/j.juro.2017.07.088. Epub 2017 Aug 15.

PMID:
28818526
46.

Salvage lymph node dissection: if yes, robotics?

Suardi N, Montorsi F.

BJU Int. 2017 Sep;120(3):304-305. doi: 10.1111/bju.13789. No abstract available.

PMID:
28815976
47.

Concomitant bladder cancer and prostate cancer: challenges and controversies.

Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M, Raspollini MR, Montironi R.

Nat Rev Urol. 2017 Oct;14(10):620-629. doi: 10.1038/nrurol.2017.124. Epub 2017 Aug 16. Review.

PMID:
28813037
48.

Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.

van den Bergh R, Gandaglia G, Tilki D, Borgmann H, Ost P, Surcel C, Valerio M, Sooriakumaran P, Salomon L, Briganti A, Graefen M, van der Poel H, de la Taille A, Montorsi F, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).

Eur Urol Focus. 2017 Aug 8. pii: S2405-4569(17)30188-8. doi: 10.1016/j.euf.2017.07.003. [Epub ahead of print]

PMID:
28801241
49.

European temporal trends in the use of lymph node dissection in patients with renal cancer.

Capitanio U, Stewart GD, Larcher A, Ouzaid I, Akdogan B, Roscigno M, Marszalek M, Dell’Oglio P, Salagierski M, Volpe A, Mir MC, Kriegmair M, Terrone C, Brookman-May SD, Montorsi F, Klatte T; Kidney Cancer Working Group of the Young Academic Urologists (YAU) Working Party of the European Association of Urology (EAU).

Eur J Surg Oncol. 2017 Nov;43(11):2184-2192. doi: 10.1016/j.ejso.2017.07.016. Epub 2017 Aug 3.

PMID:
28801061
50.

Lymph node dissection should not be dismissed in case of localized renal cell carcinoma in the presence of larger diseases.

Dell’Oglio P, Larcher A, Muttin F, Di Trapani E, Trevisani F, Ripa F, Carenzi C, Briganti A, Salonia A, Montorsi F, Bertini R, Capitanio U.

Urol Oncol. 2017 Nov;35(11):662.e9-662.e15. doi: 10.1016/j.urolonc.2017.07.010. Epub 2017 Aug 8.

PMID:
28801027
51.

Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell’Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A.

Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]

PMID:
28779974
52.

Cost of illness of urothelial bladder cancer in Italy.

Gerace C, Montorsi F, Tambaro R, Cartenì G, De Luca S, Tucci M, Martorana G, Basso U, Cardosi L, Teruzzi C.

Clinicoecon Outcomes Res. 2017 Jul 24;9:433-442. doi: 10.2147/CEOR.S135065. eCollection 2017.

53.

Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis.

Zaffuto E, Pompe R, Bondarenko HD, Moschini M, Dell’Oglio P, Gandaglia G, Fossati N, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI.

Urol Oncol. 2017 Nov;35(11):659.e7-659.e12. doi: 10.1016/j.urolonc.2017.07.004. Epub 2017 Jul 26.

PMID:
28755960
54.

The Association of Uromodulin Genotype with Renal Cancer Aggressiveness.

Trevisani F, Larcher A, Cinque A, Capitanio U, Ripa F, Vago R, Bettiga A, Benigni F, Carenzi C, Muttin F, Bertini R, Briganti A, Salonia A, Rampoldi L, Montorsi F.

Eur Urol Focus. 2017 May 12. pii: S2405-4569(17)30115-3. doi: 10.1016/j.euf.2017.04.009. [Epub ahead of print]

PMID:
28753889
55.

Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?

Capitanio U, Stewart GD, Klatte T, Akdogan B, Roscigno M, Marszalek M, Dell’Oglio P, Zaffuto E, Rodriguez Faba O, Salagierski M, Lingard J, Carini M, Ouzaid I, Mir MC, Montorsi F, Da Pozzo LF, Stief C, Minervini A, Brookman-May SD.

Eur Urol Focus. 2017 Mar 21. pii: S2405-4569(17)30068-8. doi: 10.1016/j.euf.2017.02.020. [Epub ahead of print]

PMID:
28753867
56.

Correlation Between Primary Hypospadias Repair and Subsequent Urethral Strictures in a Series of 408 Adult Patients.

Barbagli G, Fossati N, Larcher A, Montorsi F, Sansalone S, Butnaru D, Lazzeri M.

Eur Urol Focus. 2017 Apr;3(2-3):287-292. doi: 10.1016/j.euf.2017.02.005. Epub 2017 Feb 21.

PMID:
28753858
57.

Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.

Dell’Oglio P, Bishr M, Boehm K, Trudeau V, Larcher A, Tian Z, Sosa J, Moschini M, Saad F, Capitanio U, Briganti A, Graefen M, Montorsi F, Karakiewicz PI.

Eur Urol Focus. 2017 Feb 11. pii: S2405-4569(17)30026-3. doi: 10.1016/j.euf.2017.01.017. [Epub ahead of print]

PMID:
28753853
58.

Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium.

Rodriguez Faba O, Linares E, Tilki D, Capitanio U, Evans CP, Montorsi F, Martínez-Salamanca JI, Libertino J, Gontero P, Palou J.

Eur Urol Focus. 2017 Feb 9. pii: S2405-4569(17)30018-4. doi: 10.1016/j.euf.2017.01.009. [Epub ahead of print]

PMID:
28753848
59.

Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.

Moschini M, Morlacco A, Briganti A, Hu B, Colombo R, Montorsi F, Frank I, Daneshmand S, Karnes RJ.

Eur Urol Focus. 2016 Nov 23. pii: S2405-4569(16)30163-8. doi: 10.1016/j.euf.2016.11.005. [Epub ahead of print]

PMID:
28753820
60.

PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.

Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, Briganti A, Doglioni C, Bellone M.

Eur Urol Focus. 2017 Jun 21. pii: S2405-4569(17)30151-7. doi: 10.1016/j.euf.2017.05.013. [Epub ahead of print]

PMID:
28753812
61.

Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.

Moschini M, Fossati N, Sood A, Lee JK, Sammon J, Sun M, Pucheril D, Dalela D, Montorsi F, Karnes RJ, Briganti A, Trinh QD, Menon M, Abdollah F.

Eur Urol Focus. 2016 Jun 14. pii: S2405-4569(16)30061-X. doi: 10.1016/j.euf.2016.06.001. [Epub ahead of print]

PMID:
28753764
62.

Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons.

Fossati N, Di Trapani E, Gandaglia G, Dell’Oglio P, Umari P, Buffi NM, Guazzoni G, Mottrie A, Gaboardi F, Montorsi F, Briganti A, Suardi N.

J Endourol. 2017 Sep;31(9):872-877. doi: 10.1089/end.2017.0085. Epub 2017 Jul 21.

PMID:
28732186
63.

Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.

Novara G, Giannarini G, Alcaraz A, Cózar-Olmo JM, Descazeaud A, Montorsi F, Ficarra V.

Eur Urol Focus. 2016 Dec;2(5):553-561. doi: 10.1016/j.euf.2016.04.002. Epub 2016 Apr 23. Review.

PMID:
28723522
64.

Human Prostate Tissue-derived Extracellular Matrix as a Model of Prostate Microenvironment.

Cazzaniga W, Nebuloni M, Longhi E, Locatelli I, Allevi R, Lucianò R, Senatore G, Ventimiglia E, Cucchiara V, Genovese L, Montorsi F, Alfano M, Salonia A, Cavarretta I.

Eur Urol Focus. 2016 Oct;2(4):400-408. doi: 10.1016/j.euf.2016.02.016. Epub 2016 Mar 10.

PMID:
28723472
66.

Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive Factors.

Pederzoli F, Chappidi MR, Collica S, Kates M, Joice GA, Sopko NA, Montorsi F, Salonia A, Bivalacqua TJ.

J Sex Med. 2017 Aug;14(8):1059-1065. doi: 10.1016/j.jsxm.2017.06.003. Epub 2017 Jul 12.

PMID:
28709874
67.

Medical treatment of erectile dysfunction: too many medical prescriptions?

Capogrosso P, Ventimiglia E, Oreggia D, Salonia A, Montorsi F.

Urologia. 2017 Aug 1;84(3):121-129. doi: 10.5301/uj.5000250. Epub 2017 Jul 5. Review.

PMID:
28708203
68.

Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.

Gandaglia G, Boorjian SA, Parker WP, Zaffuto E, Fossati N, Bandini M, Dell’Oglio P, Suardi N, Montorsi F, Karnes RJ, Briganti A.

Eur Urol. 2017 Dec;72(6):910-917. doi: 10.1016/j.eururo.2017.06.001. Epub 2017 Jun 13.

PMID:
28622831
69.

Re: Giovanni Corona, Giulia Rastrelli, Abraham Morgentaler, Alessandra Sforza, Edoardo Mannucci, Mario Maggi. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol 2017;72:1000-11.

Ventimiglia E, Capogrosso P, Cazzaniga W, Montorsi F, Salonia A.

Eur Urol. 2017 Dec;72(6):e160-e161. doi: 10.1016/j.eururo.2017.05.050. Epub 2017 Jun 7. No abstract available.

PMID:
28601351
70.

Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790-807.

Montironi R, Gasparrini S, Lopez-Beltran A, Cheng L, Massari F, Montorsi F, Scarpelli M.

Eur Urol. 2017 Nov;72(5):e139-e141. doi: 10.1016/j.eururo.2017.05.029. Epub 2017 May 31. No abstract available.

PMID:
28576502
71.

Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.

Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah SR, Moschini M, Dell’Oglio P, Gandaglia G, Fossati N, Stabile A, Zorn KC, Montorsi F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2017 Oct;15(5):e793-e800. doi: 10.1016/j.clgc.2017.04.006. Epub 2017 Apr 13.

PMID:
28506524
72.

Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis.

Abdollah F, Dalela D, Sood A, Sammon J, Cho R, Nocera L, Diaz M, Jeong W, Peabody JO, Fossati N, Gandaglia G, Briganti A, Montorsi F, Menon M.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):395-400. doi: 10.1038/pcan.2017.26. Epub 2017 May 2.

PMID:
28462944
73.

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer.

Bandini M, Gandaglia G, Fossati N, Montorsi F, Briganti A.

Urol Case Rep. 2017 Mar 10;12:34-36. doi: 10.1016/j.eucr.2017.02.011. eCollection 2017 May.

74.

Orgasmic Dysfunction after Radical Prostatectomy.

Capogrosso P, Ventimiglia E, Cazzaniga W, Montorsi F, Salonia A.

World J Mens Health. 2017 Apr;35(1):1-13. doi: 10.5534/wjmh.2017.35.1.1. Review.

75.

The Microbiome of the Prostate Tumor Microenvironment.

Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Lucianò R, Ceresola ER, Locatelli I, Visconti L, Lavorgna G, Briganti A, Nebuloni M, Doglioni C, Clementi M, Montorsi F, Canducci F, Salonia A.

Eur Urol. 2017 Oct;72(4):625-631. doi: 10.1016/j.eururo.2017.03.029. Epub 2017 Apr 20.

PMID:
28434677
76.

Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.

Moschini M, Shariat SF, Freschi M, Soria F, D’Andrea D, Abufaraj M, Foerster B, Dell’Oglio P, Zaffuto E, Mattei A, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R.

Urol Oncol. 2017 Aug;35(8):528.e1-528.e5. doi: 10.1016/j.urolonc.2017.03.024. Epub 2017 Apr 19.

PMID:
28433471
77.

Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence.

Chapple CR, Cruz F, Deffieux X, Milani AL, Arlandis S, Artibani W, Bauer RM, Burkhard F, Cardozo L, Castro-Diaz D, Cornu JN, Deprest J, Gunnemann A, Gyhagen M, Heesakkers J, Koelbl H, MacNeil S, Naumann G, Roovers JWR, Salvatore S, Sievert KD, Tarcan T, Van der Aa F, Montorsi F, Wirth M, Abdel-Fattah M.

Eur Urol. 2017 Sep;72(3):424-431. doi: 10.1016/j.eururo.2017.03.048. Epub 2017 Apr 14. Review.

PMID:
28413126
78.

Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell’Oglio P, Bravi CA, Fallara G, Pellegrino F, Nocera L, Karakiewicz PI, Tian Z, Freschi M, Montironi R, Montorsi F, Briganti A.

Eur Urol. 2017 Oct;72(4):632-640. doi: 10.1016/j.eururo.2017.03.049. Epub 2017 Apr 12.

PMID:
28412062
79.

Primary, secondary and compensated hypogonadism: a novel risk stratification for infertile men.

Ventimiglia E, Ippolito S, Capogrosso P, Pederzoli F, Cazzaniga W, Boeri L, Cavarretta I, Alfano M, Viganò P, Montorsi F, Salonia A.

Andrology. 2017 May;5(3):505-510. doi: 10.1111/andr.12335.

PMID:
28409903
80.

Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?

Gandaglia G, Fossati N, Dell’Oglio P, Montorsi F, Briganti A.

BJU Int. 2017 May;119(5):652-653. doi: 10.1111/bju.13833. No abstract available.

PMID:
28393494
81.

Local Therapy Improves Survival in Metastatic Prostate Cancer.

Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI.

Eur Urol. 2017 Jul;72(1):118-124. doi: 10.1016/j.eururo.2017.03.020. Epub 2017 Apr 3.

PMID:
28385454
82.

Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping.

Gandaglia G, Karnes RJ, Sivaraman A, Moschini M, Fossati N, Zaffuto E, DellʼOglio P, Cathelineau X, Montorsi F, Sanchez-Salas R, Briganti A.

Urol Oncol. 2017 Jul;35(7):461.e7-461.e14. doi: 10.1016/j.urolonc.2017.02.012. Epub 2017 Mar 27.

PMID:
28359746
83.

Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer.

Dell’Oglio P, Zaffuto E, Boehm K, Trudeau V, Larcher A, Tian Z, Moschini M, Shariat SF, Graefen M, Saad F, Capitanio U, Briganti A, Montorsi F, Karakiewicz PI.

Eur J Surg Oncol. 2017 Aug;43(8):1581-1588. doi: 10.1016/j.ejso.2017.02.018. Epub 2017 Mar 10.

PMID:
28330822
84.

Six Out of Ten Women with Recurrent Urinary Tract Infections Complain of Distressful Sexual Dysfunction – A Case-Control Study.

Boeri L, Capogrosso P, Ventimiglia E, Scano R, Graziottin A, Dehò F, Montanari E, Montorsi F, Salonia A.

Sci Rep. 2017 Mar 15;7:44380. doi: 10.1038/srep44380.

86.

Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical Cystectomy.

Dell’Oglio P, Tian Z, Leyh-Bannurah SR, Trudeau V, Larcher A, Moschini M, Di Trapani E, Capitanio U, Briganti A, Montorsi F, Saad F, Karakiewicz PI.

J Natl Compr Canc Netw. 2017 Mar;15(3):327-333.

PMID:
28275033
87.

Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy.

Moschini M, Foerster B, Abufaraj M, Soria F, Seisen T, Roupret M, Colin P, De la Taille A, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Chlosta P, Bandini M, Montorsi F, Simone G, Gallucci M, Romeo G, Matsumoto K, Karakiewicz P, Briganti A, Shariat SF.

World J Urol. 2017 Oct;35(10):1541-1547. doi: 10.1007/s00345-017-2026-4. Epub 2017 Feb 28.

PMID:
28247066
88.

Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients.

Spahn M, Morlacco A, Boxler S, Joniau S, Briganti A, Montorsi F, Gontero P, Bader P, Frohneberg D, van Poppel H, Karnes RJ; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPAcT).

BJU Int. 2017 Nov;120(5B):E52-E58. doi: 10.1111/bju.13818. Epub 2017 Mar 26.

PMID:
28220605
90.

Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism.

Bettiga A, Aureli M, Colciago G, Murdica V, Moschini M, Lucianò R, Canals D, Hannun Y, Hedlund P, Lavorgna G, Colombo R, Bassi R, Samarani M, Montorsi F, Salonia A, Benigni F.

Sci Rep. 2017 Feb 13;7:42157. doi: 10.1038/srep42157.

91.

Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy.

Moschini M, Soria F, Abufaraj M, Foerster B, D’Andrea D, Damiano R, Klatte T, Montorsi F, Briganti A, Colombo R, Gallina A, Shariat SF.

Clin Genitourin Cancer. 2017 Aug;15(4):e681-e688. doi: 10.1016/j.clgc.2017.01.001. Epub 2017 Jan 11.

PMID:
28162943
92.

From “gold standard” resection to reproducible “future standard” endoscopic enucleation of the prostate: what we know about anatomical enucleation.

Naspro R, Gomez Sancha F, Manica M, Meneghini A, Ahyai S, Aho T, Fiori C, Vavassori I, DA Pozzo LF, Pansadoro V, Montorsi F, Herrmann TR.

Minerva Urol Nefrol. 2017 Oct;69(5):446-458. doi: 10.23736/S0393-2249.17.02834-X. Epub 2017 Feb 1.

93.

Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.

Moschini M, Shariat SF, Freschi M, Soria F, Abufaraj M, Gandaglia G, Dell’Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R.

Urol Int. 2017;98(3):290-297. doi: 10.1159/000454736. Epub 2017 Feb 1.

PMID:
28142141
94.

Time of onset of vardenafil orodispersible tablet in a real-life setting – looking beyond randomized clinical trials.

Capogrosso P, Ventimiglia E, Boeri L, Serino A, Russo A, La Croce G, Capitanio U, Dehò F, Montorsi F, Salonia A.

Expert Rev Clin Pharmacol. 2017 Mar;10(3):339-344. doi: 10.1080/17512433.2017.1288567. Epub 2017 Feb 13.

PMID:
28129714
95.

North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer.

Leyh-Bannurah SR, Budäus L, Pompe R, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI.

Prostate. 2017 Apr;77(5):542-548. doi: 10.1002/pros.23292. Epub 2017 Jan 17.

PMID:
28093788
96.

Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy.

Moschini M, Dell’Oglio P, Luciano’ R, Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.

Urol Oncol. 2017 Jun;35(6):335-341. doi: 10.1016/j.urolonc.2016.12.006. Epub 2017 Jan 10.

PMID:
28087131
97.

Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How?

Fossati N, Cozzarini C, Fiorino C, Gandaglia G, Montorsi F, Briganti A.

J Clin Oncol. 2017 Feb;35(4):469-470. doi: 10.1200/JCO.2016.70.2118. Epub 2016 Nov 7. No abstract available.

PMID:
28052707
98.

Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?

Suardi N, Briganti A, Gandaglia G, Fossati N, Montorsi F.

Eur Urol. 2017 May;71(5):693-694. doi: 10.1016/j.eururo.2016.12.001. Epub 2016 Dec 30.

PMID:
28043707
99.

Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients.

Moschini M, Shariat SF, Lucianò R, D’Andrea D, Foerster B, Abufaraj M, Bandini M, Dell’Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.

Clin Genitourin Cancer. 2017 Aug;15(4):e603-e607. doi: 10.1016/j.clgc.2016.12.006. Epub 2016 Dec 14.

PMID:
28040422
100.

Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection.

Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, Van Der Poel H, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, Briganti A, Joniau S.

Front Surg. 2016 Dec 16;3:65. doi: 10.3389/fsurg.2016.00065. eCollection 2016.

101.

Sexual functioning mirrors overall men’s health status, even irrespective of cardiovascular risk factors.

Capogrosso P, Ventimiglia E, Boeri L, Capitanio U, Gandaglia G, Dehò F, Pederzoli F, Cazzaniga W, Scano R, Montorsi F, Salonia A.

Andrology. 2017 Jan;5(1):63-69. doi: 10.1111/andr.12299.

102.

Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?

Fossati N, Rossi MS, Cucchiara V, Gandaglia G, Dell’Oglio P, Moschini M, Suardi N, Dehò F, Montorsi F, Schiavina R, Mottrie A, Briganti A.

Urol Oncol. 2017 Apr;35(4):150.e9-150.e15. doi: 10.1016/j.urolonc.2016.11.010. Epub 2016 Dec 13.

PMID:
27986374
103.

The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes.

Moschini M, Shariat SF, Abufaraj M, Soria F, Klatte T, Croce G, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.

Urol Oncol. 2017 Apr;35(4):151.e17-151.e23. doi: 10.1016/j.urolonc.2016.11.003. Epub 2016 Dec 5.

PMID:
27932269
104.

Impact of neoadjuvant chemotherapy on complications of minimally invasive radical cystectomy.

Lizée D, Salas RS, Barret E, Galiano M, Di Trapani E, Montorsi F, Cathelineau X.

Actas Urol Esp. 2017 Mar;41(2):88-96. doi: 10.1016/j.acuro.2016.05.008. Epub 2016 Nov 28. English, Spanish.

PMID:
27908636
105.

The role of prostatic inflammation in the development and progression of benign and malignant diseases.

Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F, Briganti A.

Curr Opin Urol. 2017 Mar;27(2):99-106. doi: 10.1097/MOU.0000000000000369.

PMID:
27906778
106.

Low Birth Weight Is Associated with a Decreased Overall Adult Health Status and Reproductive Capability – Results of a Cross-Sectional Study in Primary Infertile Patients.

Boeri L, Ventimiglia E, Capogrosso P, Ippolito S, Pecoraro A, Paciotti M, Scano R, Galdini A, Valsecchi L, Papaleo E, Montorsi F, Salonia A.

PLoS One. 2016 Nov 28;11(11):e0166728. doi: 10.1371/journal.pone.0166728. eCollection 2016.

107.

Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management?

Tutolo M, Fossati N, Van der Aa F, Gandaglia G, Montorsi F, Briganti A.

Eur Urol. 2017 Mar;71(3):379-380. doi: 10.1016/j.eururo.2016.11.011. Epub 2016 Nov 22. No abstract available.

PMID:
27887943
109.

Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer.

Larcher A, Trudeau V, Dell’Oglio P, Tian Z, Boehm K, Fossati N, Capitanio U, Briganti A, Montorsi F, Karakiewicz P.

Urology. 2017 Apr;102:130-137. doi: 10.1016/j.urology.2016.08.069. Epub 2016 Nov 21.

PMID:
27884597
110.

Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy.

Schiffmann J, Larcher A, Sun M, Tian Z, Berdugo J, Leva I, Widmer H, Lattouf JB, Zorn KC, Shariat SF, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Can Urol Assoc J. 2016 Aug;10(7-8):269-276.

111.

Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA.

Zaffuto E, Gazdovich S, Leyh-Bannurah SR, Huland H, Abdollah F, Shariat SF, Menon M, Briganti A, Montorsi F, Karakiewicz PI.

Int J Urol. 2017 Feb;24(2):117-123. doi: 10.1111/iju.13261. Epub 2016 Nov 22.

112.

Sexual dysfunction and prostate cancer risk: one more piece of a complex puzzle.

Capogrosso P, Montorsi F, Salonia A.

Asian J Androl. 2017 Mar-Apr;19(2):264. doi: 10.4103/1008-682X.190330. No abstract available.

113.

When to perform preoperative chest computed tomography for renal cancer staging.

Larcher A, Dell’Oglio P, Fossati N, Nini A, Muttin F, Suardi N, De Cobelli F, Salonia A, Briganti A, Zhang X, Montorsi F, Bertini R, Capitanio U.

BJU Int. 2017 Oct;120(4):490-496. doi: 10.1111/bju.13670. Epub 2016 Nov 2.

PMID:
27684653
114.

MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.

Trevisani F, Ghidini M, Larcher A, Lampis A, Lote H, Manunta P, Alibrandi MT, Zagato L, Citterio L, Dell’Antonio G, Carenzi C, Capasso G, Rugge M, Rigotti P, Bertini R, Cascione L, Briganti A, Salonia A, Benigni F, Braconi C, Fassan M, Hahne JC, Montorsi F, Valeri N.

Br J Cancer. 2016 Nov 22;115(11):1343-1350. doi: 10.1038/bjc.2016.329. Epub 2016 Nov 1.

115.

Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.

Boehm K, Dell’Oglio P, Tian Z, Capitanio U, Chun FKH, Tilki D, Haferkamp A, Saad F, Montorsi F, Graefen M, Karakiewicz PI.

World J Urol. 2017 Jul;35(7):1031-1036. doi: 10.1007/s00345-016-1963-7. Epub 2016 Oct 28.

PMID:
27796538
116.

Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival.

Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O’Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R.

J Surg Oncol. 2016 Nov;114(6):764-768. doi: 10.1002/jso.24395. Epub 2016 Aug 26.

117.

Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches.

Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, Shariat SF, Montorsi F, Briganti A.

Urologia. 2017 Feb 3;84(1):9-19. doi: 10.5301/uro.5000139. Epub 2015 Dec 16. Review.

PMID:
26689534
118.

Linearized texture of three-dimensional extracellular matrix is mandatory for bladder cancer cell invasion.

Alfano M, Nebuloni M, Allevi R, Zerbi P, Longhi E, Lucianò R, Locatelli I, Pecoraro A, Indrieri M, Speziali C, Doglioni C, Milani P, Montorsi F, Salonia A.

Sci Rep. 2016 Oct 25;6:36128. doi: 10.1038/srep36128.

119.

Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine.

Capogrosso P, Ventimiglia E, Moschini M, Boeri L, Farina E, Finocchio N, Gandaglia G, Fossati N, Briganti A, Montorsi F, Salonia A.

Prostate. 2017 Feb;77(2):234-241. doi: 10.1002/pros.23266. Epub 2016 Oct 24.

PMID:
27775173
120.

Robotic and Open Radical Prostatectomy: The First Prospective Randomised Controlled Trial Fuels Debate Rather than Closing the Question.

Fossati N, Wiklund P, Rochat CH, Montorsi F, Dasgupta P, Sanchez-Salas R, Canda AE, Piechaud T, Artibani W, Mottrie A.

Eur Urol. 2017 Mar;71(3):307-308. doi: 10.1016/j.eururo.2016.08.068. Epub 2016 Sep 13.

PMID:
27616721
121.

Perioperative and oncologic outcomes of robot-assisted vs. open radical cystectomy in bladder cancer patients: A comparison of two high-volume referral centers.

Gandaglia G, Karl A, Novara G, de Groote R, Buchner A, D’Hondt F, Montorsi F, Stief C, Mottrie A, Gratzke C.

Eur J Surg Oncol. 2016 Nov;42(11):1736-1743. doi: 10.1016/j.ejso.2016.02.254. Epub 2016 Mar 19.

PMID:
27032295
122.

Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury.

Villa L, Buono R, Ferrandi M, Molinari I, Benigni F, Bettiga A, Colciago G, Ikehata M, Messaggio E, Rastaldi MP, Montorsi F, Salonia A, Manunta P.

Int J Mol Sci. 2016 Oct 14;17(10). pii: E1728.

123.

Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.

Moschini M, Sharma V, Gandaglia G, Dell’Oglio P, Fossati N, Zaffuto E, Montorsi F, Briganti A, Karnes RJ.

BJU Int. 2017 Jul;120(1):69-75. doi: 10.1111/bju.13683. Epub 2016 Nov 11.

PMID:
27753192
124.

The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.

Dell’Oglio P, Karnes RJ, Gandaglia G, Fossati N, Stabile A, Moschini M, Cucchiara V, Zaffuto E, Karakiewicz PI, Suardi N, Montorsi F, Briganti A.

Prostate. 2017 Feb;77(3):263-273. doi: 10.1002/pros.23265. Epub 2016 Oct 18.

PMID:
27753114
125.

Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database.

Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Briganti A, McCORMACK M, Shariat SF, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Minerva Urol Nefrol. 2017 Apr;69(2):173-180. doi: 10.23736/S0393-2249.16.02713-2. Epub 2016 Oct 12.

126.

The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience.

Moschini M, Luzzago S, Zaffuto E, Dell’Oglio P, Gandaglia G, Mattei A, Damiano R, Soria F, Klatte T, Shariat SF, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R.

Eur J Surg Oncol. 2017 Apr;43(4):808-814. doi: 10.1016/j.ejso.2016.08.024. Epub 2016 Sep 28.

PMID:
27720312
127.

Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol Lancet 2016;17:1317-24: Active Surveillance in Metastatic Renal Cell Carcinoma: Option or Exception?

Capitanio U, Larcher A, Dell’Oglio P, Montorsi F.

Eur Urol. 2017 May;71(5):e139-e140. doi: 10.1016/j.eururo.2016.09.034. Epub 2016 Sep 29. No abstract available.

PMID:
27692706
128.

Mortality, morbidity and healthcare expenditures after local tumour ablation or partial nephrectomy for T1A kidney cancer.

Larcher A, Sun M, Dell’Oglio P, Trudeau V, Boehm K, Schiffmann J, Tian Z, Fossati N, Capitanio U, Briganti A, Montorsi F, Karakiewicz P.

Eur J Surg Oncol. 2017 Apr;43(4):815-822. doi: 10.1016/j.ejso.2016.08.023. Epub 2016 Sep 17.

PMID:
27692535
129.

Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients.

Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Dell’Oglio P, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Graefen M, Karakiewicz PI.

Prostate. 2017 Jan;77(1):105-113. doi: 10.1002/pros.23253. Epub 2016 Sep 29.

PMID:
27683103
130.

Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V.

J Urol. 2017 Mar;197(3 Pt 1):580-589. doi: 10.1016/j.juro.2016.09.078. Epub 2016 Sep 23.

PMID:
27670916
131.

Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer.

Zaffuto E, Gandaglia G, Fossati N, Dell’Oglio P, Moschini M, Cucchiara V, Suardi N, Mirone V, Bandini M, Shariat SF, Karakiewicz PI, Montorsi F, Briganti A.

J Urol. 2017 Mar;197(3 Pt 1):669-675. doi: 10.1016/j.juro.2016.09.079. Epub 2016 Sep 23.

PMID:
27670915
132.

Reply to Marc A. Bjurlin, Lee C. Zhao, and Michael D. Stifelman’s Letter to the Editor Re: Nicolò Maria Buffi, Giovanni Lughezzani, Rodolfo Hurle, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.022.

Buffi NM, Lughezzani G, Hurle R, Lazzeri M, Taverna G, Bozzini G, Bertolo R, Checcucci E, Porpiglia F, Fossati N, Gandaglia G, Larcher A, Suardi N, Montorsi F, Lista G, Guazzoni G, Mottrie A.

Eur Urol. 2017 Mar;71(3):e92-e93. doi: 10.1016/j.eururo.2016.09.012. Epub 2016 Sep 16. No abstract available.

PMID:
27641789
134.

Recovery of urinary continence after radical prostatectomy.

Capogrosso P, Sanchez-Salas R, Salonia A, Cathala N, Mombet A, Sivaraman A, Barret E, Montorsi F, Cathelineau X.

Expert Rev Anticancer Ther. 2016 Oct;16(10):1039-52. doi: 10.1080/14737140.2016.1233818. Epub 2016 Sep 21. Review.

PMID:
27636115
135.

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.

Schiavina R, Bianchi L, Borghesi M, Briganti A, Brunocilla E, Carini M, Terrone C, Mottrie A, Dente D, Gacci M, Gontero P, Gurioli A, Imbimbo C, La Manna G, Marchioro G, Milanese G, Mirone V, Montorsi F, Morgia G, Munegato S, Novara G, Panarello D, Porreca A, Russo GI, Serni S, Simonato A, Urzì D, Verze P, Volpe A, Martorana G.

Int J Urol. 2016 Dec;23(12):1000-1008. doi: 10.1111/iju.13203. Epub 2016 Sep 12.

136.

Re: Family History and Probability of Prostate Cancer, Differentiated by Risk Category – A Nationwide Population-based Study.

Ventimiglia E, Salonia A, Briganti A, Montorsi F.

Eur Urol. 2017 Jan;71(1):143-144. doi: 10.1016/j.eururo.2016.08.063. Epub 2016 Sep 5. No abstract available.

PMID:
27609559
137.

Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.

Montorsi F, Gandaglia G, Fossati N, Suardi N, Pultrone C, De Groote R, Dovey Z, Umari P, Gallina A, Briganti A, Mottrie A.

Eur Urol. 2017 Sep;72(3):432-438. doi: 10.1016/j.eururo.2016.08.051. Epub 2016 Sep 3.

PMID:
27600589
138.

Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years.

Moschini M, Luzzago S, Cazzaniga W, Cucchiara V, Bandini M, Damiano R, Soria F, Klatte T, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.

Clin Genitourin Cancer. 2017 Apr;15(2):e223-e228. doi: 10.1016/j.clgc.2016.07.024. Epub 2016 Aug 8.

PMID:
27589904
139.

Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.

Gandaglia G, Fossati N, Stabile A, Bandini M, Rigatti P, Montorsi F, Briganti A.

Eur Urol. 2017 Aug;72(2):289-292. doi: 10.1016/j.eururo.2016.08.040. Epub 2016 Aug 27.

PMID:
27574820
140.

Postprostatectomy Erectile Dysfunction: A Review.

Capogrosso P, Salonia A, Briganti A, Montorsi F.

World J Mens Health. 2016 Aug;34(2):73-88. doi: 10.5534/wjmh.2016.34.2.73. Epub 2016 Aug 23. Review.

141.

Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides.

Montironi R, Gasparrini S, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montorsi F, Scarpelli M.

Eur Urol. 2017 Feb;71(2):e73-e75. doi: 10.1016/j.eururo.2016.08.036. Epub 2016 Aug 25. No abstract available.

PMID:
27568062
142.

Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy.

Castiglione F, Dell’Oglio P, Tosco L, Everaerts W, Albersen M, Hakim L, Van den Broeck T, Moris L, Claessens F, Briganti A, Montorsi F, Van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).

Prostate. 2017 Jan;77(1):3-9. doi: 10.1002/pros.23242. Epub 2016 Aug 16.

PMID:
27527377
143.

Salvage radiotherapy for patients with rising PSA.

Fossati N, Cozzarini C, Fiorino C, Gandaglia G, Montorsi F, Briganti A.

Lancet Oncol. 2016 Aug;17(8):e314-e315. doi: 10.1016/S1470-2045(16)30276-5. No abstract available.

PMID:
27511150
144.

Timing of androgen-deprivation therapy for prostate cancer: still a long way to go.

Fossati N, Gandaglia G, Dell’Oglio P, Montorsi F, Briganti A.

Lancet Oncol. 2016 Aug;17(8):e313. doi: 10.1016/S1470-2045(16)30309-6. No abstract available.

PMID:
27511149
145.

Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model.

Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F, Shariat S, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):333-340. doi: 10.1016/j.ijrobp.2016.06.014. Epub 2016 Jun 18.

PMID:
27497691
146.

Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice – Analysis of Surveillance, Epidemiology, and End Results Database.

Schiffmann J, Larcher A, Sun M, Tian Z, Berdugo J, Leva I, Widmer H, Lattouf JB, Zorn K, Haese A, Shariat SF, Saad F, Montorsi F, Graefen M, Karakiewicz PI.

Urol Int. 2017;98(1):40-48. doi: 10.1159/000447495. Epub 2016 Aug 4.

147.

Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.

Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Noris Chiorda B, Gandaglia G, Dell’Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2017 Jun;71(6):886-893. doi: 10.1016/j.eururo.2016.07.028. Epub 2016 Jul 30.

PMID:
27484843
148.

STAMPEDE trial and patients with non-metastatic prostate cancer.

Gandaglia G, Fossati N, Suardi N, Montorsi F, Briganti A.

Lancet. 2016 Jul 16;388(10041):234-5. doi: 10.1016/S0140-6736(16)31038-8. No abstract available.

PMID:
27479564
149.

Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer.

Dell’Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR, Moschini M, Capitanio U, Shariat SF, Briganti A, Montorsi F, Saad F, Karakiewicz PI.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1037-1045. doi: 10.1016/j.ijrobp.2016.05.004. Epub 2016 May 10.

PMID:
27478167
150.

Validation of the American Society for Reproductive Medicine guidelines/recommendations in white European men presenting for couple’s infertility.

Ventimiglia E, Capogrosso P, Boeri L, Ippolito S, Scano R, Moschini M, Gandaglia G, Papaleo E, Montorsi F, Salonia A.

Fertil Steril. 2016 Oct;106(5):1076-1082.e1. doi: 10.1016/j.fertnstert.2016.06.044. Epub 2016 Jul 26.

PMID:
27473348
151.

Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions.

Buffi NM, Lughezzani G, Hurle R, Lazzeri M, Taverna G, Bozzini G, Bertolo R, Checcucci E, Porpiglia F, Fossati N, Gandaglia G, Larcher A, Suardi N, Montorsi F, Lista G, Guazzoni G, Mottrie A.

Eur Urol. 2017 Jun;71(6):945-951. doi: 10.1016/j.eururo.2016.07.022. Epub 2016 Jul 26.

PMID:
27473298
152.

Long-term sexual outcomes after holmium laser enucleation of the prostate: which patients could benefit the most?

Capogrosso P, Ventimiglia E, Ferrari M, Serino A, Boeri L, Capitanio U, Briganti A, Damiano R, Montorsi F, Salonia A.

Int J Impot Res. 2016 Sep;28(5):189-93. doi: 10.1038/ijir.2016.29. Epub 2016 Jul 28.

PMID:
27465782
153.

Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.

Russo A, Capogrosso P, Ventimiglia E, La Croce G, Boeri L, Montorsi F, Salonia A.

Int J Clin Pract. 2016 Sep;70(9):723-33. doi: 10.1111/ijcp.12843. Epub 2016 Jul 25. Review.

PMID:
27456527
154.

Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy.

Moschini M, Gandaglia G, Fossati N, Dell’Oglio P, Cucchiara V, Luzzago S, Zaffuto E, Suardi N, Damiano R, Shariat SF, Montorsi F, Briganti A.

Clin Genitourin Cancer. 2017 Feb;15(1):67-71. doi: 10.1016/j.clgc.2016.06.002. Epub 2016 Jun 29.

PMID:
27452733
155.

Editorial Comment to Perioperative blood transfusion in radical cystectomy: Analysis of the National Surgical Quality Improvement Program database.

Gandaglia G, Dell’Oglio P, Montorsi F, Briganti A.

Int J Urol. 2016 Sep;23(9):750-1. doi: 10.1111/iju.13169. Epub 2016 Jul 19. No abstract available.

156.

Metabolic syndrome in white European men presenting for primary couple’s infertility: investigation of the clinical and reproductive burden.

Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, Castagna G, Clementi MC, La Croce G, Regina C, Bianchi M, Mirone V, Damiano R, Montorsi F, Salonia A.

Andrology. 2016 Sep;4(5):944-51. doi: 10.1111/andr.12232. Epub 2016 Jul 1.

157.

Re: Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database.

Gandaglia G, Mottrie A, Montorsi F, Stief C, Gratzke C.

Eur Urol. 2016 Aug;70(2):398. doi: 10.1016/j.eururo.2016.03.064. Epub 2016 Apr 18. No abstract available.

PMID:
27353964
158.

When to Perform Karyotype Analysis in Infertile Men? Validation of the European Association of Urology Guidelines with the Proposal of a New Predictive Model.

Ventimiglia E, Capogrosso P, Boeri L, Pederzoli F, Cazzaniga W, Scano R, Ippolito S, Fossati N, Alfano M, Montorsi F, Salonia A.

Eur Urol. 2016 Dec;70(6):920-923. doi: 10.1016/j.eururo.2016.06.015. Epub 2016 Jun 21.

PMID:
27343001
159.

Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study.

Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Meskawi M, Briganti A, McCormack M, Shariat SF, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):E82-6. doi: 10.5489/cuaj.3292.

160.

Rationale for local treatment in the management of metastatic prostate cancer.

Gandaglia G, Fossati N, Dell’Oglio P, Moschini M, Cucchiara V, Suardi N, Mottrie A, Mirone V, Montorsi F, Briganti A.

Curr Opin Support Palliat Care. 2016 Sep;10(3):266-72. doi: 10.1097/SPC.0000000000000218. Review.

PMID:
27328411
161.
162.

[Management of erectile dysfunction in patients with preexisting cardiovascular disease].

Gandaglia G, Montorsi F, Montorsi P.

G Ital Cardiol (Rome). 2016 May;17(5):356-62. doi: 10.1714/2252.24262. Review. Italian.

PMID:
27310909
163.

Effectiveness of a Combination of Cranberries, Lactobacillus rhamnosus, and Vitamin C for the Management of Recurrent Urinary Tract Infections in Women: Results of a Pilot Study.

Montorsi F, Gandaglia G, Salonia A, Briganti A, Mirone V.

Eur Urol. 2016 Dec;70(6):912-915. doi: 10.1016/j.eururo.2016.05.042. Epub 2016 Jun 7.

PMID:
27283213
164.

Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma.

Larcher A, Capitanio U, Terrone C, Volpe A, De Angelis P, Dehó F, Fossati N, Dell’Oglio P, Antonelli A, Furlan M, Simeone C, Serni S, Carini M, Minervini A, Fiori C, Porpiglia F, Briganti A, Montorsi F, Bertini R.

J Urol. 2016 Oct;196(4):1008-13. doi: 10.1016/j.juro.2016.04.093. Epub 2016 May 25.

165.

Avanafil – a further step to tailoring patient needs and expectations.

Boeri L, Capogrosso P, Ventimiglia E, Serino A, La Croce G, Russo A, Damiano R, Montorsi F, Salonia A.

Expert Rev Clin Pharmacol. 2016 Sep;9(9):1171-81. doi: 10.1080/17512433.2016.1195261. Epub 2016 Jun 13. Review.

PMID:
27232892
166.

Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.

Russo A, Capogrosso P, La Croce G, Ventimiglia E, Boeri L, Briganti A, Damiano R, Montorsi F, Salonia A.

Expert Opin Drug Saf. 2016 Dec;15(12):1661-1670. Epub 2016 Jun 1. Review.

PMID:
27232207
167.

Long non-coding RNAs as novel therapeutic targets in cancer.

Lavorgna G, Vago R, Sarmini M, Montorsi F, Salonia A, Bellone M.

Pharmacol Res. 2016 Aug;110:131-138. doi: 10.1016/j.phrs.2016.05.018. Epub 2016 May 19. Review.

PMID:
27210721
168.

Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.

Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groote R, Dovey Z, Suardi N, Montorsi F, Briganti A, Rocco B, Mottrie A.

Eur Urol. 2017 Feb;71(2):249-256. doi: 10.1016/j.eururo.2016.05.008. Epub 2016 May 18.

PMID:
27209538
169.

One-stage Penile Urethroplasty Using Oral Mucosal Graft and Glue.

Barbagli G, Pellegrini G, Corradini F, Montorsi F, Sansalone S, Butnaru D, Lazzeri M.

Eur Urol. 2016 Dec;70(6):1069-1075. doi: 10.1016/j.eururo.2016.04.025. Epub 2016 May 6.

PMID:
27160949
170.

Adipose-derived Stem Cells Counteract Urethral Stricture Formation in Rats.

Castiglione F, Dewulf K, Hakim L, Weyne E, Montorsi F, Russo A, Boeri L, Bivalacqua TJ, De Ridder D, Joniau S, Albersen M, Hedlund P.

Eur Urol. 2016 Dec;70(6):1032-1041. doi: 10.1016/j.eururo.2016.04.022. Epub 2016 May 3.

PMID:
27156445
172.

A minimum of 1-year follow-up for MiniArc single incision slings compared to Monarc transobturator slings: An analysis to evaluate durability of continence and medium-term outcomes.

Tutolo M, De Ridder DJ, Montorsi F, Castagna G, Deprest J, Schellart RP, Ammirati E, Van Der Aa F.

Neurourol Urodyn. 2017 Mar;36(3):803-807. doi: 10.1002/nau.23036. Epub 2016 May 5.

PMID:
27148678
173.
174.

Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study.

Cozzarini C, Noris Chiorda B, Sini C, Fiorino C, Briganti A, Montorsi F, Di Muzio N.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):690-5. doi: 10.1016/j.ijrobp.2016.01.022. Epub 2016 Jan 28.

PMID:
27131081
175.

Current Standard Technique for Modern Flexible Ureteroscopy: Tips and Tricks.

Giusti G, Proietti S, Villa L, Cloutier J, Rosso M, Gadda GM, Doizi S, Suardi N, Montorsi F, Gaboardi F, Traxer O.

Eur Urol. 2016 Jul;70(1):188-194. doi: 10.1016/j.eururo.2016.03.035. Epub 2016 Apr 14.

PMID:
27086502
176.

Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?

Rossi MS, Moschini M, Bianchi M, Gandaglia G, Fossati N, Dell’Oglio P, Schiavina R, Brunocilla E, Farina E, Picozzi M, Salonia A, Montorsi F, Briganti A.

J Sex Med. 2016 Apr;13(4):669-78. doi: 10.1016/j.jsxm.2016.02.160. Epub 2016 Mar 25.

PMID:
27045263
177.

The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status.

Moschini M, Bianchi M, Gandaglia G, Cucchiara V, Luzzago S, Pellucchi F, Damiano R, Serretta V, Briganti A, Montorsi F, Salonia A, Colombo R.

Eur Urol Focus. 2016 Apr;2(1):86-91. doi: 10.1016/j.euf.2015.03.002. Epub 2015 Jun 3.

PMID:
28723456
178.

A Clinician’s Guide to Avoiding and Managing Common Complications During and After Robot-assisted Laparoscopic Radical Prostatectomy.

Pucheril D, Campbell L, Bauer RM, Montorsi F, Sammon JD, Schlomm T.

Eur Urol Focus. 2016 Apr;2(1):30-48. doi: 10.1016/j.euf.2016.03.013. Epub 2016 Apr 13. Review.

PMID:
28723448
179.

The European Association of Urology Robotic Training Curriculum: An Update.

Mottrie A, Novara G, van der Poel H, Dasgupta P, Montorsi F, Gandaglia G.

Eur Urol Focus. 2016 Apr;2(1):105-108. doi: 10.1016/j.euf.2015.09.002. Epub 2015 Oct 1.

PMID:
28723444
180.

End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline.

Capitanio U, Larcher A, Terrone C, Antonelli A, Volpe A, Fiori C, Furlan M, Dehò F, Minervini A, Serni S, Porpiglia F, Trevisani F, Salonia A, Carini M, Simeone C, Montorsi F, Bertini R.

Eur Urol. 2016 Oct;70(4):558-561. doi: 10.1016/j.eururo.2016.03.023. Epub 2016 Mar 25.

PMID:
27021797
181.

Oncologic Surveillance for Renal Cell Carcinoma: What Is Still Needed?

Capitanio U, Gandaglia G, Larcher A, Montorsi F.

Eur Urol. 2016 Nov;70(5):899-900. doi: 10.1016/j.eururo.2016.03.030. Epub 2016 Mar 25. No abstract available.

PMID:
27021796
182.

Prostate cancer: from Gleason scoring to prognostic grade grouping.

Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB, Cheng L, Lopez-Beltran A, Briganti A, Montorsi F, Scarpelli M.

Expert Rev Anticancer Ther. 2016;16(4):433-40. doi: 10.1586/14737140.2016.1160780. Review.

PMID:
27008205
183.

Metabolic syndrome in White-European men presenting for secondary couple’s infertility: an investigation of the clinical and reproductive burden.

Ventimiglia E, Capogrosso P, Serino A, Boeri L, Colicchia M, La Croce G, Scano R, Papaleo E, Damiano R, Montorsi F, Salonia A.

Asian J Androl. 2017 May-Jun;19(3):368-373. doi: 10.4103/1008-682X.175783.

184.

Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: Development and external validation of a nomogram of clinical use.

Giganti F, Coppola A, Ambrosi A, Ravelli S, Esposito A, Freschi M, Briganti A, Scattoni V, Salonia A, Gallina A, Dehò F, Cardone G, Balconi G, Gaboardi F, Montorsi F, Maschio AD, De Cobelli F.

Urol Oncol. 2016 Jul;34(7):291.e9-291.e17. doi: 10.1016/j.urolonc.2016.02.015. Epub 2016 Mar 15.

PMID:
26992933
186.

Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).

Montorsi F, Gandaglia G, Chapple C, Cruz F, Desgrandchamps F, Llorente C.

Int J Urol. 2016 Jul;23(7):572-9. doi: 10.1111/iju.13088. Epub 2016 Mar 11.

187.

Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.

Dell’Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, Fossati N, Shariat SF, Capitanio U, Briganti A, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Eur Urol. 2016 Sep;70(3):429-35. doi: 10.1016/j.eururo.2016.02.057. Epub 2016 Mar 4.

PMID:
26951945
188.

Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit.

Cozzarini C, Briganti A, Fossati N, Montorsi F, Di Muzio N, Fiorino C.

J Clin Oncol. 2016 May 10;34(14):1704-5. doi: 10.1200/JCO.2016.66.7139. Epub 2016 Mar 7. No abstract available.

PMID:
26951317
189.

Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4.

Piva F, Santoni M, Scarpelli M, Briganti A, Lopez-Beltran A, Cheng L, Berardi R, Montorsi F, Montironi R.

Eur Urol. 2016 Sep;70(3):e72-4. doi: 10.1016/j.eururo.2016.02.049. Epub 2016 Mar 3. No abstract available.

PMID:
26947604
190.

Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.

Montorsi F, Oelke M, Henneges C, Brock G, Salonia A, d’Anzeo G, Rossi A, Mulhall JP, Büttner H.

Eur Urol. 2016 Sep;70(3):529-37. doi: 10.1016/j.eururo.2016.02.036. Epub 2016 Mar 3.

191.

Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.

Mathieu R, Lucca I, Vartolomei MD, Mbeutcha A, Klatte T, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Rieken M, Kenner L, Susani M, Wolgang L, Shariat SF.

BJU Int. 2017 Feb;119(2):234-238. doi: 10.1111/bju.13472. Epub 2016 Apr 5.

192.

Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience.

Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell’Oglio P, Cucchiara V, Capogrosso P, Shariat SF, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R.

Eur J Surg Oncol. 2016 May;42(5):735-43. doi: 10.1016/j.ejso.2016.02.011. Epub 2016 Feb 18.

PMID:
26927300
193.

How can we optimize the use of prostate cancer registries?

Gandaglia G, Fossati N, Montorsi F, Briganti A.

Future Oncol. 2016 May;12(9):1093-5. doi: 10.2217/fon-2016-0001. Epub 2016 Mar 1. No abstract available.

194.

The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.

Gandaglia G, Briganti A, Fossati N, Salonia A, Mottrie A, Catto J, Montorsi F.

Eur Urol. 2016 Oct;70(4):547-548. doi: 10.1016/j.eururo.2016.02.032. Epub 2016 Feb 22.

PMID:
26916048
195.

Diagnostic and Therapeutic Implications of Erectile Dysfunction in Patients with Cardiovascular Disease.

Gandaglia G, Briganti A, Montorsi P, Mottrie A, Salonia A, Montorsi F.

Eur Urol. 2016 Aug;70(2):219-22. doi: 10.1016/j.eururo.2016.01.054. Epub 2016 Feb 9.

PMID:
26873841
196.

Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.

Abdollah F, Dalela D, Sood A, Sammon J, Jeong W, Beyer B, Fossati N, Rogers CG, Diaz-Insua M, Peabody J, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

World J Urol. 2016 Oct;34(10):1357-66. doi: 10.1007/s00345-016-1781-y. Epub 2016 Feb 12.

PMID:
26873596
197.

Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.

Gandaglia G, Lista G, Fossati N, Suardi N, Gallina A, Moschini M, Bianchi L, Rossi MS, Schiavina R, Shariat SF, Salonia A, Montorsi F, Briganti A.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):185-90. doi: 10.1038/pcan.2016.1. Epub 2016 Feb 9.

PMID:
26857023
198.

Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution.

Moschini M, Bianchi M, Rossi MS, Dell׳Oglio P, Gandaglia G, Fossati N, Mattei A, Damiano R, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.

Urol Oncol. 2016 Jun;34(6):256.e7-256.e13. doi: 10.1016/j.urolonc.2015.12.016. Epub 2016 Feb 2.

PMID:
26850780
199.

Ureteric colic and clinical evidence.

Villa L, Salonia A, Montorsi F.

Lancet. 2015 Nov 7;386(10006):1822-3. doi: 10.1016/S0140-6736(15)00763-1. No abstract available.

PMID:
26843307
200.

Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines.

Capogrosso P, Capitanio U, La Croce G, Nini A, Salonia A, Montorsi F, Bertini R.

Eur Urol Focus. 2016 Feb;1(3):272-281. doi: 10.1016/j.euf.2015.04.001. Epub 2015 Jun 1. Review.

PMID:
28723399

Prevention and management of post prostatectomy erectile dysfunction.

Salonia A, Castagna G, Capogrosso P, Castiglione F, Briganti A, Montorsi F.

Transl Androl Urol. 2015 Aug;4(4):421-37. doi: 10.3978/j.issn.2223-4683.2013.09.10. Review.

202.

Penile rehabilitation after radical prostatectomy: does it work?

Gandaglia G, Suardi N, Cucchiara V, Bianchi M, Shariat SF, Roupret M, Salonia A, Montorsi F, Briganti A.

Transl Androl Urol. 2015 Apr;4(2):110-23. doi: 10.3978/j.issn.2223-4683.2015.02.01. Review.

203.

Men’s health and quality of life.

Capogrosso P, Montorsi F.

Curr Opin Urol. 2016 Mar;26(2):121-2. doi: 10.1097/MOU.0000000000000272. No abstract available.

PMID:
26814885
204.

Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience.

Moschini M, Gandaglia G, Dell’Oglio P, Fossati N, Cucchiara V, Burgio G, Mattei A, Damiano R, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.

Clin Genitourin Cancer. 2016 Aug;14(4):e341-6. doi: 10.1016/j.clgc.2015.12.017. Epub 2015 Dec 23.

PMID:
26797584
205.

Editorial Comment to Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.

Gandaglia G, Montorsi F, Briganti A.

Int J Urol. 2016 Apr;23(4):312. doi: 10.1111/iju.13046. Epub 2016 Jan 20. No abstract available.

206.

Comorbidities and male infertility: a worrisome picture.

Ventimiglia E, Montorsi F, Salonia A.

Curr Opin Urol. 2016 Mar;26(2):146-51. doi: 10.1097/MOU.0000000000000259. Review.

PMID:
26765042
207.

Words of Wisdom. Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer.

Gandaglia G, Briganti A, Montorsi F.

Eur Urol. 2016 Feb;69(2):370. doi: 10.1016/j.eururo.2015.10.059. No abstract available.

PMID:
26758517
208.

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.

Ventimiglia E, Capogrosso P, Montorsi F, Salonia A.

Expert Opin Drug Saf. 2016;15(2):141-52. doi: 10.1517/14740338.2016.1131818. Epub 2016 Jan 9. Review.

PMID:
26752541
209.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell’Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
210.

Men’s health and quality of life.

Capogrosso P, Montorsi F.

Curr Opin Urol. 2016 Jan 5. [Epub ahead of print] No abstract available.

PMID:
26736095
211.

Testosterone Therapy in Men With Prostate Cancer.

Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F.

Eur Urol. 2016 May;69(5):894-903. doi: 10.1016/j.eururo.2015.12.005. Epub 2015 Dec 21. Review.

212.

Erectile dysfunction in young patients is a proxy of overall men’s health status.

Capogrosso P, Montorsi F, Salonia A.

Curr Opin Urol. 2016 Mar;26(2):140-5. doi: 10.1097/MOU.0000000000000257. Review.

PMID:
26716563
213.

Predicting survival of men with recurrent prostate cancer after radical prostatectomy.

Dell’Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Moschini M, Capitanio U, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.

Eur J Cancer. 2016 Feb;54:27-34. doi: 10.1016/j.ejca.2015.11.004. Epub 2015 Dec 19.

PMID:
26707594
214.

Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.

Dell’Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).

Urol Oncol. 2016 May;34(5):234.e13-9. doi: 10.1016/j.urolonc.2015.11.018. Epub 2015 Dec 17.

PMID:
26706120
215.

Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.

Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, Bianchi M, Sacco V, Briganti A, Montorsi F, Calandrino R, Di Muzio N, Cozzarini C.

Radiother Oncol. 2016 Jan;118(1):79-84. doi: 10.1016/j.radonc.2015.11.020. Epub 2015 Dec 15.

PMID:
26702990
216.

Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings.

Villa L, Cloutier J, Letendre J, Ploumidis A, Salonia A, Cornu JN, Montorsi F, Traxer O.

World J Urol. 2016 Sep;34(9):1201-6. doi: 10.1007/s00345-015-1753-7. Epub 2015 Dec 23.

PMID:
26699629
217.

Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Conti A, Santoni M, Burattini L, Scarpelli M, Mazzucchelli R, Galosi AB, Cheng L, Lopez-Beltran A, Briganti A, Montorsi F, Montironi R.

World J Urol. 2017 Apr;35(4):517-526. doi: 10.1007/s00345-015-1752-8. Epub 2015 Dec 22. Review.

PMID:
26694187
218.

Reply from Authors re: Matthew C. Hayes, David J. Breen. Excision Versus Ablation in Renal Cancer: Optimising Outcome and Minimising Risk. Eur Urol 2016;69:683-4.

Larcher A, Fossati N, Dell’Oglio P, Montorsi F, Karakiewicz PI.

Eur Urol. 2016 Apr;69(4):684-5. doi: 10.1016/j.eururo.2015.11.035. Epub 2015 Dec 13. No abstract available.

PMID:
26691494
219.

Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis.

Moschini M, Karnes RJ, Gandaglia G, Luzzago S, Dell’Oglio P, Rossi MS, di Trapani E, La Croce G, Damiano R, Salonia A, Shariat SF, Montorsi F, Briganti A, Gallina A, Colombo R.

Urology. 2016 Feb;88:97-103. doi: 10.1016/j.urology.2015.12.005. Epub 2015 Dec 9.

PMID:
26683751
220.

Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion.

Capitanio U, Deho’ F, Dell’Oglio P, Larcher A, Capogrosso P, Nini A, Carenzi C, Freschi M, Briganti A, Salonia A, Montorsi F, Bertini R.

World J Urol. 2016 Aug;34(8):1139-45. doi: 10.1007/s00345-015-1747-5. Epub 2015 Dec 15.

PMID:
26670425
221.

The interplay of extracellular matrix and microbiome in urothelial bladder cancer.

Alfano M, Canducci F, Nebuloni M, Clementi M, Montorsi F, Salonia A.

Nat Rev Urol. 2016 Feb;13(2):77-90. doi: 10.1038/nrurol.2015.292. Epub 2015 Dec 15. Review.

PMID:
26666363
222.

Excellent Erectile Function Recovery after Focal Therapy: Is This Enough?

Gandaglia G, Briganti A, Salonia A, Montorsi F.

Eur Urol. 2016 May;69(5):852-3. doi: 10.1016/j.eururo.2015.11.014. Epub 2015 Nov 26. No abstract available.

PMID:
26632145
223.

Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?

Capogrosso P, Capitanio U, Ventimiglia E, Boeri L, Briganti A, Colombo R, Montorsi F, Salonia A.

J Endourol. 2016 Apr;30(4):400-5. doi: 10.1089/end.2015.0591. Epub 2015 Dec 30.

PMID:
26597334
224.

Orgasmic Dysfunction After Robot-assisted Versus Open Radical Prostatectomy.

Capogrosso P, Ventimiglia E, Serino A, Stabile A, Boeri L, Gandaglia G, Dehò F, Briganti A, Montorsi F, Salonia A.

Eur Urol. 2016 Aug;70(2):223-6. doi: 10.1016/j.eururo.2015.10.046. Epub 2015 Nov 10.

PMID:
26572706
225.

The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer.

Fossati N, Nguyen DP, Trinh QD, Sammon J, Sood A, Larcher A, Guazzoni G, Montorsi F, Briganti A, Menon M, Abdollah F.

J Natl Compr Canc Netw. 2015 Nov;13(11):1351-8.

PMID:
26553765
226.

Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection.

Moschini M, Fossati N, Abdollah F, Gandaglia G, Cucchiara V, Dell’Oglio P, Luzzago S, Shariat SF, Dehò F, Salonia A, Montorsi F, Briganti A.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):63-7. doi: 10.1038/pcan.2015.51. Epub 2015 Nov 10.

PMID:
26553644
227.

DFL23448, A Novel Transient Receptor Potential Melastin 8-Selective Ion Channel Antagonist, Modifies Bladder Function and Reduces Bladder Overactivity in Awake Rats.

Mistretta FA, Russo A, Castiglione F, Bettiga A, Colciago G, Montorsi F, Brandolini L, Aramini A, Bianchini G, Allegretti M, Bovolenta S, Russo R, Benigni F, Hedlund P.

J Pharmacol Exp Ther. 2016 Jan;356(1):200-11. doi: 10.1124/jpet.115.228684. Epub 2015 Nov 6.

228.

Résultats oncologiques du traitement des TVES≤pT2 de l’uretère pelvien par néphro-urétérectomie, résection segmentaire et chirurgie endoscopique : résultats d’une étude multicentrique européenne.

Nison L, Colin P, Remzi M, Shariat S, Klatte T, Yakoubi R, Bozzini G, Capitanio U, Babjuk M, Merseburger A, Cha E, Fritsche H, Novara G, Montorsi F, Hora M, Roupret M.

Prog Urol. 2015 Nov;25(13):807. doi: 10.1016/j.purol.2015.08.182. French. No abstract available.

PMID:
26544377
229.

Second-look précoce par urétéroscopie souple après traitement endoscopique conservatif pour tumeur de la voie excrétrice urinaire supérieure : résultats préliminaires.

Doizi S, Villa L, Cloutier J, Cornu J, Letendre J, Ploumidis A, Salonia A, Montorsi F, Traxer O.

Prog Urol. 2015 Nov;25(13):804. doi: 10.1016/j.purol.2015.08.175. French. No abstract available.

PMID:
26544370
230.

Doit-on porter des lunettes protectrices lors de l’utilisation du laser Holmium:YAG lors des procédures endourologiques ? Étude chez un modèle animal.

Doizi S, Villa L, Cloutier J, Compérat E, Kronenberg P, Charlotte F, Berthe L, Rouchausse Y, Salonia A, Montorsi F, Traxer O.

Prog Urol. 2015 Nov;25(13):751. doi: 10.1016/j.purol.2015.08.072. French. No abstract available.

PMID:
26544267
231.

Valeur pronostique de Caveolin-1 dans le cancer de prostate : une étude multicentrique internationale.

Mathieu R, Lucca I, Mbeutcha A, Seitz C, Karakiewicz P, Sun M, Montorsi F, Briganti A, Rouprêt M, Robinson B, Xylinas E, Shariat S.

Prog Urol. 2015 Nov;25(13):741-2. doi: 10.1016/j.purol.2015.08.053. French. No abstract available.

PMID:
26544248
232.

Prognostic marker and target in prostate cancer.

Lavorgna G, Montorsi F, Salonia A.

Aging (Albany NY). 2015 Oct;7(10):746-7. No abstract available.

233.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-33. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
234.

The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee.

Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. Review.

PMID:
26492179
235.

Expression-profiling of apoptosis induced by ablation of the long ncRNA TRPM2-AS in prostate cancer cell.

Lavorgna G, Chiacchiera F, Briganti A, Montorsi F, Pasini D, Salonia A.

Genom Data. 2014 Nov 7;3:4-5. doi: 10.1016/j.gdata.2014.10.020. eCollection 2015 Mar.

236.

Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy.

Moschini M, Gallina A, Freschi M, Luzzago S, Fossati N, Gandaglia G, Dell’oglio P, Damiano R, Serretta V, Salonia A, Montorsi F, Briganti A, Colombo R.

Urol Oncol. 2016 Feb;34(2):59.e15-22. doi: 10.1016/j.urolonc.2015.09.001. Epub 2015 Oct 9.

PMID:
26482391
237.

Confocal Laser Endomicroscopy in the Management of Endoscopically Treated Upper Urinary Tract Transitional Cell Carcinoma: Preliminary Data.

Villa L, Cloutier J, Cotè JF, Salonia A, Montorsi F, Traxer O.

J Endourol. 2016 Feb;30(2):237-42. doi: 10.1089/end.2015.0644. Epub 2015 Dec 30.

PMID:
26472615
238.

Do We Really Need to Wear Proper Eye Protection When Using Holmium:YAG Laser During Endourologic Procedures? Results from an Ex Vivo Animal Model on Pig Eyes.

Villa L, Cloutier J, Compérat E, Kronemberg P, Charlotte F, Berthe L, Rouchausse Y, Salonia A, Montorsi F, Traxer O.

J Endourol. 2016 Mar;30(3):332-7. doi: 10.1089/end.2015.0232. Epub 2015 Nov 23.

PMID:
26472513
239.

The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.

Gandaglia G, Cozzarini C, Mottrie A, Bossi A, Fossati N, Montorsi F, Briganti A.

Curr Oncol Rep. 2015 Dec;17(12):53. doi: 10.1007/s11912-015-0478-5. Review.

PMID:
26449841
240.

Effects of silodosin on sexual function – realistic picture from the everyday clinical practice.

Capogrosso P, Serino A, Ventimiglia E, Boeri L, Dehò F, Damiano R, Briganti A, Montorsi F, Salonia A.

Andrology. 2015 Nov;3(6):1076-81. doi: 10.1111/andr.12095. Epub 2015 Oct 7.

241.

Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3.

Santoni M, Scarpelli M, Lopez-Beltran A, Cheng L, Briganti A, Montorsi F, Montironi R, Santini D.

Eur Urol. 2016 Sep;70(3):e69-70. doi: 10.1016/j.eururo.2015.09.022. Epub 2015 Oct 1. No abstract available.

PMID:
26431914
242.

Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups.

Suardi N, Dell’Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, Fossati N, Lughezzani G, Karakiewicz PI, Freschi M, Lucianò R, Shariat SF, Guazzoni G, Gaboardi F, Montorsi F, Briganti A.

Urol Oncol. 2016 Feb;34(2):57.e1-7. doi: 10.1016/j.urolonc.2015.08.019. Epub 2015 Oct 1.

PMID:
26427694
243.

The Surgical Learning Curve for One-stage Anterior Urethroplasty: A Prospective Single-surgeon Study.

Fossati N, Barbagli G, Larcher A, Dell’Oglio P, Sansalone S, Lughezzani G, Guazzoni G, Montorsi F, Lazzeri M.

Eur Urol. 2016 Apr;69(4):686-90. doi: 10.1016/j.eururo.2015.09.023. Epub 2015 Oct 1.

PMID:
26427564
244.

Lower urinary tract symptoms among Caucasian-European men who have sex with men: findings from a real-life survey.

Boeri L, Capogrosso P, Ventimiglia E, Serino A, La Croce G, Russo A, Castagna G, Scano R, Briganti A, Damiano R, Montorsi F, Salonia A.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):376-81. doi: 10.1038/pcan.2015.41. Epub 2015 Sep 29.

PMID:
26415556
245.

When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database.

Abdollah F, Moschini M, Sood A, Sammon J, Dalela D, Hsu L, Beyer B, Haese A, Graefen M, Gandaglia G, Montorsi F, Briganti A, Menon M.

J Endourol. 2016 Feb;30(2):201-7. doi: 10.1089/end.2015.0465. Epub 2015 Oct 8.

PMID:
26415003
246.

Oncologic Outcomes of Robot-Assisted Radical Cystectomy: Results of a High-Volume Robotic Center.

Gandaglia G, De Groote R, Geurts N, D’Hondt F, Montorsi F, Novara G, Mottrie A.

J Endourol. 2016 Jan;30(1):75-82. doi: 10.1089/end.2015.0482. Epub 2015 Sep 24.

PMID:
26401724
247.

Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis.

Larcher A, Trudeau V, Sun M, Boehm K, Meskawi M, Tian Z, Fossati N, Dell’Oglio P, Capitanio U, Briganti A, Shariat SF, Montorsi F, Karakiewicz PI.

BJU Int. 2016 Oct;118(4):541-6. doi: 10.1111/bju.13326. Epub 2015 Oct 16.

248.

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.

Moschini M, Karnes RJ, Suardi N, Bianchi M, Pellucchi F, Rocchini L, Damiano R, Serretta V, Salonia A, Montorsi F, Briganti A, Colombo R.

Clin Genitourin Cancer. 2016 Jun;14(3):e245-50. doi: 10.1016/j.clgc.2015.08.003. Epub 2015 Aug 18.

PMID:
26382220
249.

Robot-assisted radical prostatectomy in prostate cancer.

Gandaglia G, Montorsi F, Karakiewicz PI, Sun M.

Future Oncol. 2015;11(20):2767-73. doi: 10.2217/fon.15.169. Epub 2015 Sep 11. Review.

PMID:
26358012
250.

Re: epithelial-to-mesenchymal transition in renal neoplasms.

Montironi R, Santoni M, Scarpelli M, Piva F, Lopez-Beltran A, Cheng L, Briganti A, Montorsi F.

Eur Urol. 2015 Oct;68(4):736-7. doi: 10.1016/j.eururo.2015.06.031. No abstract available.

PMID:
26334119
251.

Renal cancer.

Capitanio U, Montorsi F.

Lancet. 2016 Feb 27;387(10021):894-906. doi: 10.1016/S0140-6736(15)00046-X. Epub 2015 Aug 25. Review.

PMID:
26318520
252.

Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics.

Abdollah F, Karakiewicz PI, Gandaglia G, Dalela D, Klett DE, Shiffmann J, Montorsi F, Briganti A, Saad F, Graefen M, Peabody JO, Menon M, Sun M.

Eur Urol Focus. 2015 Sep;1(2):191-199. doi: 10.1016/j.euf.2015.06.008. Epub 2015 Jul 10.

PMID:
28723433
253.

Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy.

Moschini M, Briganti A, Murphy CR, Bianchi M, Gandaglia G, Montorsi F, Quevedo JF, Carlson R, Kwon E, Karnes RJ.

Eur Urol. 2016 Feb;69(2):193-6. doi: 10.1016/j.eururo.2015.07.047. Epub 2015 Aug 8.

PMID:
26264160
254.

Minimally Invasive Partial Nephrectomy Versus Laparoscopic Cryoablation for Patients Newly Diagnosed with a Single Small Renal Mass.

Fossati N, Larcher A, Gadda GM, Sjoberg DD, Mistretta FA, Dell’Oglio P, Lista G, Carenzi C, Lughezzani G, Lazzeri M, Montorsi F, Vickers AJ, Guazzoni G, Buffi NM.

Eur Urol Focus. 2015 Aug;1(1):66-72. doi: 10.1016/j.euf.2015.02.002. Epub 2015 May 20.

PMID:
28723359
255.

Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer?

Gandaglia G, Fossati N, Montorsi F, Briganti A.

J Clin Oncol. 2015 Sep 1;33(25):2831-2. doi: 10.1200/JCO.2015.61.0964. Epub 2015 Jul 27. No abstract available.

PMID:
26215938
256.

Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. Eur Urol 2015;67:819-22.

Piva F, Santoni M, Scarpelli M, Briganti A, Montorsi F, Montironi R.

Eur Urol. 2015 Dec;68(6):e134-5. doi: 10.1016/j.eururo.2015.07.011. Epub 2015 Jul 26. No abstract available.

PMID:
26215609
257.

RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer.

Briganti A, Gandaglia G, Fossati N, Moschini M, Montorsi F.

J Natl Cancer Inst. 2015 Jul 23;107(9). pii: djv200. doi: 10.1093/jnci/djv200. Print 2015 Sep. No abstract available.

258.

Prediction of Complications Following Partial Nephrectomy: Implications for Ablative Techniques Candidates.

Larcher A, Fossati N, Tian Z, Boehm K, Meskawi M, Valdivieso R, Trudeau V, Dell’Oglio P, Buffi N, Montorsi F, Guazzoni G, Sun M, Karakiewicz PI.

Eur Urol. 2016 Apr;69(4):676-82. doi: 10.1016/j.eururo.2015.07.003. Epub 2015 Jul 21.

PMID:
26206408
259.

A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy.

Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, Suardi N, Briganti A, Montorsi F, Cathelineau X.

World J Urol. 2016 Feb;34(2):207-13. doi: 10.1007/s00345-015-1640-2. Epub 2015 Jul 22.

PMID:
26198750
260.

Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study.

Mathieu R, Klatte T, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Kluth LA, Rieken M, Kenner L, Susani M, Robinson BD, Xylinas E, Loidl W, Shariat SF.

BJU Int. 2016 Aug;118(2):243-9. doi: 10.1111/bju.13224. Epub 2015 Aug 13.

261.

URB937, a peripherally restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E2 -induced bladder overactivity and hyperactivity of bladder mechano-afferent nerve fibres in rats.

Aizawa N, Gandaglia G, Hedlund P, Fujimura T, Fukuhara H, Montorsi F, Homma Y, Igawa Y.

BJU Int. 2016 May;117(5):821-8. doi: 10.1111/bju.13223. Epub 2015 Aug 19.

262.

Pelvic nerve injury negatively impacts female genital blood flow and induces vaginal fibrosis-implications for human nerve-sparing radical hysterectomy.

Castiglione F, Bergamini A, Albersen M, Hannan JL, Bivalacqua TJ, Bettiga A, Benigni F, Salonia A, Montorsi F, Hedlund P.

BJOG. 2015 Oct;122(11):1457-65. doi: 10.1111/1471-0528.13506. Epub 2015 Jul 14.

263.

Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.

Gandaglia G, Schiffmann J, Schlomm T, Fossati N, Moschini M, Suardi N, Chun FK, Montorsi F, Graefen M, Briganti A.

Prostate. 2015 Sep;75(13):1484-91. doi: 10.1002/pros.23040. Epub 2015 Jul 14.

PMID:
26177942
264.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559
265.

Long-term recovery of normal sexual function in testicular cancer survivors.

Capogrosso P, Boeri L, Ferrari M, Ventimiglia E, La Croce G, Capitanio U, Briganti A, Damiano R, Montorsi F, Salonia A.

Asian J Androl. 2016 Jan-Feb;18(1):85-9. doi: 10.4103/1008-682X.149180.

266.

Corrigendum to “Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort” [Eur Urol 2010;57:300-9].

Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF.

Eur Urol. 2015 Jul;68(1):171. doi: 10.1016/j.eururo.2015.02.007. Epub 2015 Feb 18. No abstract available.

PMID:
26088736
267.

Dismiss Systematic Transrectal Ultrasound-guided and Embrace Targeted Magnetic Resonance Imaging-informed Prostate Biopsy: Is the Paradigm Ready to Shift?

Giannarini G, Briganti A, Crestani A, Rossanese M, Montorsi F, Ficarra V.

Eur Urol. 2016 Mar;69(3):381-3. doi: 10.1016/j.eururo.2015.05.049. Epub 2015 Jun 10. No abstract available.

PMID:
26070515
268.

Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies.

Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Epstein JI, Cascinu S, Briganti A, Catto JW, Montorsi F, Montironi R.

Eur Urol. 2016 Feb;69(2):186-90. doi: 10.1016/j.eururo.2015.05.041. Epub 2015 Jun 10.

PMID:
26070514
269.

A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.

Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, Beyer B, Moschini M, Gratzke C, Steuber T, Suardi N, Briganti A, Manka L, Nyberg T, Dutton SJ, Wiklund P, Graefen M.

Eur Urol. 2016 May;69(5):788-94. doi: 10.1016/j.eururo.2015.05.023. Epub 2015 May 30.

PMID:
26038098
270.

Infertility as a proxy of general male health: results of a cross-sectional survey.

Ventimiglia E, Capogrosso P, Boeri L, Serino A, Colicchia M, Ippolito S, Scano R, Papaleo E, Damiano R, Montorsi F, Salonia A.

Fertil Steril. 2015 Jul;104(1):48-55. doi: 10.1016/j.fertnstert.2015.04.020. Epub 2015 May 23.

PMID:
26006735
271.

Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution.

Moschini M, Dell’ Oglio P, Capogrosso P, Cucchiara V, Luzzago S, Gandaglia G, Zattoni F, Briganti A, Damiano R, Montorsi F, Salonia A, Colombo R.

Clin Genitourin Cancer. 2015 Dec;13(6):562-7. doi: 10.1016/j.clgc.2015.04.009. Epub 2015 May 4.

PMID:
26004301
272.

Sexual and bladder comorbidity in women.

Castagna G, Montorsi F, Salonia A.

Handb Clin Neurol. 2015;130:165-76. doi: 10.1016/B978-0-444-63247-0.00010-9. Review.

PMID:
26003244
273.

Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.

Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF.

Eur Urol. 2016 May;69(5):775-87. doi: 10.1016/j.eururo.2015.04.036. Epub 2015 May 21. Review.

PMID:
26003223
274.

Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.

Nini A, Gandaglia G, Fossati N, Suardi N, Cucchiara V, Dell’Oglio P, Cazzaniga W, Luzzago S, Montorsi F, Briganti A.

Eur Urol. 2015 Nov;68(5):777-84. doi: 10.1016/j.eururo.2015.04.035. Epub 2015 May 8.

PMID:
25959166
275.

TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma.

Youssef RF, Krabbe LM, Shariat SF, Lotan Y, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F, Bolenz C, Remzi M, Bensalah K, Kassouf W, Margulis V.

World J Urol. 2015 Dec;33(12):1965-72. doi: 10.1007/s00345-015-1566-8. Epub 2015 May 10.

PMID:
25957592
276.

Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.

Sønksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C.

Eur Urol. 2015 Oct;68(4):643-52. doi: 10.1016/j.eururo.2015.04.024. Epub 2015 Apr 30.

277.

Patterns of use and patient characteristics: brachytherapy for localized prostate cancer in octo- and nonagenarians.

Valdivieso R, Boehm K, Meskawi M, Larcher A, Tian Z, Parent ME, Wong P, Graefen M, Montorsi F, Sun M, Saad F, Karakiewicz PI.

World J Urol. 2015 Dec;33(12):1985-91. doi: 10.1007/s00345-015-1553-0. Epub 2015 Apr 9.

PMID:
25854524
278.

Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.

Moschini M, Sharma V, Dell’oglio P, Cucchiara V, Gandaglia G, Cantiello F, Zattoni F, Pellucchi F, Briganti A, Damiano R, Montorsi F, Salonia A, Colombo R.

BJU Int. 2016 Apr;117(4):604-10. doi: 10.1111/bju.13146. Epub 2015 Jun 3.

279.

Reply to C.G. Rusthoven et al.

Abdollah F, Karnes RJ, Gandaglia G, Fossati N, Montorsi F, Briganti A.

J Clin Oncol. 2015 Jun 10;33(17):1989. doi: 10.1200/JCO.2015.60.9552. Epub 2015 Apr 6. No abstract available.

PMID:
25847935
280.

Effect of Tadalafil Once Daily on Penile Length Loss and Morning Erections in Patients After Bilateral Nerve-sparing Radical Prostatectomy: Results From a Randomized Controlled Trial.

Brock G, Montorsi F, Costa P, Shah N, Martinez-Jabaloyas JM, Hammerer P, Ludovico GM, Lee JC, Henneges C, Hamidi K, Rossi A, Mulhall J, Büttner H.

Urology. 2015 May;85(5):1090-6. doi: 10.1016/j.urology.2014.11.058. Epub 2015 Mar 24.

PMID:
25813656
281.
282.

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.

Nguyen HG, Tilki D, Dall’Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

J Urol. 2015 Aug;194(2):304-308. doi: 10.1016/j.juro.2015.02.2948. Epub 2015 Mar 19.

283.

Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats.

Füllhase C, Schreiber A, Giese A, Schmidt M, Montorsi F, Gratzke C, La Croce G, Castiglione F, Stief C, Hedlund P.

Neurourol Urodyn. 2016 Apr;35(4):464-70. doi: 10.1002/nau.22753. Epub 2015 Mar 18.

PMID:
25788026
284.

Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.

Fossati N, Passoni NM, Moschini M, Gandaglia G, Larcher A, Freschi M, Guazzoni G, Sjoberg DD, Vickers AJ, Montorsi F, Briganti A.

BJU Int. 2016 May;117(5):740-7. doi: 10.1111/bju.13125. Epub 2015 Jun 10.

285.

Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer.

Moschini M, Gandaglia G, Suardi N, Fossati N, Cucchiara V, Damiano R, Cantiello F, Shariat SF, Montorsi F, Briganti A.

Int J Urol. 2015 Jun;22(6):555-61. doi: 10.1111/iju.12748. Epub 2015 Mar 17.

286.

Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?

Loeb S, Montorsi F, Catto JW.

Eur Urol. 2015 Jul;68(1):1-2. doi: 10.1016/j.eururo.2015.02.038. Epub 2015 Mar 11.

287.

Corrigendum to “Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer” [Eur Urol 2013;64:865-72].

Montironi R, Montorsi F.

Eur Urol. 2015 Apr;67(4):e85. doi: 10.1016/j.eururo.2014.12.020. Epub 2014 Dec 22. No abstract available.

PMID:
25765215
288.

Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non-muscle-invasive bladder cancer. A step forward or back?

Pellucchi F, Freschi M, Moschini M, Rocchini L, Maccagnano C, Nazareno S, Bergamaschi F, Montorsi F, Colombo R.

BJU Int. 2015 Feb;115(2):267-73.

PMID:
25756136
289.

Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen.

De Cobelli F, Ravelli S, Esposito A, Giganti F, Gallina A, Montorsi F, Del Maschio A.

AJR Am J Roentgenol. 2015 Mar;204(3):550-7. doi: 10.2214/AJR.14.13146.

PMID:
25714284
290.

A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.

Gallina A, Bianchi M, Gandaglia G, Cucchiara V, Suardi N, Montorsi F, Briganti A.

Eur Urol. 2015 Nov;68(5):750-3. doi: 10.1016/j.eururo.2015.02.002. Epub 2015 Feb 17.

PMID:
25700565
291.

[¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.

Giovacchini G, Incerti E, Mapelli P, Kirienko M, Briganti A, Gandaglia G, Montorsi F, Gianolli L, Picchio M.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):877-84. doi: 10.1007/s00259-015-3015-8. Epub 2015 Feb 20.

PMID:
25697127
292.

Node-positive prostate cancer: a call for level 1 evidence.

Gandaglia G, Karnes RJ, Cozzarini C, Montorsi F, Briganti A.

Oncology (Williston Park). 2015 Feb;29(2):118, 125, 141. No abstract available.

293.

Natural history of surgically treated high-risk prostate cancer.

Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M, Graefen M, Marchioro G, Frohneberg D, Giona S, Karakiewicz PI, Van Poppel H, Montorsi F, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).

Urol Oncol. 2015 Apr;33(4):163.e7-13. doi: 10.1016/j.urolonc.2014.11.018. Epub 2015 Feb 7.

PMID:
25665508
295.

Repeated biopsy in the detection of prostate cancer: when and how many cores.

Scattoni V, Russo A, Di Trapani E, Capitanio U, La Croce G, Montorsi F.

Arch Ital Urol Androl. 2014 Dec 30;86(4):311-3. doi: 10.4081/aiua.2014.4.311. Review.

296.

Peyronie’s disease and autoimmunity—a real-life clinical study and comprehensive review.

Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, La Croce G, Russo A, Capitanio U, Briganti A, Cantiello F, Mirone V, Damiano R, Montorsi F, Salonia A.

J Sex Med. 2015 Apr;12(4):1062-9. doi: 10.1111/jsm.12825. Epub 2015 Jan 29.

PMID:
25630575
297.

What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.

Gandaglia G, Ploussard G, Isbarn H, Suardi N, De Visschere PJ, Futterer JJ, Ghadjar P, Massard C, Ost P, Sooriakumaran P, Surcel CI, van der Bergh RC, Montorsi F, Ficarra V, Giannarini G, Briganti A; Prostate Cancer Working Group of Young Academic Urologists Working Party of European Association of Urology.

Urol Oncol. 2015 Apr;33(4):164.e1-9. doi: 10.1016/j.urolonc.2014.12.011. Epub 2015 Jan 22.

PMID:
25620154
298.

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Picchio M, Mapelli P, Panebianco V, Castellucci P, Incerti E, Briganti A, Gandaglia G, Kirienko M, Barchetti F, Nanni C, Montorsi F, Gianolli L, Fanti S.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):644-55. doi: 10.1007/s00259-014-2982-5. Epub 2015 Jan 17. Review.

PMID:
25595344
299.

Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel.

Wilson TG, Guru K, Rosen RC, Wiklund P, Annerstedt M, Bochner BH, Chan KG, Montorsi F, Mottrie A, Murphy D, Novara G, Peabody JO, Palou Redorta J, Skinner EC, Thalmann G, Stenzl A, Yuh B, Catto J; Pasadena Consensus Panel.

Eur Urol. 2015 Mar;67(3):363-75. doi: 10.1016/j.eururo.2014.12.009. Epub 2015 Jan 9. Review.

PMID:
25582930
300.

Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients.

Colombo R, Pellucchi F, Moschini M, Gallina A, Bertini R, Salonia A, Rigatti P, Montorsi F.

World J Urol. 2015 Oct;33(10):1389-95. doi: 10.1007/s00345-015-1482-y. Epub 2015 Jan 11.

PMID:
25577131
301.

Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.

Yuh B, Wilson T, Bochner B, Chan K, Palou J, Stenzl A, Montorsi F, Thalmann G, Guru K, Catto JW, Wiklund PN, Novara G.

Eur Urol. 2015 Mar;67(3):402-22. doi: 10.1016/j.eururo.2014.12.008. Epub 2015 Jan 2. Review.

PMID:
25560797
302.

Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat SF, Trinh QD, Graefen M, Widmer H, Saad F, Briganti A, Montorsi F, Karakiewicz PI.

Clin Genitourin Cancer. 2015 Jun;13(3):e123-30. doi: 10.1016/j.clgc.2014.12.003. Epub 2014 Dec 9.

PMID:
25547676
303.

Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy.

Simone G, Bianchi M, Giannarelli D, Daneshmand S, Papalia R, Ferriero M, Guaglianone S, Sentinelli S, Colombo R, Montorsi F, Collura D, Muto G, Novara G, Hurle R, Rink M, Fisch M, Abol-Enein H, Miranda G, Desai M, Gill I, Gallucci M.

World J Urol. 2015 Oct;33(10):1419-28. doi: 10.1007/s00345-014-1465-4. Epub 2014 Dec 27.

PMID:
25542395
304.

Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.

Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P, Briganti A, Montorsi F, Van Poppel H, Joniau S, Spahn M.

Prostate Cancer Prostatic Dis. 2015 Mar;18(1):31-7. doi: 10.1038/pcan.2014.41. Epub 2014 Dec 23.

PMID:
25535100
305.

Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.

Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F.

Eur Urol. 2016 Jan;69(1):107-15. doi: 10.1016/j.eururo.2014.11.038. Epub 2014 Dec 4. Review.

PMID:
25481455
306.

Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer.

Larcher A, Sun M, Schiffmann J, Tian Z, Shariat SF, McCormack M, Saad F, Fossati N, Abdollah F, Briganti A, Buffi N, Graefen M, Guazzoni G, Montorsi F, Karakiewicz PI.

Eur J Surg Oncol. 2015 Mar;41(3):353-60. doi: 10.1016/j.ejso.2014.10.061. Epub 2014 Nov 21.

PMID:
25477269
307.

Contemporary 90-day mortality rates after radical cystectomy in the elderly.

Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF, McCormack M, Valiquette L, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Eur J Surg Oncol. 2014 Dec;40(12):1738-45. doi: 10.1016/j.ejso.2014.10.004. Epub 2014 Oct 15.

PMID:
25454826
308.

Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model.

Lucca I, Shariat SF, Briganti A, Lotan Y, Roehrborn CG, Montorsi F, Remzi M, Seitz C, Fajkovic H, Klingler C, Karakiewicz PI, Sun M, Rouprêt M, Loidl W, Pummer K, Klatte T.

Urol Oncol. 2015 Feb;33(2):71.e21-6. doi: 10.1016/j.urolonc.2014.08.011. Epub 2014 Oct 23.

PMID:
25443275
309.

Robot-assisted versus laparoscopic nephroureterectomy for upper-tract urothelial cancer: A population-based assessment of costs and perioperative outcomes.

Trudeau V, Gandaglia G, Shiffmann J, Popa I, Shariat SF, Montorsi F, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.

Can Urol Assoc J. 2014 Sep;8(9-10):E695-701. doi: 10.5489/cuaj.2051.

310.

Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database.

Gandaglia G, Varda B, Sood A, Pucheril D, Konijeti R, Sammon JD, Sukumar S, Menon M, Sun M, Chang SL, Montorsi F, Kibel AS, Trinh QD.

Can Urol Assoc J. 2014 Sep;8(9-10):E681-7. doi: 10.5489/cuaj.2069.

311.

Risk of myocardial infarction in patients receiving testosterone therapy: still a matter of debate.

Gandaglia G, Salonia A, Montorsi F.

Ann Pharmacother. 2014 Dec;48(12):1665-6. doi: 10.1177/1060028014553833. No abstract available.

PMID:
25388541
312.

Long-term outcomes of robot-assisted radical prostatectomy: Where do we stand?

Montorsi F, Gandaglia G, Briganti A.

BJU Int. 2015 Dec;116(6):845-6. doi: 10.1111/bju.12981. Epub 2015 May 23. No abstract available.

313.

Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts.

Ahmed K, Khan R, Mottrie A, Lovegrove C, Abaza R, Ahlawat R, Ahlering T, Ahlgren G, Artibani W, Barret E, Cathelineau X, Challacombe B, Coloby P, Khan MS, Hubert J, Michel MS, Montorsi F, Murphy D, Palou J, Patel V, Piechaud PT, Van Poppel H, Rischmann P, Sanchez-Salas R, Siemer S, Stoeckle M, Stolzenburg JU, Terrier JE, Thüroff JW, Vaessen C, Van Der Poel HG, Van Cleynenbreugel B, Volpe A, Wagner C, Wiklund P, Wilson T, Wirth M, Witt J, Dasgupta P.

BJU Int. 2015 Jul;116(1):93-101. doi: 10.1111/bju.12974. Epub 2015 Mar 23.

314.

Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.

Mathieu R, Shariat SF, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Tewari A, Montorsi F, Briganti A, Rouprêt M, Lucca I, Margulis V, Rink M, Kluth LA, Rieken M, Bachman A, Xylinas E, Robinson BD, Bensalah K, Margreiter M.

World J Urol. 2015 Aug;33(8):1165-71. doi: 10.1007/s00345-014-1421-3. Epub 2014 Oct 26.

PMID:
25344896
315.

Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?

Montironi R, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Santoni M, Briganti A, Montorsi F, Cheng L.

Diagn Pathol. 2014 Oct 18;9:190. doi: 10.1186/s13000-014-0190-z.

316.

Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses.

Larcher A, Fossati N, Mistretta F, Lughezzani G, Lista G, Dell’Oglio P, Abrate A, Sun M, Karakiewicz P, Suardi N, Lazzeri M, Montorsi F, Guazzoni G, Buffi N.

Urol Oncol. 2015 Jan;33(1):22.e1-22.e9. doi: 10.1016/j.urolonc.2014.09.003. Epub 2014 Oct 7.

PMID:
25301741
317.

Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function.

Capitanio U, Terrone C, Antonelli A, Minervini A, Volpe A, Furlan M, Matloob R, Regis F, Fiori C, Porpiglia F, Di Trapani E, Zacchero M, Serni S, Salonia A, Carini M, Simeone C, Montorsi F, Bertini R.

Eur Urol. 2015 Apr;67(4):683-9. doi: 10.1016/j.eururo.2014.09.027. Epub 2014 Oct 3.

PMID:
25282367
318.

What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer?

Briganti A, Giannarini G, Karnes RJ, Gandaglia G, Ficarra V, Montorsi F.

Eur Urol. 2015 Apr;67(4):597-8. doi: 10.1016/j.eururo.2014.09.025. Epub 2014 Oct 1. No abstract available.

PMID:
25281390
319.
320.

Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates.

Buono R, Briganti A, Freschi M, Villa L, La Croce G, Moschini M, Benigni F, Castiglione F, Montorsi F, Hedlund P.

Eur J Pharmacol. 2014 Dec 5;744:42-51. doi: 10.1016/j.ejphar.2014.09.030. Epub 2014 Sep 23.

PMID:
25261033
321.

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Vizziello D, Sun M, Karakiewicz PI, Menon M, Montorsi F, Briganti A.

J Clin Oncol. 2014 Dec 10;32(35):3939-47. doi: 10.1200/JCO.2013.54.7893. Epub 2014 Sep 22.

PMID:
25245445
322.

Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens.

Cai T, Tiscione D, Verze P, Pomara G, Racioppi M, Nesi G, Barbareschi M, Brausi M, Gacci M, Luciani LG, Liguori G, Gontero P, Campodonico F, Simonato A, Boddi V, Di Stasi SM, Colombo R, Serretta V, Carmignani G, Malossini G, Altieri V, Carini M, Terrone C, Bassi P, Montorsi F, Ficarra V, Selli C, Mirone V, Bartoletti R.

Urology. 2014 Nov;84(5):1141-6. doi: 10.1016/j.urology.2014.06.032. Epub 2014 Sep 18.

PMID:
25239253
324.

Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey.

Montorsi F, Tomlinson P.

Eur Urol. 2015 Jan;67(1):177-179. doi: 10.1016/j.eururo.2014.08.055. Epub 2014 Sep 12. No abstract available.

PMID:
25220374
325.

Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.

Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, Karakiewicz P, Guazzoni G, Montorsi F, Briganti A, Menon M, Abdollah F.

Eur Urol. 2015 Jan;67(1):3-6. doi: 10.1016/j.eururo.2014.08.056. Epub 2014 Sep 10.

PMID:
25217422
326.

Onset of hydronephrosis and lower urinary tract symptoms in a previously healthy young man: Phyllodes tumour of the prostate as a potential diagnosis.

Ferrari M, Capitanio U, Rizzo N, Freschi M, Montorsi F, Rigatti P.

Can Urol Assoc J. 2014 Jul;8(7-8):E561-3. doi: 10.5489/cuaj.1984.

327.
329.

Sentinel node biopsy for prostate cancer: a useless surgical exercise?

Montorsi F, Gandaglia G.

Eur Urol. 2014 Dec;66(6):999-1000. doi: 10.1016/j.eururo.2014.08.052. Epub 2014 Sep 6. No abstract available.

PMID:
25199716
330.

A better understating of the morphological features and molecular characteristics of intraductal carcinoma helps clinicians further explain prostate cancer aggressiveness.

Montironi R, Cheng L, Lopez-Beltran A, Scarpelli M, Montorsi F.

Eur Urol. 2015 Mar;67(3):504-7. doi: 10.1016/j.eururo.2014.08.060. Epub 2014 Sep 4. No abstract available.

PMID:
25194910
331.

Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs.

Capogrosso P, Ventimiglia E, Matloob R, Colicchia M, Serino A, Castagna G, Clementi MC, La Croce G, Capitanio U, Gandaglia G, Damiano R, Mirone V, Montorsi F, Salonia A.

World J Urol. 2015 Jun;33(6):873-80. doi: 10.1007/s00345-014-1379-1. Epub 2014 Sep 2.

PMID:
25179010
332.

Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms.

Fossati N, Sjoberg DD, Capitanio U, Gandaglia G, Larcher A, Nini A, Mirone V, Vickers AJ, Montorsi F, Briganti A.

BJU Int. 2015 Sep;116(3):366-72. doi: 10.1111/bju.12912. Epub 2015 Jan 21.

333.

Latest pharmacotherapy options for benign prostatic hyperplasia.

Russo A, La Croce G, Capogrosso P, Ventimiglia E, Colicchia M, Serino A, Mirone V, Damiano R, Montorsi F, Salonia A.

Expert Opin Pharmacother. 2014 Nov;15(16):2319-28. doi: 10.1517/14656566.2014.955470. Epub 2014 Aug 28. Review.

PMID:
25164497
334.

Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology.

Montironi R, Scarpelli M, Galosi AB, Lopez-Beltran A, Mazzucchelli R, Montorsi F, Cheng L.

Hum Pathol. 2014 Oct;45(10):2059-62. doi: 10.1016/j.humpath.2014.06.023. Epub 2014 Jul 17.

PMID:
25149553
335.

Conditional survival after radical nephroureterectomy for upper tract carcinoma.

Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, Shariat SF, Kassouf W.

Eur Urol. 2015 Apr;67(4):803-12. doi: 10.1016/j.eururo.2014.08.003. Epub 2014 Aug 19.

PMID:
25145551
336.

Effect of minimally invasive surgery on the risk for surgical site infections: results from the National Surgical Quality Improvement Program (NSQIP) Database.

Gandaglia G, Ghani KR, Sood A, Meyers JR, Sammon JD, Schmid M, Varda B, Briganti A, Montorsi F, Sun M, Menon M, Kibel AS, Trinh QD.

JAMA Surg. 2014 Oct;149(10):1039-44. doi: 10.1001/jamasurg.2014.292.

PMID:
25143176
337.

Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria.

Gandaglia G, Karakiewicz PI, Briganti A, Trudeau V, Trinh QD, Kim SP, Montorsi F, Nguyen PL, Abdollah F, Sun M.

Int J Urol. 2015 Jan;22(1):89-95. doi: 10.1111/iju.12605. Epub 2014 Aug 21.

338.

Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer.

Castiglione F, Montorsi F, Briganti A.

JAMA. 2014 Aug 20;312(7):748. doi: 10.1001/jama.2014.7920. No abstract available.

PMID:
25138338
339.

Reply to M. Valerio et al.

Giannarini G, Gandaglia G, Montorsi F, Briganti A.

J Clin Oncol. 2014 Nov 10;32(32):3681-2. doi: 10.1200/JCO.2014.57.7353. Epub 2014 Aug 18. No abstract available.

PMID:
25135993
341.

Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.

Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M.

Eur Urol. 2015 Aug;68(2):325-34. doi: 10.1016/j.eururo.2014.07.020. Epub 2014 Aug 6.

PMID:
25108577
342.

Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy.

Tilki D, Hu B, Nguyen HG, Dall’Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

J Urol. 2015 Feb;193(2):436-42. doi: 10.1016/j.juro.2014.07.087. Epub 2014 Jul 22.

PMID:
25063493
343.

Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression.

Abrate A, Buono R, Canu T, Esposito A, Del Maschio A, Lucianò R, Bettiga A, Colciago G, Guazzoni G, Benigni F, Hedlund P, Altaner C, Montorsi F, Cavarretta IT.

Eur J Cancer. 2014 Sep;50(14):2478-88. doi: 10.1016/j.ejca.2014.06.014. Epub 2014 Jul 21.

PMID:
25060826
344.

The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.

Villa L, Salonia A, Capitanio U, Scattoni V, Abdollah F, Suardi N, Dell’Oglio P, Freschi M, Montorsi F, Briganti A.

Urology. 2014 Sep;84(3):634-41. doi: 10.1016/j.urology.2014.02.070. Epub 2014 Jul 22.

PMID:
25059594
345.

Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment.

Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y, Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, Briganti A, Shariat SF.

Br J Cancer. 2014 Jul 15;111(2):213-9. doi: 10.1038/bjc.2014.311. Epub 2014 Jul 8.

346.

Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff.

Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ.

Urol Oncol. 2014 Oct;32(7):1024-30. doi: 10.1016/j.urolonc.2014.03.012. Epub 2014 Jul 2.

PMID:
24996775
347.

Effects of Difaprost® on voiding dysfunction, histology and inflammation markers in patients with benign prostatic hyperplasia who are candidates for surgical treatment.

Suardi N, Gandaglia G, Nini A, Montorsi F, Pellucchi F, Agostini A, Rigatti P.

Minerva Urol Nefrol. 2014 Jun;66(2):119-25.

PMID:
24988203
348.

Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.

Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La Macchia M, Noris Chiorda B, Rancoita PM, Suardi N, Zerbetto F, Calandrino R, Montorsi F, Di Muzio N.

Eur Urol. 2014 Dec;66(6):1024-30. doi: 10.1016/j.eururo.2014.06.012. Epub 2014 Jun 27.

PMID:
24985964
349.

Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.

Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A, Montorsi F.

Eur Urol. 2014 Oct;66(4):655-63. doi: 10.1016/j.eururo.2014.05.037. Epub 2014 Jun 18.

PMID:
24954791
350.
351.

Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer.

Orfanelli U, Jachetti E, Chiacchiera F, Grioni M, Brambilla P, Briganti A, Freschi M, Martinelli-Boneschi F, Doglioni C, Montorsi F, Bellone M, Casari G, Pasini D, Lavorgna G.

Oncogene. 2015 Apr 16;34(16):2094-102. doi: 10.1038/onc.2014.144. Epub 2014 Jun 16.

PMID:
24931166
352.

Prevalence and predictors of concomitant low sexual desire/interest and new-onset erectile dysfunction – a picture from the everyday clinical practice.

Salonia A, Clementi MC, Ventimiglia E, Colicchia M, Capogrosso P, Castiglione F, Castagna G, Boeri L, Suardi N, Cantiello F, Damiano R, Montorsi F.

Andrology. 2014 Sep;2(5):702-8. doi: 10.1111/j.2047-2927.2014.00236.x. Epub 2014 Jun 13.

353.

Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.

Moschini M, Suardi N, Pellucchi F, Rocchini L, La Croce G, Capitanio U, Briganti A, Damiano R, Montorsi F, Colombo R.

Anticancer Res. 2014 Jun;34(6):3225-30.

PMID:
24922698
354.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

Andriole GL, Bostwick DG, Gomella LG, Marberger M, Montorsi F, Tammela TL, Tindall DJ, Fowler IL, Garges HP, Wilson TH, Castro R.

Urology. 2014 Aug;84(2):393-9. doi: 10.1016/j.urology.2014.04.016. Epub 2014 Jun 7.

PMID:
24916669
355.

The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis.

Gandaglia G, Karakiewicz PI, Abdollah F, Becker A, Roghmann F, Sammon JD, Kim SP, Perrotte P, Briganti A, Montorsi F, Trinh QD, Sun M.

Eur J Surg Oncol. 2014 Dec;40(12):1706-15. doi: 10.1016/j.ejso.2014.05.001. Epub 2014 May 22.

PMID:
24915856
356.

Random biopsy: when, how many and where to take the cores?

Scattoni V, Maccagnano C, Capitanio U, Gallina A, Briganti A, Montorsi F.

World J Urol. 2014 Aug;32(4):859-69. doi: 10.1007/s00345-014-1335-0. Epub 2014 Jun 8. Review.

PMID:
24908067
357.

Bladder cancer and urothelial impairment: the role of TRPV1 as potential drug target.

Mistretta F, Buffi NM, Lughezzani G, Lista G, Larcher A, Fossati N, Abrate A, Dell’Oglio P, Montorsi F, Guazzoni G, Lazzeri M.

Biomed Res Int. 2014;2014:987149. doi: 10.1155/2014/987149. Epub 2014 May 8. Review.

358.

More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.

Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A, Moschini M, Sun M, Karakiewicz PI, Shariat SF, Montorsi F, Briganti A.

Eur Urol. 2015 Feb;67(2):212-9. doi: 10.1016/j.eururo.2014.05.011. Epub 2014 Jun 2.

PMID:
24882672
359.

Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC).

Capitanio U, Suardi N, Matloob R, Roscigno M, Abdollah F, Di Trapani E, Moschini M, Gallina A, Salonia A, Briganti A, Montorsi F, Bertini R.

BJU Int. 2014 Aug;114(2):210-5. doi: 10.1111/bju.12508. Epub 2014 May 22.

360.

Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?

Gandaglia G, Giannarini G, Suardi N, Montorsi F, Briganti A.

Eur Urol. 2014 Aug;66(2):186-7. doi: 10.1016/j.eururo.2014.04.020. Epub 2014 May 13.

PMID:
24836154
361.

Clear cell renal cell carcinoma (ccRCC) with hemangioblastoma-like features: a previously unreported pattern of ccRCC with possible clinical significance.

Montironi R, Lopez-Beltran A, Cheng L, Galosi AB, Montorsi F, Scarpelli M.

Eur Urol. 2014 Nov;66(5):806-10. doi: 10.1016/j.eururo.2014.04.022. Epub 2014 May 2.

PMID:
24821578
362.

Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy.

Gandaglia G, Gallina A, Suardi N, Abdollah F, Passoni N, Bianchi M, Zaffuto E, Nini A, Vizziello D, Salonia A, Montorsi F, Briganti A.

Int J Impot Res. 2014 Nov-Dec;26(6):201-4. doi: 10.1038/ijir.2014.10. Epub 2014 May 1.

PMID:
24784890
363.

Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era.

Gandaglia G, Sammon JD, Chang SL, Choueiri TK, Hu JC, Karakiewicz PI, Kibel AS, Kim SP, Konijeti R, Montorsi F, Nguyen PL, Sukumar S, Menon M, Sun M, Trinh QD.

J Clin Oncol. 2014 May 10;32(14):1419-26. doi: 10.1200/JCO.2013.53.5096. Epub 2014 Apr 14.

PMID:
24733797
364.

Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.

Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, Van Poppel H, Touijer K.

Eur Urol. 2015 May;67(5):839-49. doi: 10.1016/j.eururo.2014.03.019. Epub 2014 Mar 26. Review.

PMID:
24698524
365.
366.

Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?

Giannarini G, Gandaglia G, Montorsi F, Briganti A.

J Clin Oncol. 2014 May 1;32(13):1299-301. doi: 10.1200/JCO.2013.54.8214. Epub 2014 Mar 31. No abstract available.

PMID:
24687824
367.

Metabolic syndrome as a marker for prostate cancer: still a work in progress.

Gallina A, Nini A, Montorsi F, Briganti A.

Eur Urol. 2015 Jan;67(1):71-72. doi: 10.1016/j.eururo.2014.03.018. Epub 2014 Mar 25. No abstract available.

PMID:
24685434
368.

Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.

Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).

Eur Urol. 2015 Feb;67(2):319-25. doi: 10.1016/j.eururo.2014.03.013. Epub 2014 Mar 21.

PMID:
24684960
369.

Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA.

Curr Urol Rep. 2014 May;15(5):404. doi: 10.1007/s11934-014-0404-7. Review.

PMID:
24682884
370.

How to optimize patient selection for robot-assisted radical prostatectomy: functional outcome analyses from a tertiary referral center.

Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, Shariat S, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A.

J Endourol. 2014 Jul;28(7):792-800. doi: 10.1089/end.2014.0007. Epub 2014 Mar 24.

PMID:
24660774
371.

Seminal vesicle intraepithelial neoplasia versus basal cell hyperplasia in a seminal vesicle.

Montironi R, Lopez-Beltran A, Cheng L, Galosi AB, Montorsi F, Scarpelli M.

Eur Urol. 2014 Oct;66(4):623-7. doi: 10.1016/j.eururo.2014.02.054. Epub 2014 Mar 4. Review.

PMID:
24631410
372.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-E89. doi: 10.1111/bju.12732. Epub 2014 Jul 27.

373.

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.

Eur Urol. 2015 Feb;67(2):299-309. doi: 10.1016/j.eururo.2014.02.011. Epub 2014 Feb 18.

PMID:
24571959
375.

Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study.

Gandaglia G, Karakiewicz PI, Briganti A, Trinh QD, Schiffmann J, Tian Z, Kim SP, Nguyen PL, Graefen M, Montorsi F, Sun M, Abdollah F.

Ann Oncol. 2014 May;25(5):979-86. doi: 10.1093/annonc/mdu087. Epub 2014 Feb 20.

PMID:
24562445
376.

EAU policy on live surgery events.

Artibani W, Ficarra V, Challacombe BJ, Abbou CC, Bedke J, Boscolo-Berto R, Brausi M, de la Rosette JJ, Deger S, Denis L, Guazzoni G, Guillonneau B, Heesakkers JP, Jacqmin D, Knoll T, Martínez-Piñeiro L, Montorsi F, Mottrie A, Piechaud PT, Rane A, Rassweiler J, Stenzl A, Van Moorselaar J, Van Velthoven RF, van Poppel H, Wirth M, Abrahamsson PA, Parsons KF.

Eur Urol. 2014 Jul;66(1):87-97. doi: 10.1016/j.eururo.2014.01.028. Epub 2014 Jan 30. Review.

PMID:
24560818
377.

Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments.

Gandaglia G, Abdollah F, Hu J, Kim S, Briganti A, Sammon JD, Becker A, Roghmann F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI, Trinh QD, Sun M.

J Endourol. 2014 Jul;28(7):784-91. doi: 10.1089/end.2013.0774. Epub 2014 Mar 24.

PMID:
24499306
378.

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.

Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.

Eur Urol. 2014 Dec;66(6):1125-32. doi: 10.1016/j.eururo.2014.01.026. Epub 2014 Jan 28.

PMID:
24495466
379.

Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study.

Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).

Eur Urol. 2015 Jan;67(1):157-164. doi: 10.1016/j.eururo.2014.01.020. Epub 2014 Jan 25.

PMID:
24486307
380.

The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study.

Gandaglia G, Popa I, Abdollah F, Schiffmann J, Shariat SF, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI, Sun M.

Eur Urol. 2014 Sep;66(3):561-8. doi: 10.1016/j.eururo.2014.01.014. Epub 2014 Jan 24.

PMID:
24486024
381.

Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.

Gandaglia G, Sun M, Trinh QD, Becker A, Schiffmann J, Hu JC, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Abdollah F.

BJU Int. 2014 Dec;114(6b):E62-E69. doi: 10.1111/bju.12645. Epub 2014 Jul 15.

382.

Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis.

Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, Shariat SF, Rouprêt M.

BJU Int. 2014 Nov;114(5):733-40. doi: 10.1111/bju.12631. Epub 2014 Jul 27.

383.

Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.

Suardi N, Larcher A, Haese A, Ficarra V, Govorov A, Buffi NM, Walz J, Rocco B, Borghesi M, Steuber T, Pini G, Briganti A, Mottrie AM, Guazzoni G, Montorsi F, Pushkar D, Van Der Poel H; EAU Young Academic Urologists–Robotic Section.

Eur Urol. 2014 Oct;66(4):635-43. doi: 10.1016/j.eururo.2013.12.059. Epub 2014 Jan 4.

PMID:
24411992
384.

The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the “post-dissemination” period.

Gandaglia G, Trinh QD, Hu JC, Schiffmann J, Becker A, Roghmann F, Popa I, Tian Z, Perrotte P, Montorsi F, Briganti A, Karakiewicz PI, Sun M, Abdollah F.

Eur J Surg Oncol. 2014 Sep;40(9):1080-6. doi: 10.1016/j.ejso.2013.12.016. Epub 2014 Jan 2.

PMID:
24411705
385.

A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.

Ismail S, Meskawi M, Hansen J, Bianchi M, Tian Z, Latour M, Graefen M, Montorsi F, Trinh QD, Perrotte P, Karakiewicz PI, Sun M.

Crit Rev Oncol Hematol. 2014 Apr;90(1):49-57. doi: 10.1016/j.critrevonc.2013.12.003. Epub 2013 Dec 12. Review.

PMID:
24411587
386.

11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.

Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L, Schindler C, Montorsi F, Messa C, Fazio F.

J Nucl Med. 2014 Feb;55(2):233-41. doi: 10.2967/jnumed.113.123380. Epub 2014 Jan 9.

387.

Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma.

Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, Shariat SF, Robinson BD, Margulis V.

Eur Urol. 2014 Aug;66(2):379-85. doi: 10.1016/j.eururo.2013.12.008. Epub 2013 Dec 25.

PMID:
24388440
388.

Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.

Briganti A, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, Haustermans K, Hinkelbein W, Shariat SF, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):960-7. doi: 10.1016/j.ijrobp.2013.09.015. Epub 2013 Oct 23.

PMID:
24351411
389.

Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.

Eur Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.

PMID:
24345725
390.

Salvage therapy of small volume prostate cancer nodal failures: a review of the literature.

De Bari B, Alongi F, Buglione M, Campostrini F, Briganti A, Berardi G, Petralia G, Bellomi M, Chiti A, Fodor A, Suardi N, Cozzarini C, Nadia DM, Scorsetti M, Orecchia R, Montorsi F, Bertoni F, Magrini SM, Jereczek-Fossa BA.

Crit Rev Oncol Hematol. 2014 Apr;90(1):24-35. doi: 10.1016/j.critrevonc.2013.11.003. Epub 2013 Nov 21. Review.

PMID:
24315428
391.

Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.

Lazzeri M, Abrate A, Lughezzani G, Gadda GM, Freschi M, Mistretta F, Lista G, Fossati N, Larcher A, Kinzikeeva E, Buffi N, Dell’Acqua V, Bini V, Montorsi F, Guazzoni G.

Urology. 2014 Mar;83(3):606-12. doi: 10.1016/j.urology.2013.10.016. Epub 2013 Dec 6.

PMID:
24315305
393.

Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?

Youssef RF, Lotan Y, Sagalowsky AI, Shariat SF, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V.

Int Braz J Urol. 2013 Sep-Oct;39(5):614-21. doi: 10.1590/S1677-5538.IBJU.2013.05.02.

394.

Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.

Castiglione F, Benigni F, Briganti A, Salonia A, Villa L, Nini A, Di Trapani E, Capitanio U, Hedlund P, Montorsi F.

Curr Med Res Opin. 2014 Apr;30(4):719-32. doi: 10.1185/03007995.2013.861813. Epub 2013 Dec 18. Review.

PMID:
24188134
395.

External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy.

Dell’Oglio P, Abdollah F, Suardi N, Gallina A, Cucchiara V, Vizziello D, Zaffuto E, Cantiello F, Damiano R, Shariat S, Montorsi F, Briganti A.

J Endourol. 2014 Apr;28(4):416-23. doi: 10.1089/end.2013.0571. Epub 2014 Jan 9.

PMID:
24188052
396.

Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).

Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Henneges C, Dickson R, Büttner H.

Eur Urol. 2014 Mar;65(3):587-96. doi: 10.1016/j.eururo.2013.09.051. Epub 2013 Oct 13.

PMID:
24169081
397.

Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.

Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M.

Prostate. 2014 Feb;74(2):210-6. doi: 10.1002/pros.22742. Epub 2013 Oct 16.

PMID:
24132735
398.

Predictive accuracy of nephrometric scores can be improved by adding clinical patient characteristics: a novel algorithm combining anatomic tumour complexity, body mass index, and Charlson comorbidity index to depict perioperative complications after nephron-sparing surgery.

Roscigno M, Ceresoli F, Naspro R, Montorsi F, Bertini R, Da Pozzo LF.

Eur Urol. 2014 Jan;65(1):259-62. doi: 10.1016/j.eururo.2013.09.044. Epub 2013 Oct 8. No abstract available.

PMID:
24128941
399.

Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis.

Gandaglia G, Becker A, Trinh QD, Abdollah F, Schiffmann J, Roghmann F, Tian Z, Montorsi F, Briganti A, Karakiewicz PI, Sun M.

Eur J Surg Oncol. 2014 Jan;40(1):103-12. doi: 10.1016/j.ejso.2013.09.019. Epub 2013 Sep 25.

PMID:
24099755
400.

Predicting survival of patients with node-positive prostate cancer following multimodal treatment.

Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Bianchi M, Boorjian SA, Sun M, Karakiewicz PI, Montorsi F, Briganti A.

Eur Urol. 2014 Mar;65(3):554-62. doi: 10.1016/j.eururo.2013.09.025. Epub 2013 Sep 27.

PMID:
24094576
401.

Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool.

Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Rouprêt M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, Shariat SF; UTUC Collaboration.

Eur Urol. 2014 Mar;65(3):650-8. doi: 10.1016/j.eururo.2013.09.003. Epub 2013 Sep 19.

PMID:
24070577
402.

A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.

Bianchi M, Gandaglia G, Trinh QD, Hansen J, Becker A, Abdollah F, Tian Z, Lughezzani G, Roghmann F, Briganti A, Montorsi F, Karakiewicz PI, Sun M.

Urol Oncol. 2014 Jan;32(1):46.e1-7. doi: 10.1016/j.urolonc.2013.06.010. Epub 2013 Sep 17.

PMID:
24054864
403.

Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis.

Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Rouprêt M, Chun FK, Lotan Y, Roehrborn CG, Crivelli JJ, Karakiewicz PI, Scherr DS, Rink M, Graefen M, Schramek P, Briganti A, Montorsi F, Tewari A, Shariat SF.

BJU Int. 2014 Oct;114(4):503-10. doi: 10.1111/bju.12342. Epub 2014 Apr 3.

404.

Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score.

Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, Shariat SF, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK.

BJU Int. 2014 Mar;113(3):399-407. doi: 10.1111/bju.12424. Epub 2013 Dec 2.

405.

The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats.

Gandaglia G, Strittmatter F, La Croce G, Benigni F, Bettiga A, Castiglione F, Moschini M, Mistretta F, Gratzke C, Montorsi F, Stief C, Hedlund P.

Neurourol Urodyn. 2014 Nov;33(8):1251-8. doi: 10.1002/nau.22482. Epub 2013 Aug 29.

PMID:
24038381
406.

Survival after nephroureterectomy for upper tract urothelial carcinoma: a population-based competing-risks analysis.

Gandaglia G, Bianchi M, Trinh QD, Becker A, Larouche A, Abdollah F, Roghmann F, Tian Z, Shariat SF, Briganti A, Montorsi F, Karakiewicz PI, Sun M.

Int J Urol. 2014 Mar;21(3):249-56. doi: 10.1111/iju.12267. Epub 2013 Aug 29.

407.

A systematic review of the association between erectile dysfunction and cardiovascular disease.

Gandaglia G, Briganti A, Jackson G, Kloner RA, Montorsi F, Montorsi P, Vlachopoulos C.

Eur Urol. 2014 May;65(5):968-78. doi: 10.1016/j.eururo.2013.08.023. Epub 2013 Aug 23. Review.

PMID:
24011423
408.

Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis.

Ravi P, Bianchi M, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

BJU Int. 2014 May;113(5):733-40. doi: 10.1111/bju.12288. Epub 2013 Sep 5.

409.

Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study.

Mirone V, Arcaniolo D, Rivas D, Bull S, Aquilina JW, Verze P; PAUSE study team.

Eur Urol. 2014 Apr;65(4):733-9. doi: 10.1016/j.eururo.2013.08.018. Epub 2013 Aug 22.

PMID:
23993257
410.

Is erectile dysfunction a reliable indicator of general health status in men?

Salonia A, Capogrosso P, Clementi MC, Castagna G, Damiano R, Montorsi F.

Arab J Urol. 2013 Sep;11(3):203-11. doi: 10.1016/j.aju.2013.07.008. Epub 2013 Sep 14. Review.

411.

Sexual function in adult life following Passerini-Glazel feminizing genitoplasty in patients with congenital adrenal hyperplasia.

Lesma A, Bocciardi A, Corti S, Chiumello G, Rigatti P, Montorsi F.

J Urol. 2014 Jan;191(1):206-11. doi: 10.1016/j.juro.2013.07.097. Epub 2013 Aug 6.

PMID:
23933397
412.

European urology: quality, impact, online.

Catto JW, Montorsi F, Schulman C.

Eur Urol. 2013 Oct;64(4):523-4. doi: 10.1016/j.eururo.2013.07.037. Epub 2013 Aug 2.

PMID:
23928576
413.

The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis.

Abdollah F, Suardi N, Capitanio U, Matloob R, Fossati N, Castiglione F, Di Trapani E, Di Trapani D, Russo A, Carenzi C, Montorsi F, Rigatti P, Bertini R.

Urol Oncol. 2014 Jan;32(1):43.e9-16. doi: 10.1016/j.urolonc.2013.05.006. Epub 2013 Aug 2.

PMID:
23911684
414.

Predicting the risk of bone metastasis in prostate cancer.

Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V, Montorsi F.

Cancer Treat Rev. 2014 Feb;40(1):3-11. doi: 10.1016/j.ctrv.2013.07.001. Epub 2013 Jul 26. Review.

PMID:
23896177
415.

Treatment of lymph node-positive prostate cancer: teaching old dogmas new tricks.

Briganti A, Passoni NM, Abdollah F, Nini A, Montorsi F, Karnes RJ.

Eur Urol. 2014 Jan;65(1):26-7; discussion 28. doi: 10.1016/j.eururo.2013.07.003. Epub 2013 Jul 10. No abstract available.

PMID:
23886795
416.

Secondary provoked vestibulodynia in sexually active women with uncomplicated recurrent urinary tract infections.

Salonia A, Clementi MC, Graziottin A, Nappi RE, Castiglione F, Ferrari M, Capitanio U, Damiano R, Montorsi F.

J Sex Med. 2013 Sep;10(9):2265-73. doi: 10.1111/jsm.12242. Epub 2013 Jul 22.

PMID:
23875698
417.

Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.

Tilki D, Nguyen HG, Dall’Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP.

Eur Urol. 2014 Sep;66(3):577-83. doi: 10.1016/j.eururo.2013.06.048. Epub 2013 Jul 10.

PMID:
23871402
418.

Decreased transcriptional activity of calcium-sensing receptor gene promoter 1 is associated with calcium nephrolithiasis.

Vezzoli G, Terranegra A, Aloia A, Arcidiacono T, Milanesi L, Mosca E, Mingione A, Spotti D, Cusi D, Hou J, Hendy GN, Soldati L; GENIAL network (Genetics and Environment in Nephrolithiasis Italian Alliance), Paloschi V, Dogliotti E, Brasacchio C, Dell’Antonio G, Montorsi F, Bertini R, Bellinzoni P, Guazzoni G, Borghi L, Guerra A, Allegri F, Ticinesi A, Meschi T, Nouvenne A, Lupo A, Fabris A, Gambaro G, Strazzullo P, Rendina D, De Filippo G, Brandi ML, Croppi E, Cianferotti L, Trinchieri A, Caudarella R, Cupisti A, Anglani F, Del Prete D.

J Clin Endocrinol Metab. 2013 Sep;98(9):3839-47. doi: 10.1210/jc.2013-1834. Epub 2013 Jul 17.

419.

Early detection of prostate cancer: European Association of Urology recommendation.

Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M, Mottet N; European Association of Urology.

Eur Urol. 2013 Sep;64(3):347-54. doi: 10.1016/j.eururo.2013.06.051. Epub 2013 Jul 9. Review.

PMID:
23856038
420.

Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool.

Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi F, Shariat SF, Briganti A.

Eur Urol. 2014 Sep;66(3):439-46. doi: 10.1016/j.eururo.2013.06.041. Epub 2013 Jul 2.

PMID:
23850255
421.

Can side-specific biopsy findings predict the side of nodal metastasis in clinically localized prostate cancer? Results from a multicenter prospective survey.

Schiavina R, Gacci M, Briganti A, Imbimbo C, Simonato A, Borghesi M, Capitanio U, Brunocilla E, Martorana G, Carini M, Montorsi F, Mirone V, Carmignani G.

Eur J Surg Oncol. 2013 Sep;39(9):1019-24. doi: 10.1016/j.ejso.2013.06.017. Epub 2013 Jul 6.

PMID:
23838373
422.

Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection.

Abdollah F, Cozzarini C, Sun M, Suardi N, Gallina A, Passoni NM, Bianchi M, Tutolo M, Fossati N, Nini A, Dell’oglio P, Salonia A, Karakiewicz P, Montorsi F, Briganti A.

Radiother Oncol. 2013 Nov;109(2):211-6. doi: 10.1016/j.radonc.2013.05.029. Epub 2013 Jun 30.

PMID:
23823866
423.

Reply to Jérôme Verine’s letter to the editor Re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer.

Montironi R, Scarpelli M, Cheng L, Lopez-Beltran A, Kirkali Z, Montorsi F.

Eur Urol. 2013 Sep;64(3):e53-4. doi: 10.1016/j.eururo.2013.06.012. Epub 2013 Jun 19. No abstract available.

PMID:
23810095
424.

When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up.

Capitanio U, Abdollah F, Matloob R, Suardi N, Castiglione F, Di Trapani E, Capogrosso P, Gallina A, Dell’Oglio P, Briganti A, Salonia A, Montorsi F, Bertini R.

BJU Int. 2013 Jul;112(2):E59-66. doi: 10.1111/bju.12125.

425.

[Profile of silodosin].

Montorsi F.

Urologiia. 2013 Mar-Apr;(2):112-4, 116-7. Review. Russian.

PMID:
23789376
426.

Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature.

Larcher A, Broglia L, Lughezzani G, Mistretta F, Abrate A, Lista G, Fossati N, Sangalli M, Kuefner D, Cestari A, Buffi N, Lazzeri M, Guazzoni G, Montorsi F.

Curr Urol Rep. 2013 Dec;14(6):620-7. doi: 10.1007/s11934-013-0348-3. Review.

PMID:
23794125
427.

Precise morphologic documentation with large-format histology of clinical findings in a bladder cancer patient.

Galosi AB, Cheng L, Lopez-Beltran A, Montorsi F, Scarpelli M, Mazzucchelli R, Montironi R.

Eur Urol. 2013 Sep;64(3):519-21. doi: 10.1016/j.eururo.2013.06.001. Epub 2013 Jun 12. No abstract available.

PMID:
23778020
428.

Robotic prostatectomy for high-risk prostate cancer: translating the evidence into lessons for clinical practice.

Montorsi F.

Eur Urol. 2014 May;65(5):928-30. doi: 10.1016/j.eururo.2013.05.056. Epub 2013 Jun 10. No abstract available.

PMID:
23773557
429.

Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.

Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, Freschi M, Montorsi F, Briganti A.

Urol Oncol. 2014 Jan;32(1):38.e9-16. doi: 10.1016/j.urolonc.2013.03.006. Epub 2013 Jun 13.

PMID:
23769269
430.

Ventral oral mucosal onlay graft urethroplasty in nontraumatic bulbar urethral strictures: surgical technique and multivariable analysis of results in 214 patients.

Barbagli G, Montorsi F, Guazzoni G, Larcher A, Fossati N, Sansalone S, Romano G, Buffi N, Lazzeri M.

Eur Urol. 2013 Sep;64(3):440-7. doi: 10.1016/j.eururo.2013.05.046. Epub 2013 Jun 5.

PMID:
23759258
431.

Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance.

Abdollah F, Suardi N, Capitanio U, Gallina A, Sun M, Villa L, Scattoni V, Bianchi M, Tutolo M, Fossati N, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2013 Aug;112(4):E234-42. doi: 10.1111/bju.12152. Epub 2013 Jun 7.

432.

Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time.

Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):E283-9. doi: 10.1111/bju.12115.

433.

Kidney endometriosis.

Maccagnano C, Freschi M, Ghezzi M, Rocchini L, Pellucchi F, Rigatti P, Montorsi F, Colombo R.

Minerva Urol Nefrol. 2013 Jun;65(2):157-9. No abstract available.

PMID:
23703102
434.

Ureteral endometriosis: proposal for a diagnostic and therapeutic algorithm with a review of the literature.

Maccagnano C, Pellucchi F, Rocchini L, Ghezzi M, Scattoni V, Montorsi F, Rigatti P, Colombo R.

Urol Int. 2013;91(1):1-9. doi: 10.1159/000345140. Epub 2013 Jan 22. Review.

435.

Sperm banking is of key importance in patients with prostate cancer.

Salonia A, Capogrosso P, Castiglione F, Russo A, Gallina A, Ferrari M, Clementi MC, Castagna G, Briganti A, Cantiello F, Damiano R, Montorsi F.

Fertil Steril. 2013 Aug;100(2):367-72.e1. doi: 10.1016/j.fertnstert.2013.03.049. Epub 2013 May 4.

PMID:
23651627
436.

An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis.

Bianchi M, Becker A, Trinh QD, Abdollah F, Tian Z, Shariat SF, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI, Sun M.

BJU Int. 2013 Jun;111(8):1184-90. doi: 10.1111/bju.12084. Epub 2013 Apr 12.

437.

One patient out of four with newly diagnosed erectile dysfunction is a young man–worrisome picture from the everyday clinical practice.

Capogrosso P, Colicchia M, Ventimiglia E, Castagna G, Clementi MC, Suardi N, Castiglione F, Briganti A, Cantiello F, Damiano R, Montorsi F, Salonia A.

J Sex Med. 2013 Jul;10(7):1833-41. doi: 10.1111/jsm.12179. Epub 2013 May 7.

PMID:
23651423
438.

The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).

Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F.

BJU Int. 2013 Aug;112(4):432-41. doi: 10.1111/bju.12118. Epub 2013 Apr 12. Review.

439.

Central prostate pathology review: should it be mandatory?

Montironi R, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M.

Eur Urol. 2013 Aug;64(2):199-201; discussion 202-3. doi: 10.1016/j.eururo.2013.04.002. Epub 2013 Apr 16. No abstract available.

PMID:
23608669
440.

Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.

Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, Fossati N, Sun M, dell’Oglio P, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A.

Ann Oncol. 2013 Jun;24(6):1459-66. doi: 10.1093/annonc/mdt120. Epub 2013 Mar 18.

PMID:
23508825
441.

Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.

Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.

Eur Urol. 2013 Oct;64(4):557-64. doi: 10.1016/j.eururo.2013.03.006. Epub 2013 Mar 13.

PMID:
23506833
442.

Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection.

Passoni NM, Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Fossati N, Gandaglia G, Salonia A, Freschi M, Rigatti P, Montorsi F, Briganti A.

Urol Oncol. 2014 Jan;32(1):29.e21-8. doi: 10.1016/j.urolonc.2012.10.009. Epub 2013 Mar 13.

PMID:
23490908
443.

Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data.

Sun M, Trinh QD, Bianchi M, Hansen J, Abdollah F, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

BJU Int. 2014 Jan;113(1):36-42. doi: 10.1111/j.1464-410X.2012.11693.x. Epub 2013 Mar 12.

444.

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis.

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.

Cancer Epidemiol. 2013 Jun;37(3):219-25. doi: 10.1016/j.canep.2013.02.002. Epub 2013 Feb 26.

PMID:
23485480
445.

Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.

Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E, Randone D, Abdollah F, Capitanio U, Larcher A, Lista G, Gadda GM, Bini V, Montorsi F, Guazzoni G.

J Urol. 2013 Aug;190(2):496-501. doi: 10.1016/j.juro.2013.02.3184. Epub 2013 Mar 1.

PMID:
23466239
446.

Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes.

Rink M, Xylinas E, Trinh QD, Lotan Y, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration (UTUCC).

BJU Int. 2013 Sep;112(5):623-37. doi: 10.1111/bju.12014. Epub 2013 Mar 6.

447.

Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.

Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Shariat SF; UTUC Collaboration.

BJU Int. 2013 Aug;112(4):453-61. doi: 10.1111/j.1464-410X.2012.11649.x. Epub 2013 Mar 6.

448.

Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy.

Suardi N, Gallina A, Lista G, Gandaglia G, Abdollah F, Capitanio U, Dell’Oglio P, Nini A, Salonia A, Montorsi F, Briganti A.

Eur Urol. 2014 Mar;65(3):546-51. doi: 10.1016/j.eururo.2013.01.027. Epub 2013 Feb 4.

PMID:
23415377
449.

Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.

Capitanio U, Salonia A, Briganti A, Montorsi F.

Int J Clin Pract. 2013 Jun;67(6):544-51. doi: 10.1111/ijcp.12135. Epub 2013 Feb 15. Review.

PMID:
23409749
450.

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.

Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, Marberger M, Montorsi F, Novara G, Oelke M, Porst H, Roehrborn C, Stief C, McVary KT.

Eur Urol. 2013 Aug;64(2):228-43. doi: 10.1016/j.eururo.2013.01.018. Epub 2013 Jan 25. Review.

PMID:
23375241
451.

Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.

Villa L, Buono R, Fossati N, Rigatti P, Montorsi F, Benigni F, Hedlund P.

Br J Pharmacol. 2013 May;169(1):230-8. doi: 10.1111/bph.12123.

452.

Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients.

Meskawi M, Sun M, Ismail S, Bianchi M, Hansen J, Tian Z, Hanna N, Trinh QD, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Mod Pathol. 2013 Aug;26(8):1144-9. doi: 10.1038/modpathol.2012.230. Epub 2013 Feb 1. Erratum in: Mod Pathol. 2013 Aug;26(8):1152.

453.

Minimally invasive prostatic urethral lift: surgical technique and multinational experience.

McNicholas TA, Woo HH, Chin PT, Bolton D, Fernández Arjona M, Sievert KD, Schoenthaler M, Wetterauer U, Vrijhof EJ, Gange S, Montorsi F.

Eur Urol. 2013 Aug;64(2):292-9. doi: 10.1016/j.eururo.2013.01.008. Epub 2013 Jan 19.

PMID:
23357348
454.

Inhibition of phosphodiesterase 4 enhances clitoral and vaginal blood flow responses to dorsal clitoral nerve stimulation or PGE1 in anesthetized female rats.

Castiglione F, Bergamini A, Russo A, La Croce G, Castagna G, Colciago G, Salonia A, Rigatti P, Montorsi F, Hedlund P.

J Sex Med. 2013 Apr;10(4):939-50. doi: 10.1111/jsm.12058. Epub 2013 Jan 24.

PMID:
23347325
455.
456.

Erectile dysfunction in heart failure patients: a critical reappraisal.

Alberti L, Torlasco C, Lauretta L, Loffi M, Maranta F, Salonia A, Margonato A, Montorsi F, Fragasso G.

Andrology. 2013 Mar;1(2):177-91. doi: 10.1111/j.2047-2927.2012.00048.x. Epub 2013 Jan 22. Review.

457.

A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy.

Abdollah F, Sun M, Suardi N, Gallina A, Tutolo M, Passoni N, Bianchi M, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, Briganti A.

BJU Int. 2013 May;111(6):905-13. doi: 10.1111/j.1464-410X.2012.11560.x. Epub 2013 Jan 17.

458.

Diagnosis of BPH and treatment of LUTS among GPs: a European survey.

Montorsi F, Mercadante D.

Int J Clin Pract. 2013 Feb;67(2):114-9. doi: 10.1111/j.1742-1241.2012.03012.x.

PMID:
23305473
459.

External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.

Gacci M, Schiavina R, Lanciotti M, Masieri L, Serni S, Vagnoni V, Abdollah F, Carini M, Martorana G, Montorsi F.

Urol Int. 2013;90(3):277-82. doi: 10.1159/000343993. Epub 2012 Dec 22.

PMID:
23296120
460.

Circulating sex steroids and prostate cancer: introducing the time-dependency theory.

Salonia A, Abdollah F, Capitanio U, Suardi N, Gallina A, Castagna G, Clementi MC, Briganti A, Rigatti P, Montorsi F.

World J Urol. 2013 Apr;31(2):267-73. doi: 10.1007/s00345-012-1009-8. Epub 2013 Jan 3.

PMID:
23283410
461.

Response to Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.

Abdollah F, Briganti A, Montorsi F, Karakiewicz PI, Sun M.

Int J Urol. 2013 May;20(5):548-9. doi: 10.1111/iju.12063. Epub 2012 Dec 20. No abstract available.

462.

Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer.

Montironi R, Scarpelli M, Cheng L, Lopez-Beltran A, Burattini M, Kirkali Z, Montorsi F.

Eur Urol. 2013 Dec;64(6):865-72. doi: 10.1016/j.eururo.2012.11.056. Epub 2012 Dec 10. No abstract available. Erratum in: Eur Urol. 2015 Apr;67(4):e85.

PMID:
23266239
463.

Reply from Authors re: Ching-Shwun Lin, Tom F. Lue. Adipose-derived Stem Cells for the Treatment of Peyronie’s Disease? Eur Urol 2013;63:561-2: Xenogeneic Adipose Stem Cell Treatment in a Rat Model of Peyronie’s Disease.

Castiglione F, Hedlund P, Van der Aa F, Bivalacqua TJ, Rigatti P, Van Poppel H, Montorsi F, De Ridder D, Albersen M.

Eur Urol. 2013 Mar;63(3):563-4. doi: 10.1016/j.eururo.2012.12.002. Epub 2012 Dec 13. No abstract available.

PMID:
23265388
464.

Somatostatin receptor expression in prostate carcinoma: the urological pathologist’s role in the era of personalised medicine.

Montironi R, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Kirkali Z.

Pathology. 2013 Jan;45(1):93-6. doi: 10.1097/PAT.0b013e32835bae76. No abstract available.

PMID:
23255037
465.

Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy.

Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Gönen M, Shariat SF; UTUC Collaboration.

J Urol. 2013 Feb;189(2):468-73. doi: 10.1016/j.juro.2012.09.036. Epub 2012 Dec 14.

PMID:
23253960
466.

Reply to Robert P. Myers’ letter to the editor re: Francesco Montorsi, Timothy G. Wilson, Raymond C. Rosen, et al. best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena consensus panel. Eur Urol 2012;62:368-81.

Ficarra V, Novara G, Mottrie A, Wilson TG, Montorsi F.

Eur Urol. 2013 Mar;63(3):e42-3. doi: 10.1016/j.eururo.2012.11.036. Epub 2012 Nov 22. No abstract available.

PMID:
23253772
467.

Response to Re: Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer.

Abdollah F, Briganti A, Montorsi F, Karakiewicz PI, Sun M.

Int J Urol. 2013 Aug;20(8):845-6. doi: 10.1111/iju.12062. Epub 2012 Dec 16. No abstract available.

468.

Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle.

Hennenberg M, Strittmatter F, Beckmann C, Rutz B, Füllhase C, Waidelich R, Montorsi F, Hedlund P, Andersson KE, Stief CG, Gratzke C.

PLoS One. 2012;7(11):e50904. doi: 10.1371/journal.pone.0050904. Epub 2012 Nov 30.

469.

Spinal cord FAAH in normal micturition control and bladder overactivity in awake rats.

Füllhase C, Russo A, Castiglione F, Benigni F, Campeau L, Montorsi F, Gratzke C, Bettiga A, Stief C, Andersson KE, Hedlund P.

J Urol. 2013 Jun;189(6):2364-70. doi: 10.1016/j.juro.2012.11.165. Epub 2012 Dec 3.

PMID:
23219540
470.

Optimizing postoperative sexual function after radical prostatectomy.

Tutolo M, Briganti A, Suardi N, Gallina A, Abdollah F, Capitanio U, Bianchi M, Passoni N, Nini A, Fossati N, Rigatti P, Montorsi F.

Ther Adv Urol. 2012 Dec;4(6):347-65. doi: 10.1177/1756287212450063.

471.
472.

Prostate cancer detection rates in different biopsy schemes. Which cores for which patients?

Cormio L, Scattoni V, Lorusso F, Perrone A, Di Fino G, Selvaggio O, Sanguedolce F, Bufo P, Montorsi F, Carrieri G.

World J Urol. 2014 Apr;32(2):341-6. doi: 10.1007/s00345-012-0989-8. Epub 2012 Nov 25.

PMID:
23184141
473.

[11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.

Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F, Gianolli L, Messa C.

J Urol. 2013 Jan;189(1):105-10. doi: 10.1016/j.juro.2012.09.001. Epub 2012 Nov 16.

PMID:
23164385
474.

Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy.

Capitanio U, Abdollah F, Matloob R, Salonia A, Suardi N, Briganti A, Carenzi C, Rigatti P, Montorsi F, Bertini R.

Int J Urol. 2013 Jun;20(6):572-9. doi: 10.1111/iju.12004. Epub 2012 Nov 19.

475.

Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre.

Briganti A, Bianchi M, Sun M, Suardi N, Gallina A, Abdollah F, Bertini R, Colombo R, Girolamo VD, Salonia A, Scattoni V, Karakiewicz PI, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 Jun;111(8):1222-30. doi: 10.1111/j.1464-410X.2012.11464.x. Epub 2012 Nov 13.

476.

Premature ejaculation results in female sexual distress: standardization and validation of a new diagnostic tool for sexual distress.

Limoncin E, Tomassetti M, Gravina GL, Ciocca G, Carosa E, Di Sante S, Gentile V, Mirone V, Montorsi F, Lenzi A, Jannini EA.

J Urol. 2013 May;189(5):1830-5. doi: 10.1016/j.juro.2012.11.007. Epub 2012 Nov 6.

PMID:
23142691
477.

Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.

Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, Bianchi M, Sun M, Fossati N, Passoni NM, Fiorino C, Di Muzio N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A.

Eur Urol. 2013 Jun;63(6):998-1008. doi: 10.1016/j.eururo.2012.10.036. Epub 2012 Oct 26.

PMID:
23122664
478.

[Silodosin. From research to clinical application: the activity, safety and long-term effectiveness].

Russo A, Hedlund P, Montorsi F.

Urologiia. 2012 Jul-Aug;(4):104-6, 108-9. Review. Russian. No abstract available.

PMID:
23116035
479.

Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis.

Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, Shariat SF; French National Database on Upper Tract Tumors; Upper Tract Urothelial Carcinoma Collaboration.

J Urol. 2013 May;189(5):1662-9. doi: 10.1016/j.juro.2012.10.057. Epub 2012 Oct 24.

PMID:
23103802
480.

Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy.

Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, Shariat SF.

Ann Surg Oncol. 2013 Mar;20(3):1027-34. doi: 10.1245/s10434-012-2708-5. Epub 2012 Oct 26.

PMID:
23099729
481.

Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study.

Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, Shariat SF, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI.

Can Urol Assoc J. 2012 Aug;6(4):245-50. doi: 10.5489/cuaj.12032.

482.

Reply to Manish Garg, Apul Goel and Jai Prakash’s letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.

Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F.

Eur Urol. 2013 Jan;63(1):e7-8. doi: 10.1016/j.eururo.2012.09.029. Epub 2012 Sep 23. No abstract available.

PMID:
23092542
483.

Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era–an ecological study.

Salonia A, Ferrari M, Saccà A, Pellucchi F, Castagna G, Clementi MC, Matloob R, Briganti A, Rigatti P, Montorsi F.

J Sex Med. 2012 Dec;9(12):3239-46. doi: 10.1111/j.1743-6109.2012.02953.x. Epub 2012 Oct 11.

PMID:
23057479
484.

Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.

Novara G, Tubaro A, Sanseverino R, Spatafora S, Artibani W, Zattoni F, Montorsi F, Chapple CR.

World J Urol. 2013 Aug;31(4):997-1008. doi: 10.1007/s00345-012-0944-8. Epub 2012 Sep 28. Review. Erratum in: World J Urol. 2013 Aug;31(4):1009.

PMID:
23053207
485.

Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease.

Castiglione F, Hedlund P, Van der Aa F, Bivalacqua TJ, Rigatti P, Van Poppel H, Montorsi F, De Ridder D, Albersen M.

Eur Urol. 2013 Mar;63(3):551-60. doi: 10.1016/j.eururo.2012.09.034. Epub 2012 Sep 24. Erratum in: Eur Urol. 2013 Jul;64(1):e21.

486.

Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines.

Abdollah F, Abdo A, Sun M, Schmitges J, Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Urol. 2013 Apr;20(4):405-10. doi: 10.1111/j.1442-2042.2012.03171.x. Epub 2012 Oct 8.

487.

Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis.

Sun M, Bianchi M, Hansen J, Abdollah F, Trinh QD, Lughezzani G, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

Int J Urol. 2013 Apr;20(4):372-80. doi: 10.1111/j.1442-2042.2012.03170.x. Epub 2012 Oct 8.

488.

The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.

Villa L, Capitanio U, Briganti A, Abdollah F, Suardi N, Salonia A, Gallina A, Freschi M, Russo A, Castiglione F, Bianchi M, Rigatti P, Montorsi F, Scattoni V.

J Urol. 2013 Mar;189(3):854-9. doi: 10.1016/j.juro.2012.09.100. Epub 2012 Sep 25.

PMID:
23022004
489.

Clinical and diagnostic assessment for therapeutic decisions in prostate cancer.

Passoni NM, Di Trapani E, Suardi N, Gallina A, Abdollah F, Bianchi M, Picchio M, Giovacchini G, Messa C, Rigatti P, Montorsi F, Briganti A.

Q J Nucl Med Mol Imaging. 2012 Aug;56(4):321-30. Review.

490.

Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.

Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, Shariat SF.

World J Urol. 2013 Feb;31(1):5-11. doi: 10.1007/s00345-012-0939-5. Epub 2012 Sep 26.

PMID:
23011256
491.

In-hospital mortality and failure to rescue after cytoreductive nephrectomy.

Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M.

Eur Urol. 2013 Jun;63(6):1107-14. doi: 10.1016/j.eururo.2012.08.069. Epub 2012 Sep 7.

PMID:
22981674
492.

Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy.

Gandaglia G, Albersen M, Suardi N, Gallina A, Abdollah F, Castiglione F, Capitanio U, Salonia A, Rigatti P, Hedlund P, Montorsi F, Briganti A.

Int J Urol. 2013 Apr;20(4):413-9. doi: 10.1111/j.1442-2042.2012.03149.x. Epub 2012 Sep 12.

493.

Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.

Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).

Eur Urol. 2013 Apr;63(4):693-701. doi: 10.1016/j.eururo.2012.08.054. Epub 2012 Sep 5.

PMID:
22959192
494.

Erectile dysfunction as a cardiovascular risk factor in patients with diabetes.

Gandaglia G, Salonia A, Passoni N, Montorsi P, Briganti A, Montorsi F.

Endocrine. 2013 Apr;43(2):285-92. doi: 10.1007/s12020-012-9780-2. Epub 2012 Sep 5. Review.

PMID:
22948773
495.

Pelvic lymph node dissection in prostate cancer: the mystery is taking shape.

Briganti A, Suardi N, Gallina A, Abdollah F, Montorsi F.

Eur Urol. 2013 Mar;63(3):459-61. doi: 10.1016/j.eururo.2012.08.029. Epub 2012 Aug 25. No abstract available.

PMID:
22939386
496.

Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.

Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; Bladder Cancer Research Consortium.

BJU Int. 2013 Mar;111(3 Pt B):E30-6. doi: 10.1111/j.1464-410X.2012.11433.x. Epub 2012 Sep 3.

497.

In reply to Yu.

Briganti A, Abdollah F, Montorsi F, Cozzarini C.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):301-2. doi: 10.1016/j.ijrobp.2012.01.097. No abstract available.

PMID:
22935385
498.

Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer.

Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, Shariat SF.

Eur Urol. 2013 Apr;63(4):724-32. doi: 10.1016/j.eururo.2012.08.025. Epub 2012 Aug 21.

499.

Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.

Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F.

Expert Opin Pharmacother. 2012 Oct;13(14):2085-96. doi: 10.1517/14656566.2012.714368. Epub 2012 Aug 28. Review.

PMID:
22924980
500.

Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.

Lazzeri M, Briganti A, Scattoni V, Lughezzani G, Larcher A, Gadda GM, Lista G, Cestari A, Buffi N, Bini V, Freschi M, Rigatti P, Montorsi F, Guazzoni G.

J Urol. 2012 Oct;188(4):1137-43. doi: 10.1016/j.juro.2012.06.017. Epub 2012 Aug 15.

PMID:
22901578
501.

Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain.

Salonia A, Castagna G, Saccà A, Ferrari M, Capitanio U, Castiglione F, Rocchini L, Briganti A, Rigatti P, Montorsi F.

J Sex Med. 2012 Oct;9(10):2708-15. doi: 10.1111/j.1743-6109.2012.02869.x. Epub 2012 Aug 15.

PMID:
22897643
502.

The effect of gender on nephrectomy perioperative outcomes: a national survey.

Sammon J, Trinh QD, Sun M, Bianchi M, Schmitges J, Shariat SF, Ghani KR, Sukumar S, Jeldres C, Briganti A, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.

Can J Urol. 2012 Aug;19(4):6337-44.

PMID:
22892256
503.

Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades.

Adibi M, Youssef R, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V.

Int J Urol. 2012 Dec;19(12):1060-6. doi: 10.1111/j.1442-2042.2012.03110.x. Epub 2012 Aug 12.

504.

Corrigendum to “The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management” [Eur Eurol 2011;60;75-7].

Capitanio U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F, Montironi R.

Eur Urol. 2012 Aug;62(2):e47. doi: 10.1016/j.eururo.2012.05.001. Epub 2012 May 8. No abstract available.

PMID:
27989299
505.

Prostate saturation biopsy following a first negative biopsy: state of the art.

Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Saccà A, Pellucchi F, Suardi N, Abdollah F, Montorsi F, Rigatti P, Scattoni V.

Urol Int. 2012;89(2):126-35. doi: 10.1159/000339521. Epub 2012 Jul 19. Review.

506.

Diagnosis and treatment of bladder endometriosis: state of the art.

Maccagnano C, Pellucchi F, Rocchini L, Ghezzi M, Scattoni V, Montorsi F, Rigatti P, Colombo R.

Urol Int. 2012;89(3):249-58. doi: 10.1159/000339519. Epub 2012 Jul 20. Review.

507.

Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.

Porst H, Brock GB, Kula K, Moncada I, Montorsi F, Basson BR, Kinchen K, Aversa A.

J Androl. 2012 Nov-Dec;33(6):1305-22. doi: 10.2164/jandrol.111.015289. Epub 2012 Jul 12.

PMID:
22790642
508.

Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.

Chung BH, Lee SH, Roehrborn CG, Siami PF, Major-Walker K, Wilson TH, Montorsi F; CombAT Study Group.

Int J Urol. 2012 Nov;19(11):1031-5. doi: 10.1111/j.1442-2042.2012.03091.x. Epub 2012 Jul 9.

509.

Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel.

Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, Costello A, Eastham JA, Ficarra V, Guazzoni G, Menon M, Novara G, Patel VR, Stolzenburg JU, Van der Poel H, Van Poppel H, Mottrie A; Pasadena Consensus Panel.

Eur Urol. 2012 Sep;62(3):368-81. doi: 10.1016/j.eururo.2012.05.057. Epub 2012 Jun 7. Review.

PMID:
22763081
510.

Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy.

Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, Graefen M, Guazzoni G, Shariat SF, Stolzenburg JU, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Wilson TG.

Eur Urol. 2012 Sep;62(3):431-52. doi: 10.1016/j.eururo.2012.05.044. Epub 2012 Jun 2. Review.

PMID:
22749853
511.

Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy.

Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A, Menon M, Montorsi F, Patel VR, Stolzenburg JU, Van der Poel H, Wilson TG, Zattoni F, Mottrie A.

Eur Urol. 2012 Sep;62(3):405-17. doi: 10.1016/j.eururo.2012.05.045. Epub 2012 Jun 1. Review.

PMID:
22749852
512.

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy.

Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, Guazzoni G, Menon M, Patel VR, Shariat SF, Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Rosen RC, Wilson TG.

Eur Urol. 2012 Sep;62(3):382-404. doi: 10.1016/j.eururo.2012.05.047. Epub 2012 Jun 2. Review.

PMID:
22749851
513.

Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.

Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK, Wilson TG, Zattoni F, Montorsi F.

Eur Urol. 2012 Sep;62(3):418-30. doi: 10.1016/j.eururo.2012.05.046. Epub 2012 Jun 1. Review.

PMID:
22749850
514.

Focal HIFU for prostate cancer.

Lazzeri M, Guazzoni G, Montorsi F.

Lancet Oncol. 2012 Jul;13(7):e281-2; author reply e284. doi: 10.1016/S1470-2045(12)70305-4. Epub 2012 Jun 28. No abstract available.

PMID:
22748264
515.

Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.

Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration.

Eur Urol. 2013 Jun;63(6):1082-90. doi: 10.1016/j.eururo.2012.06.029. Epub 2012 Jun 22.

516.

Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy.

Gandaglia G, Suardi N, Gallina A, Abdollah F, Capitanio U, Salonia A, Colombo R, Bianchi M, Chun FK, Hansen J, Rigatti P, Montorsi F, Briganti A.

J Sex Med. 2012 Aug;9(8):2187-94. doi: 10.1111/j.1743-6109.2012.02812.x. Epub 2012 Jun 27.

PMID:
22738395
517.

Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery.

Suardi N, Moschini M, Gallina A, Gandaglia G, Abdollah F, Capitanio U, Bianchi M, Tutolo M, Passoni N, Salonia A, Hedlund P, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2013 May;111(5):717-22. doi: 10.1111/j.1464-410X.2012.11315.x. Epub 2012 Jun 21.

518.

Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis.

Capitanio U, Suardi N, Matloob R, Abdollah F, Castiglione F, Briganti A, Carenzi C, Roscigno M, Montorsi F, Bertini R.

BJU Int. 2013 Mar;111(3):412-8. doi: 10.1111/j.1464-410X.2012.11313.x. Epub 2012 Jun 15.

519.

National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer.

Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A; National Comprehensive Cancer Network.

J Urol. 2012 Aug;188(2):423-8. doi: 10.1016/j.juro.2012.03.129. Epub 2012 Jun 13.

PMID:
22698627
520.

Leydig cell tumor of the spermatic cord in an adolescent affected by congenital adrenal hyperplasia.

Ferrari M, Raber M, Capitanio U, Russo G, Ferrario M, Rizzo N, Freschi M, Rigatti P, Montorsi F.

Int J Urol. 2012 Oct;19(10):954-6. doi: 10.1111/j.1442-2042.2012.03074.x. Epub 2012 Jun 13.

521.

Do not misinterpret intraductal carcinoma of the prostate as high-grade prostatic intraepithelial neoplasia!

Montironi R, Scarpelli M, Cheng L, Lopez-Beltran A, Zhou M, Montorsi F.

Eur Urol. 2012 Sep;62(3):518-22. doi: 10.1016/j.eururo.2012.05.062. Epub 2012 Jun 5. No abstract available.

PMID:
22688084
522.

Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?

Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, Briganti A, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

J Sex Med. 2012 Nov;9(11):2961-9. doi: 10.1111/j.1743-6109.2012.02806.x. Epub 2012 Jun 6.

PMID:
22672479
523.

Posterior musculofascial reconstruction after radical prostatectomy: a systematic review of the literature.

Rocco B, Cozzi G, Spinelli MG, Coelho RF, Patel VR, Tewari A, Wiklund P, Graefen M, Mottrie A, Gaboardi F, Gill IS, Montorsi F, Artibani W, Rocco F.

Eur Urol. 2012 Nov;62(5):779-90. doi: 10.1016/j.eururo.2012.05.041. Epub 2012 May 30. Review.

PMID:
22664219
524.

Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.

Briganti A, Wiegel T, Joniau S, Cozzarini C, Bianchi M, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, Montorsi F, Van Poppel H.

Eur Urol. 2012 Sep;62(3):472-87. doi: 10.1016/j.eururo.2012.04.056. Epub 2012 May 16.

PMID:
22633803
525.

Radical prostatectomy: yes or no? Your culture makes the difference.

Lazzeri M, Montorsi F.

Eur Urol. 2012 Aug;62(2):210-2. doi: 10.1016/j.eururo.2012.05.034. Epub 2012 May 23. No abstract available.

PMID:
22633364
526.

Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.

Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F.

Eur Urol. 2012 Nov;62(5):797-802. doi: 10.1016/j.eururo.2012.05.032. Epub 2012 May 18.

PMID:
22633362
527.

Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.

Sun M, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

BJU Int. 2013 Jan;111(1):67-73. doi: 10.1111/j.1464-410X.2012.11254.x. Epub 2012 May 22.

528.

Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.

Bollito E, De Luca S, Cicilano M, Passera R, Grande S, Maccagnano C, Cappia S, Milillo A, Montorsi F, Scarpa RM, Papotti M, Randone DF.

Anal Quant Cytol Histol. 2012 Apr;34(2):96-104.

PMID:
22611765
529.

The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma.

Capitanio U, Matloob R, Suardi N, Abdollah F, Castiglione F, Di Trapani D, Russo A, Briganti A, Carenzi C, Salonia A, Montorsi F, Rigatti P, Bertini R.

Urologia. 2012 Apr-Jun;79(2):109-15. doi: 10.5301/RU.2012.9255.

530.

Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification.

Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Fossati N, Castiglione F, Freschi M, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.

Urol Oncol. 2013 Nov;31(8):1497-503. doi: 10.1016/j.urolonc.2012.04.013. Epub 2012 May 15.

PMID:
22591746
531.

Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.

Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, Colombo R, Ferrari M, Castagna G, Rigatti P, Montorsi F.

Clin Cancer Res. 2012 Jul 1;18(13):3648-57. doi: 10.1158/1078-0432.CCR-11-2799. Epub 2012 May 15.

532.

Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma.

Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration.

Eur Urol. 2014 Jan;65(1):210-7. doi: 10.1016/j.eururo.2012.04.052. Epub 2012 May 4.

PMID:
22579047
533.

Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.

Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

J Urol. 2012 Jul;188(1):73-83. doi: 10.1016/j.juro.2012.03.005. Epub 2012 May 12.

PMID:
22578732
534.

Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.

Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group.

J Urol. 2012 Jul;188(1):84-90. doi: 10.1016/j.juro.2012.02.2572. Epub 2012 May 12.

PMID:
22578727
535.

A review of integrated staging systems for renal cell carcinoma.

Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

Eur Urol. 2012 Aug;62(2):303-14. doi: 10.1016/j.eururo.2012.04.049. Epub 2012 May 3. Review.

PMID:
22575911
536.

Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function.

Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, Stief C.

Eur Urol. 2012 Aug;62(2):273-86. doi: 10.1016/j.eururo.2012.04.047. Epub 2012 May 3. Review.

PMID:
22575910
537.

Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery.

Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, Stief C.

Eur Urol. 2012 Aug;62(2):261-72. doi: 10.1016/j.eururo.2012.04.046. Epub 2012 May 3. Review.

PMID:
22575909
538.

Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.

Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Urol. 2012 Sep;19(9):836-44. doi: 10.1111/j.1442-2042.2012.03052.x. Epub 2012 May 10.

539.

Adhesion blockers: a paradigm shift in the treatment of urinary tract infections.

Lazzeri M, Guazzoni G, Montorsi F.

Eur Urol. 2012 Aug;62(2):355-6. doi: 10.1016/j.eururo.2012.04.045. Epub 2012 May 3. No abstract available.

PMID:
22561077
540.

Perioperative betamethasone treatment reduces signs of bladder dysfunction in a rat model for neurapraxia in female urogenital surgery.

Castiglione F, Bergamini A, Bettiga A, Bivalacqua TJ, Benigni F, Strittmatter F, Gandaglia G, Rigatti P, Montorsi F, Hedlund P.

Eur Urol. 2012 Dec;62(6):1076-85. doi: 10.1016/j.eururo.2012.04.037. Epub 2012 Apr 19.

541.

Prognostic role of tumour multifocality in renal cell carcinoma.

Siracusano S, Novara G, Antonelli A, Artibani W, Bertini R, Carini M, Carmignani G, Ciciliato S, Cunico SC, Lampropoulou N, Longo N, Martorana G, Minervini A, Mirone V, Simeone C, Simonato A, Valotto C, Zattoni F, Ficarra V; members of the SATURN Project – LUNA Foundation.

BJU Int. 2012 Dec;110(11 Pt B):E443-8. doi: 10.1111/j.1464-410X.2012.11121.x. Epub 2012 Apr 13.

542.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

543.

Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis.

Sun M, Bianchi M, Hansen J, Trinh QD, Abdollah F, Tian Z, Sammon J, Shariat SF, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Eur Urol. 2012 Oct;62(4):696-703. doi: 10.1016/j.eururo.2012.03.051. Epub 2012 Mar 31.

PMID:
22483407
544.

Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy.

Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Hansen J, Eichelberg C, Perrotte P, Shariat SF, Menon M, Montorsi F, Graefen M, Karakiewicz PI.

Urology. 2012 Apr;79(4):796-803. doi: 10.1016/j.urology.2011.11.061.

PMID:
22469573
545.

Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool.

Briganti A, Capitanio U, Abdollah F, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Freschi M, Rigatti P, Montorsi F.

Prostate. 2012 Apr;72(5):499-506.

PMID:
22468270
546.

Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy.

Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, Briganti A, Zanni G, Ferrari M, Castiglione F, Clementi MC, Rigatti P, Montorsi F.

World J Urol. 2013 Apr;31(2):275-80. doi: 10.1007/s00345-012-0856-7. Epub 2012 Mar 24.

PMID:
22441310
547.

A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.

Rubio-Aurioles E, Porst H, Kim ED, Montorsi F, Hackett G, Morales AM, Stuckey B, Būttner H, West TM, Huynh NN, Lenero E, Burns P, Kopernicky V.

J Sex Med. 2012 May;9(5):1418-29. doi: 10.1111/j.1743-6109.2012.02667.x. Epub 2012 Mar 16.

PMID:
22429760
548.

Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses.

Abdollah F, Sun M, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, Tian Z, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, Briganti A.

Eur Urol. 2012 Jul;62(1):42-52. doi: 10.1016/j.eururo.2012.02.057. Epub 2012 Mar 8.

PMID:
22421080
549.

Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer.

Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Urol. 2012 Jul;19(7):645-51. doi: 10.1111/j.1442-2042.2012.02993.x. Epub 2012 Mar 14.

550.

The relationship between continence and perineal body tone before and after radical prostatectomy: a pilot study.

Rigatti L, Centemero A, Lughezzani G, Larcher A, Giraudo D, Scapaticci E, Sangalli M, Lista G, Lazzeri M, Montorsi F, Rigatti P, Guazzoni G.

Neurourol Urodyn. 2012 Apr;31(4):513-6. doi: 10.1002/nau.21230. Epub 2012 Mar 6.

PMID:
22396354
551.

Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.

Clin Nucl Med. 2012 Apr;37(4):325-31. doi: 10.1097/RLU.0b013e31823363b0.

PMID:
22391699
552.

High-risk prostate cancer: from definition to contemporary management.

Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M 3rd, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ.

Eur Urol. 2012 Jun;61(6):1096-106. doi: 10.1016/j.eururo.2012.02.031. Epub 2012 Feb 24. Review.

PMID:
22386839
553.

Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.

Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC).

Eur Urol. 2012 Oct;62(4):677-84. Epub 2012 Feb 15.

PMID:
22349570
554.

International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis.

Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, Shariat SF.

BJU Int. 2012 Sep;110(5):674-81. doi: 10.1111/j.1464-410X.2012.10930.x. Epub 2012 Feb 20.

555.

Discharge patterns after radical cystectomy: contemporary trends in the United States.

Bianchi M, Trinh QD, Sun M, Sammon J, Schmitges J, Shariat SF, Sukumar S, Ghani KR, Jeldres C, Perrotte P, Rogers CG, Briganti A, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.

J Urol. 2012 Apr;187(4):1206-9. doi: 10.1016/j.juro.2011.11.097. Epub 2012 Feb 14.

PMID:
22335867
556.

Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.

Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):95-103. doi: 10.1016/j.ijrobp.2011.11.034. Epub 2012 Feb 11.

PMID:
22330991
557.

Treatment management of small renal masses in the 21st century: a paradigm shift.

Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Thuret R, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

Ann Surg Oncol. 2012 Jul;19(7):2380-7. doi: 10.1245/s10434-012-2247-0. Epub 2012 Feb 10.

PMID:
22322956
558.

Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.

Schmitges J, Trinh QD, Sun M, Hansen J, Bianchi M, Jeldres C, Perrotte P, Dahlem R, Shariat SF, Chun FK, Montorsi F, Menon M, Fisch M, Graefen M, Karakiewicz PI.

BJU Int. 2012 Sep;110(6 Pt B):E183-90. doi: 10.1111/j.1464-410X.2012.10936.x. Epub 2012 Feb 9.

559.

Venous thromboembolism after radical prostatectomy: the effect of surgical caseload.

Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Salomon G, Schlomm T, Perrotte P, Shariat SF, Montorsi F, Menon M, Graefen M, Karakiewicz PI.

BJU Int. 2012 Sep;110(6):828-33. doi: 10.1111/j.1464-410X.2012.10941.x. Epub 2012 Feb 7.

560.

Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.

Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V.

Eur Urol. 2012 Apr;61(4):818-25. doi: 10.1016/j.eururo.2012.01.021. Epub 2012 Jan 23.

PMID:
22284969
561.

Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.

Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF.

Eur Urol. 2012 May;61(5):961-71. doi: 10.1016/j.eururo.2012.01.022. Epub 2012 Jan 23. Review.

PMID:
22280856
562.

Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.

Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, Shariat SF.

J Urol. 2012 Mar;187(3):845-51. doi: 10.1016/j.juro.2011.10.158. Epub 2012 Jan 15.

PMID:
22248522
563.

Pelvic floor muscle training after prostate surgery.

Lazzeri M, Guazzoni G, Montorsi F.

Lancet. 2012 Jan 14;379(9811):120-1; author reply 121. doi: 10.1016/S0140-6736(12)60059-2. No abstract available.

PMID:
22243823
564.

Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated?

Gallina A, Ferrari M, Suardi N, Capitanio U, Abdollah F, Tutolo M, Bianchi M, Saccà A, Salonia A, Rigatti P, Montorsi F, Briganti A.

J Sex Med. 2012 Mar;9(3):903-8. doi: 10.1111/j.1743-6109.2011.02622.x. Epub 2012 Jan 12.

PMID:
22240189
565.

Extent of cancer of less than 50% in any prostate needle biopsy core: how many millimeters are there?

Montironi R, Scarpelli M, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montorsi F.

Eur Urol. 2012 Apr;61(4):751-6. doi: 10.1016/j.eururo.2011.12.050. Epub 2012 Jan 5. No abstract available.

PMID:
22239991
566.

Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series.

Hanna N, Sun M, Trinh QD, Hansen J, Bianchi M, Montorsi F, Shariat SF, Graefen M, Perrotte P, Karakiewicz PI.

Eur Urol. 2012 Apr;61(4):715-21. doi: 10.1016/j.eururo.2011.12.026. Epub 2011 Dec 22.

PMID:
22209172
567.

Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample.

Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, Bianchi M, Jeong W, Shariat SF, Hansen J, Schmitges J, Jeldres C, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.

Eur Urol. 2012 Apr;61(4):679-85. doi: 10.1016/j.eururo.2011.12.027. Epub 2011 Dec 22.

PMID:
22206800
568.

Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy.

Sun M, Abdollah F, Bianchi M, Trinh QD, Shariat SF, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Eur J Cancer. 2012 Jul;48(10):1503-11. doi: 10.1016/j.ejca.2011.11.024. Epub 2011 Dec 21.

PMID:
22196034
569.

Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy.

Briganti A, Di Trapani E, Abdollah F, Gallina A, Suardi N, Capitanio U, Tutolo M, Passoni N, Salonia A, DiGirolamo V, Colombo R, Guazzoni G, Rigatti P, Montorsi F.

J Sex Med. 2012 Feb;9(2):608-17. doi: 10.1111/j.1743-6109.2011.02580.x. Epub 2011 Dec 21.

PMID:
22189164
570.

Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy.

Gandaglia G, Suardi N, Gallina A, Capitanio U, Abdollah F, Salonia A, Nava L, Colombo R, Guazzoni G, Rigatti P, Montorsi F, Briganti A.

J Urol. 2012 Feb;187(2):569-74. doi: 10.1016/j.juro.2011.10.034. Epub 2011 Dec 15.

PMID:
22177170
571.

Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy.

Sun M, Bianchi M, Trinh QD, Abdollah F, Schmitges J, Jeldres C, Shariat SF, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

J Urol. 2012 Feb;187(2):405-10. doi: 10.1016/j.juro.2011.10.025. Epub 2011 Dec 15.

PMID:
22177151
572.

High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.

Ost P, Cozzarini C, De Meerleer G, Fiorino C, De Potter B, Briganti A, Nagler EV, Montorsi F, Fonteyne V, Di Muzio N.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):960-5. doi: 10.1016/j.ijrobp.2011.09.007. Epub 2011 Dec 13.

PMID:
22172901
573.

A non-cancer-related survival benefit is associated with partial nephrectomy.

Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI.

Eur Urol. 2012 Apr;61(4):725-31. doi: 10.1016/j.eururo.2011.11.047. Epub 2011 Dec 3.

PMID:
22172373
574.

The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy.

Schmitges J, Trinh QD, Bianchi M, Sun M, Abdollah F, Ahyai SA, Jeldres C, Steuber T, Perrotte P, Shariat SF, Menon M, Montorsi F, Graefen M, Karakiewicz PI.

Int Urol Nephrol. 2012 Jun;44(3):799-806. doi: 10.1007/s11255-011-0103-y. Epub 2011 Dec 13.

PMID:
22160759
575.

Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification.

Ficarra V, Sooriakumaran P, Novara G, Schatloff O, Briganti A, Van der Poel H, Montorsi F, Patel V, Tewari A, Mottrie A.

Eur Urol. 2012 Mar;61(3):541-8. doi: 10.1016/j.eururo.2011.11.042. Epub 2011 Dec 2. Review.

PMID:
22153926
576.

Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.

Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M.

Eur Urol. 2012 Mar;61(3):584-92. doi: 10.1016/j.eururo.2011.11.043. Epub 2011 Dec 2.

PMID:
22153925
577.

Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy.

Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Tian Z, Shariat SF, Briganti A, Perrotte P, Montorsi F, Karakiewicz PI.

Urology. 2011 Dec;78(6):1363-7. doi: 10.1016/j.urology.2011.07.1423.

PMID:
22137704
578.

Discharge patterns after radical prostatectomy in the United States of America.

Trinh QD, Bianchi M, Sun M, Sammon J, Schmitges J, Shariat SF, Sukumar S, Jeldres C, Zorn K, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.

Urol Oncol. 2013 Oct;31(7):1022-32. doi: 10.1016/j.urolonc.2011.10.007. Epub 2011 Nov 18.

PMID:
22100070
579.

Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.

Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F.

Eur Urol. 2012 Jun;61(6):1132-8. doi: 10.1016/j.eururo.2011.11.008. Epub 2011 Nov 12.

PMID:
22099610
580.

Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series.

Abdollah F, Cozzarini C, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Salonia A, La Macchia M, Di Muzio N, Rigatti P, Montorsi F, Briganti A.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):624-9. doi: 10.1016/j.ijrobp.2011.06.2014. Epub 2011 Nov 16.

PMID:
22099031
581.

Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.

Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2012 Jul;110(2 Pt 2):E64-8. doi: 10.1111/j.1464-410X.2011.10762.x. Epub 2011 Nov 17.

582.

Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years.

Suardi N, Ficarra V, Willemsen P, De Wil P, Gallina A, De Naeyer G, Schatteman P, Montorsi F, Carpentier P, Mottrie A.

Urology. 2012 Jan;79(1):133-8. doi: 10.1016/j.urology.2011.08.045. Epub 2011 Nov 16.

PMID:
22088567
583.

Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.

Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F.

Eur Urol. 2012 Mar;61(3):480-7. doi: 10.1016/j.eururo.2011.10.044. Epub 2011 Nov 7.

PMID:
22078338
584.

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.

Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.

Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.

PMID:
22078333
585.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.

586.

Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors.

Pellucchi F, Freschi M, Ibrahim B, Rocchini L, Maccagnano C, Briganti A, Rigatti P, Montorsi F, Colombo R.

J Urol. 2011 Dec;186(6):2194-9. doi: 10.1016/j.juro.2011.07.070. Epub 2011 Oct 22.

PMID:
22019037
587.

Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial.

Crescenti A, Borghi G, Bignami E, Bertarelli G, Landoni G, Casiraghi GM, Briganti A, Montorsi F, Rigatti P, Zangrillo A.

BMJ. 2011 Oct 19;343:d5701. doi: 10.1136/bmj.d5701.

588.

Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.

Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, Shariat SF.

World J Urol. 2012 Dec;30(6):753-9. doi: 10.1007/s00345-011-0772-2. Epub 2011 Oct 19.

PMID:
22009117
589.

Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: a national series.

Sun M, Abdollah F, Shariat SF, Schmitges J, Trinh QD, Tian Z, Jeldres C, Abdo A, Bianchi M, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI.

Eur J Surg Oncol. 2012 Jan;38(1):80-7. doi: 10.1016/j.ejso.2011.09.035. Epub 2011 Oct 13.

PMID:
21996370
590.

There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies.

Briganti A, Tutolo M, Suardi N, Gallina A, Abdollah F, Capitanio U, Freschi M, Bianchi M, Salonia A, Colombo R, Rigatti P, Montorsi F.

Prostate. 2012 Jun 1;72(8):925-30. doi: 10.1002/pros.21497. Epub 2011 Sep 30.

PMID:
21965006
591.

Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.

Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, Shariat SF, Zorn K, Pharand D, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

BJU Int. 2012 Jun;109(12):1807-12. doi: 10.1111/j.1464-410X.2011.10569.x. Epub 2011 Sep 27.

592.

Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.

Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT.

J Urol. 2011 Nov;186(5):2107-14. doi: 10.1016/j.juro.2011.06.048. Epub 2011 Sep 23.

PMID:
21944124
593.

Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Salonia A, Gallina A, Abdollah F, Briganti A, Capitanio U, Suardi N, Ferrari M, Raber M, Colombo R, Freschi M, Rigatti P, Montorsi F.

World J Urol. 2012 Aug;30(4):533-9. doi: 10.1007/s00345-011-0761-5. Epub 2011 Sep 21.

PMID:
21935733
594.

Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats.

Strittmatter F, Gandaglia G, Benigni F, Bettiga A, Rigatti P, Montorsi F, Gratzke C, Stief C, Colciago G, Hedlund P.

Eur Urol. 2012 Jan;61(1):98-106. doi: 10.1016/j.eururo.2011.09.002. Epub 2011 Sep 12.

PMID:
21930339
595.

Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention.

Abdollah F, Briganti A, Suardi N, Castiglione F, Gallina A, Capitanio U, Montorsi F.

Korean J Urol. 2011 Aug;52(8):507-16. doi: 10.4111/kju.2011.52.8.507. Epub 2011 Aug 22.

596.

Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.

Roscigno M, Scattoni V, Freschi M, Abdollah F, Maccagnano C, Galosi A, Lacetera V, Montironi R, Muzzonigro G, Deho F, Deiana G, Belussi D, Chinaglia D, Montorsi F, Da Pozzo LF.

BJU Int. 2012 May;109(9):1329-34. doi: 10.1111/j.1464-410X.2011.10532.x. Epub 2011 Sep 2.

597.

Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.

Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI.

Ann Oncol. 2012 Apr;23(4):973-80. doi: 10.1093/annonc/mdr362. Epub 2011 Sep 2.

PMID:
21890909
598.

Editorial Comment to Risk factors for pelvic lymphoceles post-radical prostatectomy.

Capitanio U, Suardi N, Montorsi F, Briganti A.

Int J Urol. 2011 Sep;18(9):644-5. doi: 10.1111/j.1442-2042.2011.02807.x. No abstract available.

599.

Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy.

Abdollah F, Sun M, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Shariat SF, Montorsi F, Karakiewicz PI.

BJU Int. 2012 Apr;109(8):1147-54. doi: 10.1111/j.1464-410X.2011.10482.x. Epub 2011 Aug 24.

600.

A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy.

Abdollah F, Schmitges J, Sun M, Shariat SF, Briganti A, Abdo A, Tian Z, Perrotte P, Montorsi F, Karakiewicz PI.

BJU Int. 2012 Apr;109(8):1177-82. doi: 10.1111/j.1464-410X.2011.10518.x. Epub 2011 Aug 22.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team.

Eur Urol. 2011 Nov;60(5):1105-13. doi: 10.1016/j.eururo.2011.08.005. Epub 2011 Aug 12.

PMID:
21871706
602.

Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study.

Raber M, Scattoni V, Gallina A, Freschi M, De Almeyda EP, Girolamo VD, Montorsi F, Rigatti P.

BJU Int. 2012 Mar;109(5):672-7. doi: 10.1111/j.1464-410X.2011.10522.x. Epub 2011 Aug 22.

603.

A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis.

Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Tian Z, Shariat SF, Widmer H, Zorn K, Menon M, Montorsi F, Perrotte P, Karakiewicz PI.

Eur Urol. 2011 Dec;60(6):1152-9. doi: 10.1016/j.eururo.2011.07.064. Epub 2011 Aug 5.

PMID:
21868147
604.

Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

Nickel JC, Roehrborn C, Montorsi F, Wilson TH, Rittmaster RS.

J Urol. 2011 Oct;186(4):1313-8. doi: 10.1016/j.juro.2011.05.071. Epub 2011 Aug 17.

PMID:
21849186
605.

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F.

Eur Urol. 2011 Nov;60(5):935-43. doi: 10.1016/j.eururo.2011.07.060. Epub 2011 Aug 3.

PMID:
21840116
606.

Kidney-pancreas transplantation is associated with near-normal sexual function in uremic type 1 diabetic patients.

Salonia A, D’Addio F, Gremizzi C, Briganti A, Dehò F, Caldara R, Orsenigo E, Staudacher C, Socci C, Rigatti P, Secchi A, Montorsi F, Fiorina P.

Transplantation. 2011 Oct 15;92(7):802-8. doi: 10.1097/TP.0b013e31822c6eb8.

PMID:
21822170
607.

The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme.

Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, Maccagnano C, Gallina A, Saccà A, Freschi M, Doglioni C, Rigatti P, Montorsi F.

Eur Urol. 2011 Oct;60(4):834-41. doi: 10.1016/j.eururo.2011.07.036. Epub 2011 Jul 30.

PMID:
21820797
608.

Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis.

Abdollah F, Sun M, Jeldres C, Schmitges J, Thuret R, Djahangirian O, Tian Z, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

BJU Int. 2012 Feb;109(4):564-9. doi: 10.1111/j.1464-410X.2011.10357.x. Epub 2011 Aug 2.

609.

Hospital and surgical caseload are predictors of comprehensive surgical treatment for bladder cancer: a population based study.

Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Jeldres C, Shariat SF, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI.

J Urol. 2011 Sep;186(3):824-8. doi: 10.1016/j.juro.2011.04.066. Epub 2011 Jul 23.

PMID:
21788051
610.

Influence of obesity on tumour volume in patients with prostate cancer.

Capitanio U, Suardi N, Briganti A, Gallina A, Abdollah F, Lughezzani G, Salonia A, Freschi M, Montorsi F.

BJU Int. 2012 Mar;109(5):678-84. doi: 10.1111/j.1464-410X.2011.10453.x. Epub 2011 Jul 20.

611.

[Management and prevention of catheter-associated urinary tract infections: current opinions and clinical practice].

Esposito S, Emmi V, Mennini FS, Montorsi F, Sganga G, Leone S.

Infez Med. 2011 Jun;19(2):74-90. Italian.

612.

Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.

Suardi N, Gallina A, Capitanio U, Salonia A, Lughezzani G, Freschi M, Mottrie A, Rigatti P, Montorsi F, Briganti A.

Cancer. 2012 Feb 15;118(4):973-80. doi: 10.1002/cncr.26234. Epub 2011 Jul 12. Erratum in: Cancer. 2012 May 1;118(9):2560.

613.

Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.

Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Eur Urol. 2011 Nov;60(5):920-30. doi: 10.1016/j.eururo.2011.06.039. Epub 2011 Jun 29.

PMID:
21741762
614.

Treatment of localised renal cell carcinoma.

Van Poppel H, Becker F, Cadeddu JA, Gill IS, Janetschek G, Jewett MA, Laguna MP, Marberger M, Montorsi F, Polascik TJ, Ukimura O, Zhu G.

Eur Urol. 2011 Oct;60(4):662-72. doi: 10.1016/j.eururo.2011.06.040. Epub 2011 Jun 29. Review.

PMID:
21726933
615.

A population-based analysis of temporal perioperative complication rates after minimally invasive radical prostatectomy.

Schmitges J, Trinh QD, Abdollah F, Sun M, Bianchi M, Budäus L, Zorn K, Perotte P, Schlomm T, Haese A, Montorsi F, Menon M, Graefen M, Karakiewicz PI.

Eur Urol. 2011 Sep;60(3):564-71. doi: 10.1016/j.eururo.2011.06.036. Epub 2011 Jun 25.

PMID:
21723034
616.

A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.

Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C, Shane MA, Sorsaburu S.

J Sex Med. 2011 Sep;8(9):2617-24. doi: 10.1111/j.1743-6109.2011.02353.x. Epub 2011 Jun 27.

PMID:
21707928
617.

Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy.

Youssef RF, Shariat SF, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F, Bolenz C, Margulis V.

Urol Oncol. 2013 Jul;31(5):676-81. doi: 10.1016/j.urolonc.2011.05.006. Epub 2011 Jun 25.

PMID:
21704538
618.

Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study.

Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Ann Surg Oncol. 2012 Jan;19(1):309-17. doi: 10.1245/s10434-011-1852-7. Epub 2011 Jun 24.

PMID:
21701925
619.

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

620.

Are Caucasian-European men delaying fatherhood? Results of a 7 year observational study of infertile couples with male factor infertility.

Salonia A, Matloob R, Saccà A, Ferrari M, Gallina A, Castiglione F, Abdollah F, Raber M, Brigante C, Candiani M, Rigatti P, Montorsi F.

Int J Androl. 2012 Apr;35(2):125-32. doi: 10.1111/j.1365-2605.2011.01197.x. Epub 2011 Jun 22.

PMID:
21696399
621.

Anaesthesia in transrectal prostate biopsy: which is the most effective technique?

Maccagnano C, Scattoni V, Roscigno M, Raber M, Angiolilli D, Montorsi F, Rigatti P.

Urol Int. 2011;87(1):1-13. doi: 10.1159/000327827. Epub 2011 Jun 16. Review.

622.

Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery.

Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney CP, Shariat SF.

Urol Int. 2011;87(1):42-8. doi: 10.1159/000325463. Epub 2011 Jun 9.

623.

The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study.

Abdollah F, Sun M, Thuret R, Abdo A, Morgan M, Jeldres C, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Cancer Causes Control. 2011 Aug;22(8):1085-95. doi: 10.1007/s10552-011-9784-x. Epub 2011 Jun 5.

PMID:
21643929
624.

Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma.

Bertini R, Roscigno M, Freschi M, Strada E, Angiolilli D, Petralia G, Matloob R, Sozzi F, Capitanio U, Da Pozzo LF, Colombo R, Guazzoni G, Cremonini A, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):358-65. doi: 10.1016/j.eururo.2011.05.029. Epub 2011 May 24.

PMID:
21640483
625.

Corrigendum to “Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia” [Eur Urol 2009;56:727-36].

Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L.

Eur Urol. 2011 Jun;59(6):1082. doi: 10.1016/j.eururo.2011.03.001. Epub 2011 Mar 17. No abstract available.

PMID:
27993316
626.

The contemporary concept of significant versus insignificant prostate cancer.

Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH.

Eur Urol. 2011 Aug;60(2):291-303. doi: 10.1016/j.eururo.2011.05.006. Epub 2011 May 17. Review.

PMID:
21601982
627.

Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum.

Briganti A, Suardi N, Capogrosso P, Passoni N, Freschi M, di Trapani E, Gallina A, Capitanio U, Abdollah F, Tutolo M, Bianchi M, Salonia A, Da Pozzo LF, Montorsi F, Rigatti P.

Prostate. 2012 Feb 1;72(2):186-92. doi: 10.1002/pros.21420. Epub 2011 May 2.

PMID:
21538428
628.

Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study.

Sun M, Abdollah F, Budaüs L, Liberman D, Tian Z, Morgan M, Johal R, Schmitges J, Shariat SF, Montorsi F, Greafen M, Perrotte P, Karakiewicz PI.

Ann Surg Oncol. 2011 Oct;18(10):2997-3004. doi: 10.1245/s10434-011-1722-3. Epub 2011 Apr 21.

PMID:
21509630
629.

Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy.

Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, Suardi N, Capitanio U, Salonia A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.

BJU Int. 2011 Dec;108(11):1769-75. doi: 10.1111/j.1464-410X.2011.10204.x. Epub 2011 Apr 20.

630.

Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study.

Matsumoto K, Novara G, Gupta A, Margulis V, Walton TJ, Roscigno M, Ng C, Kikuchi E, Zigeuner R, Kassouf W, Fritsche HM, Ficarra V, Martignoni G, Tritschler S, Rodriguez JC, Seitz C, Weizer A, Remzi M, Raman JD, Bolenz C, Bensalah K, Koppie TM, Karakiewicz PI, Wood CG, Montorsi F, Iwamura M, Shariat SF.

BJU Int. 2011 Oct;108(8 Pt 2):E304-9. doi: 10.1111/j.1464-410X.2011.10188.x. Epub 2011 Apr 20.

631.

Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study.

Abdollah F, Sun M, Thuret R, Schmitges J, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Ann Surg Oncol. 2011 Oct;18(10):2988-96. doi: 10.1245/s10434-011-1715-2. Epub 2011 Apr 16.

PMID:
21499808
632.

The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment.

Abdollah F, Sun M, Shariat SF, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

J Urol. 2011 Jun;185(6):2078-84. doi: 10.1016/j.juro.2011.02.022. Epub 2011 Apr 15.

PMID:
21496836
633.

Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F.

Cancer. 2011 Nov 15;117(22):5029-38. doi: 10.1002/cncr.26136. Epub 2011 Apr 14.

634.

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.

PMID:
21482022
635.

A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study.

Abdollah F, Schmitges J, Sun M, Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Prostate. 2011 Oct 1;71(14):1587-94. doi: 10.1002/pros.21376. Epub 2011 Apr 7.

PMID:
21480307
636.

The therapeutic challenge of “chronic cystitis”: search well, work together, and gain results.

Lazzeri M, Montorsi F.

Eur Urol. 2011 Jul;60(1):78-80. doi: 10.1016/j.eururo.2011.03.039. Epub 2011 Apr 1. No abstract available.

PMID:
21474233
637.

The importance of interaction between urologists and pathologists in incidental prostate cancer management.

Capitanio U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F, Montironi R.

Eur Urol. 2011 Jul;60(1):75-7. doi: 10.1016/j.eururo.2011.03.012. Epub 2011 Mar 16. No abstract available. Erratum in: Eur Urol. 2012 Aug;62(2):e47.

PMID:
21444149
638.

Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues.

Capitanio U, Montorsi F.

Eur Urol. 2011 Jun;59(6):929-30. doi: 10.1016/j.eururo.2011.03.014. Epub 2011 Mar 21. No abstract available.

PMID:
21444146
639.

Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.

Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall’Oglio M, Srougi M, Scardino PT, Eastham JA.

Eur Urol. 2011 Aug;60(2):205-10. doi: 10.1016/j.eururo.2011.03.011. Epub 2011 Mar 21.

640.

Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study.

Minervini A, Ficarra V, Rocco F, Antonelli A, Bertini R, Carmignani G, Cosciani Cunico S, Fontana D, Longo N, Martorana G, Mirone V, Morgia G, Novara G, Roscigno M, Schiavina R, Serni S, Simeone C, Simonato A, Siracusano S, Volpe A, Zattoni F, Zucchi A, Carini M; SATURN Project-LUNA Foundation.

J Urol. 2011 May;185(5):1604-10. doi: 10.1016/j.juro.2010.12.048. Epub 2011 Mar 21.

PMID:
21419454
641.

The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma.

Gurbuz C, Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V.

J Endourol. 2011 May;25(5):775-9. doi: 10.1089/end.2010.0396. Epub 2011 Mar 9.

642.

Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis.

Sun M, Abdollah F, Liberman D, Abdo A, Thuret R, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

Cancer. 2011 Sep 15;117(18):4277-85. doi: 10.1002/cncr.25969. Epub 2011 Mar 8.

643.

Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, Colombo R, Freschi M, Rigatti P, Montorsi F.

Cancer. 2011 Sep 1;117(17):3953-62. doi: 10.1002/cncr.25985. Epub 2011 Mar 1.

644.

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.

Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M.

Eur Urol. 2011 May;59(5):832-40. doi: 10.1016/j.eururo.2011.02.024. Epub 2011 Feb 22.

PMID:
21354694
645.

The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.

Montorsi F, Roehrborn C, Garcia-Penit J, Borre M, Roeleveld TA, Alimi JC, Gagnier P, Wilson TH.

BJU Int. 2011 May;107(9):1426-31. doi: 10.1111/j.1464-410X.2011.10129.x. Epub 2011 Feb 23.

646.

Surgical caseload is an important determinant of continent urinary diversion rate at radical cystectomy: a population-based study.

Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI.

Ann Surg Oncol. 2011 Sep;18(9):2680-7. doi: 10.1245/s10434-011-1618-2. Epub 2011 Feb 23.

PMID:
21347778
647.

Diagnosis of high-grade prostatic intraepithelial neoplasia: the impact of the number of biopsy cores at initial sampling on cancer detection after a saturation re-biopsy.

Roscigno M, Scattoni V, Freschi M, Raber M, Angiolilli D, Galosi A, Lacetera V, Montironi R, Muzzonigro G, Deho F, Feroldi L, Deiana G, Chinaglia D, Montorsi F, Da Pozzo LF.

Arch Ital Urol Androl. 2010 Dec;82(4):242-7.

PMID:
21341572
648.

Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.

Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Kabbani W, Langner C, Guo CC, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V.

BJU Int. 2011 Oct;108(8):1286-91. doi: 10.1111/j.1464-410X.2011.10075.x. Epub 2011 Feb 18.

649.

Toxicities of targeted therapy and their management in kidney cancer.

Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C.

Eur Urol. 2011 Apr;59(4):526-40. doi: 10.1016/j.eururo.2011.01.002. Epub 2011 Jan 14. Review.

PMID:
21277078
650.

Corrigendum to “Profile of Silodosin” [Eur Urol Suppl 2010;9:491-5].

Montorsi F.

Eur Urol. 2011 Feb;59(2):315. doi: 10.1016/j.eururo.2010.11.014. Epub 2010 Nov 21. No abstract available.

PMID:
27989507
651.

What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy?

Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, Salonia A, Colombo R, Di Girolamo V, Martinez-Salamanca JI, Guazzoni G, Rigatti P, Montorsi F.

J Sex Med. 2011 Apr;8(4):1210-7. doi: 10.1111/j.1743-6109.2010.02179.x. Epub 2011 Jan 26.

PMID:
21269392
652.

Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder.

Liberman D, Lughezzani G, Sun M, Alasker A, Thuret R, Abdollah F, Budaus L, Widmer H, Graefen M, Montorsi F, Shariat SF, Perrotte P, Karakiewicz PI.

Urology. 2011 Mar;77(3):660-6. doi: 10.1016/j.urology.2010.07.537. Epub 2011 Jan 22.

PMID:
21256568
653.

Impact of caseload on total hospital charges: a direct comparison between minimally invasive and open radical prostatectomy–a population based study.

Abdollah F, Budäus L, Sun M, Morgan M, Johal R, Thuret R, Zorn KC, Isbarn H, Haese A, Jeldres C, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI.

J Urol. 2011 Mar;185(3):855-61. doi: 10.1016/j.juro.2010.10.051. Epub 2011 Jan 15.

PMID:
21238994
654.

When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy?

Capitanio U, Briganti A, Suardi N, Gallina A, Salonia A, Freschi M, Rigatti P, Montorsi F.

Int J Urol. 2011 Feb;18(2):148-53. doi: 10.1111/j.1442-2042.2010.02689.x. Epub 2010 Dec 30.

655.

Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats.

Russo A, Castiglione F, Salonia A, Benigni F, Rigatti P, Montorsi F, Andersson KE, Hedlund P.

Eur Urol. 2011 May;59(5):868-74. doi: 10.1016/j.eururo.2010.12.007. Epub 2010 Dec 21.

PMID:
21196074
656.

Corrigendum to “Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed?” [Eur Urol 2010;58:588-95].

Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cunico SC, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V, Montorsi F, Schiavina R, Simeone C, Serni S, Simonato A, Siracusano S, Volpe A, Carmignani G; members of the SATURN Project–LUNA Foundation 1.

Eur Urol. 2011 Jan;59(1):182. doi: 10.1016/j.eururo.2010.10.017. Epub 2010 Oct 15. No abstract available.

PMID:
27989306
657.

Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma.

Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V.

Urology. 2011 Apr;77(4):861-6. doi: 10.1016/j.urology.2010.09.032. Epub 2010 Dec 16.

PMID:
21167566
658.

The impact of surgical experience on total hospital charges for minimally invasive prostatectomy: a population-based study.

Budäus L, Abdollah F, Sun M, Johal R, Morgan M, Thuret R, Zorn KC, Lughezzani G, Isbarn H, Haese A, Shariat SF, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI.

BJU Int. 2011 Sep;108(6):888-93. doi: 10.1111/j.1464-410X.2010.09906.x. Epub 2010 Dec 13.

659.

Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate?

Abdollah F, Novara G, Briganti A, Scattoni V, Raber M, Roscigno M, Suardi N, Gallina A, Artibani W, Ficarra V, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Urology. 2011 Apr;77(4):921-5. doi: 10.1016/j.urology.2010.08.048. Epub 2010 Dec 4.

PMID:
21131034
660.

Inverted (endophytic) noninvasive lesions and neoplasms of the urothelium: the Cinderella group has yet to be fully exploited.

Montironi R, Cheng L, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Mikuz G, Kirkali Z, Montorsi F.

Eur Urol. 2011 Feb;59(2):225-30. doi: 10.1016/j.eururo.2010.11.018. Epub 2010 Nov 24. No abstract available.

PMID:
21122976
661.

Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients.

Cozzarini C, Fiorino C, Da Pozzo LF, Alongi F, Berardi G, Bolognesi A, Briganti A, Broggi S, Deli A, Guazzoni G, Perna L, Pasetti M, Salvadori G, Montorsi F, Rigatti P, Di Muzio N.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):191-9. doi: 10.1016/j.ijrobp.2010.09.027. Epub 2010 Nov 23.

PMID:
21109361
662.

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E; European Silodosin Study Group.

Eur Urol. 2011 Mar;59(3):342-52. doi: 10.1016/j.eururo.2010.10.046. Epub 2010 Nov 10.

PMID:
21109344
663.

The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.

Abdollah F, Scattoni V, Raber M, Roscigno M, Briganti A, Suardi N, Gallina A, Capitanio U, Freschi M, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2011 Aug;108(3):366-71. doi: 10.1111/j.1464-410X.2010.09876.x. Epub 2010 Nov 19.

664.

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group.

J Urol. 2011 Jan;185(1):126-31. doi: 10.1016/j.juro.2010.09.011. Epub 2010 Nov 12.

PMID:
21074214
665.

Summary of the recommendations on sexual dysfunctions in men.

Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, Brock G, Broderick G, Burnett A, Buvat J, Dean J, Donatucci C, Eardley I, Fugl-Meyer KS, Goldstein I, Hackett G, Hatzichristou D, Hellstrom W, Incrocci L, Jackson G, Kadioglu A, Levine L, Lewis RW, Maggi M, McCabe M, McMahon CG, Montague D, Montorsi P, Mulhall J, Pfaus J, Porst H, Ralph D, Rosen R, Rowland D, Sadeghi-Nejad H, Shabsigh R, Stief C, Vardi Y, Wallen K, Wasserman M.

J Sex Med. 2010 Nov;7(11):3572-88. doi: 10.1111/j.1743-6109.2010.02062.x. Review.

PMID:
21040491
666.

Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.

Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI.

Eur Urol. 2011 Jan;59(1):135-41. doi: 10.1016/j.eururo.2010.10.029. Epub 2010 Oct 28.

PMID:
21035250
667.

Corrigendum to “The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study” [Eur Urol 2010;57:123-31].

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group.

Eur Urol. 2010 Nov;58(5):801. doi: 10.1016/j.eururo.2010.07.035. Epub 2010 Aug 4. No abstract available.

PMID:
28065365
668.

Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension.

Martínez-Salamanca JI, Huang WC, Millán I, Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernández C, Herranz F, Haferkamp A, Hohenfellner M, Hu B, Koppie T, Martínez-Ballesteros C, Montorsi F, Palou J, Pontes JE, Russo P, Terrone C, Villavicencio H, Volpe A, Libertino JA; International Renal Cell Carcinoma-Venous Thrombus Consortium.

Eur Urol. 2011 Jan;59(1):120-7. doi: 10.1016/j.eururo.2010.10.001. Epub 2010 Oct 13.

PMID:
20980095
669.

Surgery and erectile dysfunction.

Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, Zanni G, Salonia A, Rigatti P, Montorsi F.

Arch Esp Urol. 2010 Oct;63(8):640-8. Review.

PMID:
20978296
670.

A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006.

Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.

Eur Urol. 2011 Jan;59(1):88-95. doi: 10.1016/j.eururo.2010.10.003. Epub 2010 Oct 14.

PMID:
20965646
671.

Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?

Abdollah F, Briganti A, Suardi N, Gallina A, Capitanio U, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Prostate Cancer Prostatic Dis. 2011 Mar;14(1):74-8. doi: 10.1038/pcan.2010.41. Epub 2010 Oct 19.

PMID:
20956995
672.

Impact of surgical experience on in-hospital complication rates in patients undergoing minimally invasive prostatectomy: a population-based study.

Budäus L, Sun M, Abdollah F, Zorn KC, Morgan M, Johal R, Liberman D, Thuret R, Isbarn H, Salomon G, Haese A, Montorsi F, Shariat SF, Perrotte P, Graefen M, Karakiewicz PI.

Ann Surg Oncol. 2011 Mar;18(3):839-47. doi: 10.1245/s10434-010-1300-0. Epub 2010 Oct 16.

PMID:
20953720
673.

Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trends.

Budäus L, Abdollah F, Sun M, Morgan M, Johal R, Thuret R, Zorn KC, Isbarn H, Shariat SF, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI.

J Urol. 2010 Dec;184(6):2285-90. doi: 10.1016/j.juro.2010.08.024. Epub 2010 Oct 16.

PMID:
20952010
674.

Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer.

Abdollah F, Sun M, Thuret R, Budäus L, Jeldres C, Graefen M, Briganti A, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.

Eur Urol. 2010 Dec;58(6):882-92. doi: 10.1016/j.eururo.2010.09.029. Epub 2010 Sep 28.

PMID:
20932637
675.

A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.

Crépel M, Jeldres C, Sun M, Lughezzani G, Isbarn H, Alasker A, Capitanio U, Shariat SF, Arjane P, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Urology. 2010 Oct;76(4):883-8. doi: 10.1016/j.urology.2009.08.028.

PMID:
20932408
676.

A plea to young surgeons dealing with radical prostatectomy patients: invest your time and intellectual energy in optimizing your research methodology and keep your feet on the ground.

Montorsi F.

Eur Urol. 2010 Dec;58(6):847-8. doi: 10.1016/j.eururo.2010.09.025. Epub 2010 Sep 23. No abstract available.

PMID:
20926178
677.

Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature.

Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, Shariat SF, Schröder FH, Scattoni V.

Eur Urol. 2010 Dec;58(6):851-64. doi: 10.1016/j.eururo.2010.08.041. Epub 2010 Sep 4. Review.

PMID:
20884114
678.

Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Zanni G, Suardi N, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2011 Apr;107(8):1243-9. doi: 10.1111/j.1464-410X.2010.09582.x. Epub 2010 Sep 30.

679.

How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications.

Capitanio U, Pellucchi F, Gallina A, Briganti A, Suardi N, Salonia A, Abdollah F, Di Trapani E, Jeldres C, Cestari A, Karakiewicz PI, Montorsi F.

BJU Int. 2011 Apr;107(7):1095-101. doi: 10.1111/j.1464-410X.2010.09580.x. Epub 2010 Sep 29.

680.

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.

Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN.

Eur Urol. 2011 Jan;59(1):51-60. doi: 10.1016/j.eururo.2010.09.004. Epub 2010 Sep 15. Review.

PMID:
20869161
681.

Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study.

Liberman D, Alasker A, Sun M, Ismail S, Lughezzani G, Jeldres C, Budaus L, Thuret R, Shariat SF, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI.

BJU Int. 2011 Mar;107(6):905-11. doi: 10.1111/j.1464-410X.2010.09590.x. Epub 2010 Sep 22.

682.

Laparoendoscopic single-site and natural orifice transluminal endoscopic surgery in urology: a critical analysis of the literature.

Autorino R, Cadeddu JA, Desai MM, Gettman M, Gill IS, Kavoussi LR, Lima E, Montorsi F, Richstone L, Stolzenburg JU, Kaouk JH.

Eur Urol. 2011 Jan;59(1):26-45. doi: 10.1016/j.eururo.2010.08.030. Epub 2010 Aug 27. Review.

PMID:
20828918
683.

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.

Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG.

Eur Urol. 2010 Sep;58(3):384-97. doi: 10.1016/j.eururo.2010.06.005. Epub 2010 Jun 11. Review.

PMID:
20825758
684.

A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer.

Lughezzani G, Sun M, Shariat SF, Budäus L, Thuret R, Jeldres C, Liberman D, Montorsi F, Perrotte P, Karakiewicz PI.

Cancer. 2011 Jan 1;117(1):103-9. doi: 10.1002/cncr.25345. Epub 2010 Aug 27.

685.

Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, Shariat SF, Vickers AJ.

Eur Urol. 2010 Nov;58(5):687-700. doi: 10.1016/j.eururo.2010.07.034. Epub 2010 Aug 6. Review.

686.

Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage.

Budäus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P, Chun FK, Salomon G, Steuber T, Köllermann J, Sauter G, Ahyai SA, Zacharias M, Fisch M, Schlomm T, Haese A, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz PI.

J Urol. 2010 Oct;184(4):1341-6. doi: 10.1016/j.juro.2010.06.018. Epub 2010 Aug 17.

PMID:
20723925
687.

Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).

Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R.

J Sex Med. 2011 Jan;8(1):284-93. doi: 10.1111/j.1743-6109.2010.01956.x.

PMID:
20704642
688.

Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?

Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V, Montorsi F, Schiavina R, Simeone C, Serni S, Simonato A, Siracusano S, Volpe A, Carmignani G; SATURN Project-LUNA Foundation.

Eur Urol. 2010 Oct;58(4):588-95. doi: 10.1016/j.eururo.2010.07.006. Epub 2010 Jul 23. Erratum in: Eur Urol. 2011 Jan;59(1):182. Schiavina, Roberto [corrected to Schiavina, Riccardo].

PMID:
20674150
689.

[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.

Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, Landoni C, Gianolli L, Di Muzio N, Rigatti P, Montorsi F, Messa C.

J Urol. 2010 Sep;184(3):938-43. doi: 10.1016/j.juro.2010.04.084.

PMID:
20643445
690.

Predictive models before and after radical prostatectomy.

Capitanio U, Briganti A, Gallina A, Suardi N, Karakiewicz PI, Montorsi F, Scattoni V.

Prostate. 2010 Sep 1;70(12):1371-8. doi: 10.1002/pros.21159. Review.

PMID:
20623635
691.

Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract.

Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Shariat SF; Upper Tract Urothelial Carcinoma Collaborative Group.

J Urol. 2010 Aug;184(2):453-8. doi: 10.1016/j.juro.2010.03.142. Epub 2010 Jun 17.

PMID:
20620397
692.

Irrespective of stomach conditions.

Montorsi F.

Int J Clin Pract. 2010 Jun;64(7):995-6. doi: 10.1111/j.1742-1241.2010.02401.x. No abstract available.

PMID:
20584232
693.

Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus.

Jackson G, Boon N, Eardley I, Kirby M, Dean J, Hackett G, Montorsi P, Montorsi F, Vlachopoulos C, Kloner R, Sharlip I, Miner M.

Int J Clin Pract. 2010 Jun;64(7):848-57. doi: 10.1111/j.1742-1241.2010.02410.x.

PMID:
20584218
694.

Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution.

Guazzoni G, Cestari A, Buffi N, Lughezzani G, Nava L, Cardone G, Balconi G, Lazzeri M, Montorsi F, Rigatti P.

Urology. 2010 Sep;76(3):624-9. doi: 10.1016/j.urology.2010.03.078. Epub 2010 Jun 25.

PMID:
20579705
695.

Highly predictive survival nomogram after upper urinary tract urothelial carcinoma.

Jeldres C, Sun M, Lughezzani G, Isbarn H, Shariat SF, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Cancer. 2010 Aug 15;116(16):3774-84. doi: 10.1002/cncr.25122.

696.

Systematic extended and saturation prostate biopsy: when and how.

Scattoni V, Maccagnano C, Zanni G, Angiolilli D, Raber M, Rigatti P, Montorsi F.

Minerva Urol Nefrol. 2010 Jun;62(2):179-92. Review.

PMID:
20562798
697.

Organic vs. psychogenic? The Manichean diagnosis in sexual medicine.

Jannini EA, McCabe MP, Salonia A, Montorsi F, Sachs BD.

J Sex Med. 2010 May;7(5):1726-33. doi: 10.1111/j.1743-6109.2010.01824.x. Review.

PMID:
20537061
698.

Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification.

Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, Passoni N, Salonia A, Colombo R, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F.

J Sex Med. 2010 Jul;7(7):2521-31. doi: 10.1111/j.1743-6109.2010.01845.x. Epub 2010 May 4.

PMID:
20487236
699.

Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.

Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, Black L.

Int J Clin Pract. 2010 Jul;64(8):1042-51. doi: 10.1111/j.1742-1241.2010.02428.x. Epub 2010 May 7.

PMID:
20487046
700.

[Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis].

Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R.

Aktuelle Urol. 2010 May;41(3):171-7. doi: 10.1055/s-0030-1247363. Epub 2010 May 18. German.

PMID:
20486035
701.

Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient’s pathology and clinical reports.

Montironi R, Cheng L, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Mikuz G, Kirkali Z, Montorsi F.

Eur Urol. 2010 Sep;58(3):369-73. doi: 10.1016/j.eururo.2010.04.028. Epub 2010 May 8. No abstract available.

PMID:
20478652
702.

[How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?].

Bigot P, Bernhard JC, Crepel M, Bensalah K, Azzouzi AR, de la Taille A, Salomon L, Tostain J, Ficarra V, Pantuck AJ, Belldegrun AS, Méjean A, Ferrière JM, Pfister C, Albouy B, Colombel M, Zini L, Villers A, Montorsi F, Shariat S, Rioux-Leclercq N, Patard JJ.

Prog Urol. 2010 May;20(5):350-5. doi: 10.1016/j.purol.2010.01.007. Epub 2010 Mar 29. French.

PMID:
20471579
703.

Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy.

Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernández M, Karakiewizc P, Capitanio U, Bensalah K, Patard JJ, Shariat SF.

Urol Oncol. 2012 May-Jun;30(3):252-8. doi: 10.1016/j.urolonc.2010.01.001. Epub 2010 May 6.

PMID:
20451416
704.

Testosterone measurement in patients with prostate cancer.

Schulman CC, Irani J, Morote J, Schalken JA, Montorsi F, Chlosta PL, Heidenreich A.

Eur Urol. 2010 Jul;58(1):65-74. doi: 10.1016/j.eururo.2010.04.001. Review.

PMID:
20434831
705.

Is extended and saturation biopsy necessary?

Scattoni V, Maccagnano C, Zanni G, Angiolilli D, Raber M, Roscigno M, Rigatti P, Montorsi F.

Int J Urol. 2010 May;17(5):432-47. doi: 10.1111/j.1442-2042.2010.02479.x. Review.

706.

Comparative study of inguinal hernia repair rates after radical prostatectomy or external beam radiotherapy.

Lughezzani G, Sun M, Perrotte P, Alasker A, Jeldres C, Isbarn H, Budäus L, Lattouf JB, Valiquette L, Bénard F, Saad F, Graefen M, Montorsi F, Karakiewicz PI.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1307-13. doi: 10.1016/j.ijrobp.2009.09.065. Epub 2010 Apr 8.

PMID:
20381269
707.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

708.

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1106-16. doi: 10.1007/s00259-010-1403-7. Epub 2010 Mar 20.

PMID:
20306038
709.

Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study.

Centemero A, Rigatti L, Giraudo D, Lazzeri M, Lughezzani G, Zugna D, Montorsi F, Rigatti P, Guazzoni G.

Eur Urol. 2010 Jun;57(6):1039-43. doi: 10.1016/j.eururo.2010.02.028. Epub 2010 Mar 1.

PMID:
20227168
710.

A nomogram predicting prostate cancer-specific mortality after radical prostatectomy.

Porter CR, Suardi N, Capitanio U, Hutterer GC, Kodama K, Gibbons RP, Correa R Jr, Perrotte P, Montorsi F, Karakiewicz PI.

Urol Int. 2010;84(2):132-40. doi: 10.1159/000277588. Epub 2010 Mar 4.

711.

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation.

Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E; European Association of Urology.

Eur Urol. 2010 May;57(5):804-14. doi: 10.1016/j.eururo.2010.02.020. Epub 2010 Feb 20.

PMID:
20189712
712.

Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter.

Jeldres C, Lughezzani G, Sun M, Isbarn H, Shariat SF, Budaus L, Lattouf JB, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

J Urol. 2010 Apr;183(4):1324-9. doi: 10.1016/j.juro.2009.12.018. Epub 2010 Feb 19.

PMID:
20171666
713.

The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.

Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):342-8. doi: 10.1016/j.ijrobp.2009.02.011.

PMID:
20117287
714.

Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.

Witjes JA, Redorta JP, Jacqmin D, Sofras F, Malmström PU, Riedl C, Jocham D, Conti G, Montorsi F, Arentsen HC, Zaak D, Mostafid AH, Babjuk M.

Eur Urol. 2010 Apr;57(4):607-14. doi: 10.1016/j.eururo.2010.01.025. Epub 2010 Jan 22. Review.

PMID:
20116164
715.

The Third International Consultation on Sexual Medicine: advancing science in the interest of patient care.

Montorsi F, Pierce CJ, Khoury S.

J Sex Med. 2010 Jan;7(1 Pt 2):312-3. doi: 10.1111/j.1743-6109.2009.01616.x. No abstract available.

PMID:
20092440
716.

A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma.

Baillargeon-Gagné S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, Shariat SF, Crépel M, Alasker A, Widmer H, Arjane P, Patard JJ, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI.

BJU Int. 2010 Feb;105(3):359-64. doi: 10.1111/j.1464-410X.2009.08745.x.

717.

Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection.

Sun M, Lughezzani G, Alasker A, Isbarn H, Jeldres C, Shariat SF, Budäus L, Lattouf JB, Valiquette L, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

J Urol. 2010 Mar;183(3):970-5. doi: 10.1016/j.juro.2009.11.036. Epub 2010 Jan 18.

PMID:
20083257
718.

Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?

Raman JD, Shariat SF, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V; Upper-Tract Urothelial Carcinoma Collaborative Group.

Urol Oncol. 2011 Nov-Dec;29(6):716-23. doi: 10.1016/j.urolonc.2009.11.007. Epub 2010 Jan 6.

PMID:
20056458
719.

The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.

Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI.

Eur J Cancer. 2010 Mar;46(4):713-9. doi: 10.1016/j.ejca.2009.12.007. Epub 2010 Jan 13.

PMID:
20044246
720.

Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications.

Murphy DG, Bjartell A, Ficarra V, Graefen M, Haese A, Montironi R, Montorsi F, Moul JW, Novara G, Sauter G, Sulser T, van der Poel H.

Eur Urol. 2010 May;57(5):735-46. doi: 10.1016/j.eururo.2009.12.021. Epub 2009 Dec 28. Review.

PMID:
20036784
721.

When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.

Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, Da Pozzo LF, Picchio M, Di Girolamo V, Salonia A, Gianolli L, Messa C, Rigatti P, Montorsi F.

Eur Urol. 2010 Apr;57(4):551-8. doi: 10.1016/j.eururo.2009.12.023. Epub 2009 Dec 18.

PMID:
20034730
722.

Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality.

Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, Shariat SF, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz PI.

Urology. 2010 Feb;75(2):376-81. doi: 10.1016/j.urology.2009.10.018.

PMID:
20022091
723.

Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study.

Lughezzani G, Sun M, Perrotte P, Shariat SF, Jeldres C, Budaus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz PI.

Eur Urol. 2010 Jun;57(6):956-62. doi: 10.1016/j.eururo.2009.12.001. Epub 2009 Dec 10.

PMID:
20018438
724.

Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy.

Lughezzani G, Budäus L, Isbarn H, Sun M, Perrotte P, Haese A, Chun FK, Schlomm T, Steuber T, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz PI.

Eur Urol. 2010 Apr;57(4):562-8. doi: 10.1016/j.eururo.2009.12.003. Epub 2009 Dec 10.

PMID:
20018437
725.

Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.

Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R.

Eur Urol. 2010 Apr;57(4):595-606. doi: 10.1016/j.eururo.2009.11.041. Epub 2009 Dec 2. Review.

PMID:
20004052
726.

Simplifying patient positioning and port placement during robotic-assisted laparoscopic prostatectomy.

Cestari A, Buffi NM, Scapaticci E, Lughezzani G, Salonia A, Briganti A, Rigatti P, Montorsi F, Guazzoni G.

Eur Urol. 2010 Mar;57(3):530-3. doi: 10.1016/j.eururo.2009.11.028. Epub 2009 Nov 17.

PMID:
19963314
727.

A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma.

Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, Shariat SF, Lattouf JB, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Urology. 2010 Feb;75(2):315-20. doi: 10.1016/j.urology.2009.10.004. Epub 2009 Dec 6.

PMID:
19963237
728.

Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment.

Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, Shariat SF, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI.

Urology. 2010 Feb;75(2):271-5. doi: 10.1016/j.urology.2009.04.098. Epub 2009 Dec 4.

PMID:
19962740
729.

Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database.

Lughezzani G, Sun M, Perrotte P, Shariat SF, Jeldres C, Budäus L, Latour M, Widmer H, Duclos A, Bénard F, McCormack M, Montorsi F, Karakiewicz PI.

Urology. 2010 Feb;75(2):321-7. doi: 10.1016/j.urology.2009.09.048. Epub 2009 Dec 4.

PMID:
19962727
730.

Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract.

Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernández MI, Wood CG, Montorsi F, Ströbel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C.

Eur Urol. 2010 Apr;57(4):575-81. doi: 10.1016/j.eururo.2009.11.035. Epub 2009 Nov 25.

PMID:
19959276
731.

A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy.

Walz J, Burnett AL, Costello AJ, Eastham JA, Graefen M, Guillonneau B, Menon M, Montorsi F, Myers RP, Rocco B, Villers A.

Eur Urol. 2010 Feb;57(2):179-92. doi: 10.1016/j.eururo.2009.11.009. Epub 2009 Nov 11. Review.

PMID:
19931974
732.

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.

Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y.

J Urol. 2010 Jan;183(1):68-75. doi: 10.1016/j.juro.2009.08.115.

PMID:
19913255
733.

Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer.

Suardi N, Briganti A, Gallina A, Salonia A, Karakiewicz PI, Capitanio U, Freschi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2010 Jun;105(11):1548-52. doi: 10.1111/j.1464-410X.2009.09057.x. Epub 2009 Nov 13.

734.

Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.

Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y.

Clin Cancer Res. 2009 Nov 15;15(22):7012-9. doi: 10.1158/1078-0432.CCR-08-2554. Epub 2009 Nov 10. Erratum in: Clin Cancer Res. 2015 Jul 1;21(13):3096.

735.

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.

Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F.

Prostate Cancer Prostatic Dis. 2009;12(4):369-74. doi: 10.1038/pcan.2009.37. Epub 2009 Sep 1.

PMID:
19901936
736.

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.

Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P.

Int J Clin Pract. 2010 Jan;64(2):240-55. doi: 10.1111/j.1742-1241.2009.02254.x. Epub 2009 Nov 9. Review.

737.

Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer.

Roscigno M, Shariat SF, Freschi M, Margulis V, Karakiewizc P, Suardi N, Remzi M, Zigeuner R, Bolenz C, Kikuchi E, Weizer A, Bensalah K, Sagalowsky A, Koppie TM, Raman J, Fernández M, Ströbel P, Kabbani W, Langner C, Wheat J, Guo CC, Kassouf W, Haitel A, Wood CG, Montorsi F.

Urology. 2009 Nov;74(5):1070-4. doi: 10.1016/j.urology.2009.04.084.

PMID:
19883824
738.

Unilateral prostate cancer cannot be accurately predicted in low-risk patients.

Isbarn H, Karakiewicz PI, Vogel S, Jeldres C, Lughezzani G, Briganti A, Montorsi F, Perrotte P, Ahyai SA, Budäus L, Eichelberg C, Heuer R, Köllermann J, Sauter G, Schlomm T, Steuber T, Haese A, Zacharias M, Fisch M, Heinzer H, Huland H, Chun FK, Graefen M.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):784-7. doi: 10.1016/j.ijrobp.2009.05.068. Epub 2009 Oct 26.

PMID:
19864083
739.

A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma.

Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Urology. 2010 Jan;75(1):118-24. doi: 10.1016/j.urology.2009.07.1296. Epub 2009 Oct 28.

PMID:
19864000
740.

Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors.

Deho F, Gallina A, Salonia A, Briganti A, Suardi N, Zanni G, Guazzoni G, Rigatti P, Montorsi F.

Curr Pharm Des. 2009;15(30):3496-501. Review.

PMID:
19860695
741.

The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications.

Touijer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG, Russo P, Uzzo RG, Van Poppel H.

Eur Urol. 2010 Feb;57(2):214-22. doi: 10.1016/j.eururo.2009.10.019. Epub 2009 Oct 20. Review.

PMID:
19853988
742.

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group.

Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Erratum in: Eur Urol. 2010 Nov;58(5):801.

PMID:
19825505
743.

Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective.

Lughezzani G, Capitanio U, Jeldres C, Isbarn H, Shariat SF, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI.

Cancer. 2009 Dec 15;115(24):5680-7. doi: 10.1002/cncr.24682.

744.

Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Colombo R, Bertini R, Da Pozzo LF, Zanni G, Sacca A, Rocchini L, Guazzoni G, Rigatti P, Montorsi F.

J Sex Med. 2010 Jan;7(1 Pt 1):149-55. doi: 10.1111/j.1743-6109.2009.01518.x. Epub 2009 Sep 30.

PMID:
19796018
745.

Open prostatectomy and the evolution of HoLEP in the management of benign prostatic hyperplasia.

Suardi N, Gallina A, Salonia A, Briganti A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Minerva Urol Nefrol. 2009 Sep;61(3):301-8. Review.

PMID:
19773730
746.

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF.

Eur Urol. 2010 Feb;57(2):300-9. doi: 10.1016/j.eururo.2009.09.024. Epub 2009 Sep 12. Erratum in: Eur Urol. 2015 Jul;68(1):171.

PMID:
19766384
747.

Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.

Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

J Urol. 2009 Nov;182(5):2177-81. doi: 10.1016/j.juro.2009.07.035. Epub 2009 Sep 16.

PMID:
19758662
748.

Unsuccessful investigation of preoperative sexual health issues in the prostate cancer “couple”: results of a real-life psychometric survey at a major tertiary academic center.

Salonia A, Zanni G, Gallina A, Briganti A, Saccà A, Suardi N, Matloob R, Da Pozzo LF, Bertini R, Colombo R, Rigatti P, Montorsi F.

J Sex Med. 2009 Dec;6(12):3347-55. doi: 10.1111/j.1743-6109.2009.01483.x. Epub 2009 Sep 14.

PMID:
19751390
749.

Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study.

Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S, Maggi M, Nicita G, Carini M, Montorsi F.

J Sex Med. 2010 Jan;7(1 Pt 1):234-43. doi: 10.1111/j.1743-6109.2009.01471.x. Epub 2009 Sep 1.

PMID:
19732303
750.

Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma.

Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Widmer H, Arjane P, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI.

BJU Int. 2010 Mar;105(6):799-804. doi: 10.1111/j.1464-410X.2009.08818.x. Epub 2009 Sep 2.

751.

Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.

Scattoni V, Raber M, Abdollah F, Roscigno M, Dehò F, Angiolilli D, Maccagnano C, Gallina A, Capitanio U, Freschi M, Doglioni C, Rigatti P, Montorsi F.

Eur Urol. 2010 Jan;57(1):1-8. doi: 10.1016/j.eururo.2009.08.011. Epub 2009 Aug 19.

PMID:
19720449
752.

Joint appraisal of the radical prostatectomy specimen by the urologist and the uropathologist: together, we can do it better.

Montironi R, Cheng L, Lopez-Beltran A, Mazzucchelli R, Scarpelli M, Kirkali Z, Montorsi F.

Eur Urol. 2009 Dec;56(6):951-5. doi: 10.1016/j.eururo.2009.08.016. Epub 2009 Aug 26. No abstract available.

PMID:
19717223
753.

Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.

Fusco F, Sicuteri R, Rossi A, Kontodimas S, Haro JM, Imbimbo C, Mirone V; Italian EDOS Study Group.

Asian J Androl. 2009 Sep;11(5):629-37. doi: 10.1038/aja.2009.48. Epub 2009 Aug 24.

754.

Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis.

Lughezzani G, Jeldres C, Isbarn H, Perrotte P, Shariat SF, Sun M, Widmer H, Arjane P, Peloquin F, Pharand D, Patard JJ, Graefen M, Montorsi F, Karakiewicz PI.

J Urol. 2009 Oct;182(4):1287-93. doi: 10.1016/j.juro.2009.06.018. Epub 2009 Aug 14.

PMID:
19683281
755.

p53 expression in patients with advanced urothelial cancer of the urinary bladder.

Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, Lotan Y.

BJU Int. 2010 Feb;105(4):489-95. doi: 10.1111/j.1464-410X.2009.08742.x. Epub 2009 Jul 31. Erratum in: BJU Int. 2015 Jun;115(6):E13.

756.

Assessing the impact of ischaemia time during partial nephrectomy.

Becker F, Van Poppel H, Hakenberg OW, Stief C, Gill I, Guazzoni G, Montorsi F, Russo P, Stöckle M.

Eur Urol. 2009 Oct;56(4):625-34. doi: 10.1016/j.eururo.2009.07.016. Epub 2009 Jul 28. Review.

PMID:
19656615
757.

Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation.

Salonia A, Rocchini L, Sacca’ A, Pellucchi F, Ferrari M, Carro UD, Ribotto P, Gallina A, Zanni G, Deho’ F, Rigatti P, Montorsi F.

J Sex Med. 2009 Oct;6(10):2868-77. doi: 10.1111/j.1743-6109.2009.01404.x. Epub 2009 Jul 28.

PMID:
19656274
758.

Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?

Crépel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M, Shariat SF, Widmer H, Arjane P, Graefen M, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI.

Urology. 2009 Oct;74(4):842-5. doi: 10.1016/j.urology.2009.02.013. Epub 2009 Jul 22.

PMID:
19628262
759.

Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist.

Capitanio U, Isbarn H, Shariat SF, Jeldres C, Zini L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Urology. 2009 Oct;74(4):858-64. doi: 10.1016/j.urology.2009.03.052. Epub 2009 Jul 22.

PMID:
19628260
760.

Secondary neoplasms of the urinary system and male genital organs.

Morichetti D, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montorsi F, Montironi R.

BJU Int. 2009 Sep;104(6):770-6. doi: 10.1111/j.1464-410X.2009.08746.x. Epub 2009 Jul 14. Review.

761.

Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.

Cozzarini C, Montorsi F, Fiorino C, Alongi F, Bolognesi A, Da Pozzo LF, Guazzoni G, Freschi M, Roscigno M, Scattoni V, Rigatti P, Di Muzio N.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):966-74. doi: 10.1016/j.ijrobp.2008.12.059. Epub 2009 Jul 18.

PMID:
19619960
762.

Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.

Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF.

Eur Urol. 2010 Jun;57(6):1072-9. doi: 10.1016/j.eururo.2009.07.002. Epub 2009 Jul 15.

PMID:
19619934
763.

A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States.

Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, Shariat SF, Sun M, Lughezzani G, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI.

Urology. 2009 Oct;74(4):837-41. doi: 10.1016/j.urology.2009.04.019. Epub 2009 Jul 18.

PMID:
19616828
764.

Is sperm banking of interest to patients with nongerm cell urological cancer before potentially fertility damaging treatments?

Salonia A, Gallina A, Matloob R, Rocchini L, Saccà A, Abdollah F, Colombo R, Suardi N, Briganti A, Guazzoni G, Rigatti P, Montorsi F.

J Urol. 2009 Sep;182(3):1101-7. doi: 10.1016/j.juro.2009.05.026. Epub 2009 Jul 18.

PMID:
19616800
765.

p53 predictive value for pT1-2 N0 disease at radical cystectomy.

Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ.

J Urol. 2009 Sep;182(3):907-13. doi: 10.1016/j.juro.2009.05.024. Epub 2009 Jul 17.

PMID:
19616250
766.

Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.

Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM.

J Urol. 2009 Sep;182(3):900-6. doi: 10.1016/j.juro.2009.05.011. Epub 2009 Jul 17.

PMID:
19616245
767.

Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients.

Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Eur J Cancer. 2009 Dec;45(18):3291-7. doi: 10.1016/j.ejca.2009.06.016. Epub 2009 Jul 15.

PMID:
19615885
768.

Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.

Briganti A, Karakiewicz PI, Chun FK, Suardi N, Gallina A, Abdollah F, Freschi M, Doglioni C, Rigatti P, Montorsi F.

Int J Urol. 2009 Aug;16(8):676-81. doi: 10.1111/j.1442-2042.2009.02330.x. Epub 2009 Jul 8.

769.

Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma.

Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ.

Eur Urol. 2009 Oct;56(4):636-43. doi: 10.1016/j.eururo.2009.06.036. Epub 2009 Jul 7. Review.

PMID:
19595500
770.

Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy.

Isbarn H, Jeldres C, Capitanio U, Zini L, Shariat SF, Lughezzani G, Sun M, Ahyai SA, Duclos A, Jolivet-Tremblay M, Lattouf JB, Valiquette L, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI.

J Endourol. 2009 Aug;23(8):1347-52. doi: 10.1089/end.2008.0618.

PMID:
19591615
771.

The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?

Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Sagalowsky A, Bensalah K, Raman JD, Bolenz C, Kassou W, Koppie TM, Wood CG, Wheat J, Langner C, Ng CK, Capitanio U, Bertini R, Fernández MI, Mikami S, Isida M, Ströbel P, Montorsi F.

Eur Urol. 2009 Sep;56(3):512-8. doi: 10.1016/j.eururo.2009.06.004. Epub 2009 Jun 18.

PMID:
19559518
772.

Prediction of sexual function after radical prostatectomy.

Briganti A, Capitanio U, Chun FK, Karakiewicz PI, Salonia A, Bianchi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Cancer. 2009 Jul 1;115(13 Suppl):3150-9. doi: 10.1002/cncr.24349. Review.

773.

Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia.

Jeldres C, Isbarn H, Capitanio U, Zini L, Bhojani N, Shariat SF, Cloutier V, Lattouf JB, Duclos A, Jolivet-Tremblay M, Valiquette L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

J Urol. 2009 Aug;182(2):626-32. doi: 10.1016/j.juro.2009.04.008. Epub 2009 Jun 17.

PMID:
19535100
774.

Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors.

Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V, Baillargeon-Gagne S, Shariat SF, Duclos A, Arjane P, Widmer H, Saad F, Montorsi F, Karakiewicz PI.

Urology. 2009 Aug;74(2):373-7. doi: 10.1016/j.urology.2009.01.085. Epub 2009 Jun 7.

PMID:
19501893
775.

External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma.

Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI.

BJU Int. 2009 Dec;104(11):1661-7. doi: 10.1111/j.1464-410X.2009.08660.x. Epub 2009 Jun 2.

776.

Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners.

Teloken P, Mesquita G, Montorsi F, Mulhall J.

J Sex Med. 2009 Jul;6(7):2032-8. doi: 10.1111/j.1743-6109.2009.01269.x. Epub 2009 Apr 23.

PMID:
19453918
777.

Quantitative sensory testing of peripheral thresholds in patients with lifelong premature ejaculation: a case-controlled study.

Salonia A, Saccà A, Briganti A, Del Carro U, Dehò F, Zanni G, Rocchini L, Raber M, Guazzoni G, Rigatti P, Montorsi F.

J Sex Med. 2009 Jun;6(6):1755-62. doi: 10.1111/j.1743-6109.2009.01276.x. Epub 2009 Apr 23.

PMID:
19453912
778.

A population based assessment of perioperative mortality after cystectomy for bladder cancer.

Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, Shariat SF, Arjane P, Saad F, McCormack M, Valiquette L, Peloquin F, Duclos A, Montorsi F, Graefen M, Karakiewicz PI.

J Urol. 2009 Jul;182(1):70-7. doi: 10.1016/j.juro.2009.02.120. Epub 2009 May 17.

PMID:
19447427
779.

Stage pT0 in radical prostatectomy with no residual carcinoma and with a previous positive biopsy conveys a wrong message to clinicians and patients: why is cancer not present in the radical prostatectomy specimen?

Montironi R, Cheng L, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Mikuz G, Kirkali Z, Montorsi F.

Eur Urol. 2009 Aug;56(2):272-4. doi: 10.1016/j.eururo.2009.04.042. Epub 2009 May 3. No abstract available.

PMID:
19443101
780.

Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L.

Eur Urol. 2009 Oct;56(4):727-35. doi: 10.1016/j.eururo.2009.04.033. Epub 2009 Apr 22. Erratum in: Eur Urol. 2011 Jun;59(6):1082.

PMID:
19409693
781.

The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted.

Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.

Int J Urol. 2009 May;16(5):526-9. doi: 10.1111/j.1442-2042.2009.02270.x. Epub 2009 Mar 26.

782.

Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma).

Capitanio U, Perrotte P, Zini L, Jeldres C, Shariat SF, Isbarn H, Arjane P, Peloquin F, Pharand D, Montorsi F, Karakiewicz PI.

BJU Int. 2009 Sep;104(6):795-9. doi: 10.1111/j.1464-410X.2009.08484.x. Epub 2009 Apr 15.

783.

Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort.

Capitanio U, Perrotte P, Zini L, Suardi N, Antebi E, Cloutier V, Jeldres C, Shariat SF, Duclos A, Arjane P, Saad F, Montorsi F, Karakiewicz PI.

Urology. 2009 Jun;73(6):1323-7. doi: 10.1016/j.urology.2008.10.026. Epub 2009 Apr 18.

PMID:
19376563
784.

Testosterone and prostate cancer: revisiting old paradigms.

Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C.

Eur Urol. 2009 Jul;56(1):48-56. doi: 10.1016/j.eururo.2009.03.088. Epub 2009 Apr 8. Review.

PMID:
19375844
785.

Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.

Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F.

J Urol. 2009 Jun;181(6):2482-9. doi: 10.1016/j.juro.2009.02.021. Epub 2009 Apr 16.

PMID:
19371878
786.

Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases.

Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernández MI, Ströbel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz PI.

Eur Urol. 2009 Jul;56(1):1-9. doi: 10.1016/j.eururo.2009.03.072. Epub 2009 Apr 3.

PMID:
19361911
787.

A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate.

Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, Reich O, Stief C, Vavassori I.

Eur Urol. 2009 Jun;55(6):1345-57. doi: 10.1016/j.eururo.2009.03.070. Epub 2009 Apr 3. Review.

PMID:
19361906
788.

Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.

Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De la Taille A, Avakian R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot F, Rigaud J, Pfister C, Albouy B, Guy L, Joniau S, van Poppel H, Lebret T, Culty T, Saint F, Zisman A, Raz O, Lang H, Spie R, Wille A, Roigas J, Aguilera A, Rambeaud B, Martinez Piñeiro L, Nativ O, Farfara R, Richard F, Roupret M, Doehn C, Bastian PJ, Muller SC, Tostain J, Belldegrun AS, Patard JJ.

Eur Urol. 2010 Mar;57(3):466-71. doi: 10.1016/j.eururo.2009.03.048. Epub 2009 Mar 31.

PMID:
19359089
789.

Corrigendum to: “The Influence of Baseline Parameters on Changes in IPSS with Dutasteride, Tamsulosin, and Combination Therapy: Two-Year Data from the Combination of Avodart® and Tamsulosin (CombAT) Study” [Eur Urol Suppl 2008;7:171 (Abstract no. 403)].

Roehrborn CG, Tubaro A, Montorsi F, Maffezzini M, Lebret T, Chantada V, Barkin J, Castro R, Wilson T.

Eur Urol. 2009 Apr;55(4):1000-1001. doi: 10.1016/j.eururo.2008.06.035. Epub 2008 Jun 20. No abstract available.

PMID:
28011054
790.

Pelvic lymph node dissection in prostate cancer.

Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE.

Eur Urol. 2009 Jun;55(6):1251-65. doi: 10.1016/j.eururo.2009.03.012. Epub 2009 Mar 10. Review.

PMID:
19297079
791.

Are infertile men less healthy than fertile men? Results of a prospective case-control survey.

Salonia A, Matloob R, Gallina A, Abdollah F, Saccà A, Briganti A, Suardi N, Colombo R, Rocchini L, Guazzoni G, Rigatti P, Montorsi F.

Eur Urol. 2009 Dec;56(6):1025-31. doi: 10.1016/j.eururo.2009.03.001. Epub 2009 Mar 10.

PMID:
19297076
792.

Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F.

Eur Urol. 2009 Jun;55(6):1321-30. doi: 10.1016/j.eururo.2009.02.028. Epub 2009 Mar 6. Review.

PMID:
19286302
793.

Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.

Bertini R, Roscigno M, Freschi M, Strada E, Petralia G, Pasta A, Matloob R, Sozzi F, Da Pozzo L, Colombo R, Guazzoni G, Doglioni C, Montorsi F, Rigatti P.

J Urol. 2009 May;181(5):2027-32. doi: 10.1016/j.juro.2009.01.048. Epub 2009 Mar 14.

PMID:
19286201
794.

A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.

Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.

Prostate. 2009 Jun 1;69(8):895-907. doi: 10.1002/pros.20939. Review.

PMID:
19267353
795.

Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.

Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B, Black L, Montorsi F; CombAT Study Group.

BJU Int. 2009 Apr;103(7):919-26. doi: 10.1111/j.1464-410X.2009.08196.x. Epub 2009 Feb 23.

796.

Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.

Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, Shariat SF.

Prostate. 2009 Jun 1;69(8):886-94. doi: 10.1002/pros.20938.

PMID:
19229851
797.

Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.

Schröder FH, Bangma CH, Wolff JM, Alcaraz A, Montorsi F, Mongiat-Artus P, Abrahamsson PA, McNicholas TA, Castro RS, Nandy IM.

BJU Int. 2009 Mar;103(5):590-6. doi: 10.1111/j.1464-410X.2009.08373.x.

798.

Anatomical radical retropubic prostatectomy in patients with a preexisting three-piece inflatable prosthesis: a series of case reports.

Deho’ F, Salonia A, Briganti A, Zanni G, Gallina A, Rokkas K, Guazzoni G, Rigatti P, Montorsi F.

J Sex Med. 2009 Feb;6(2):578-83. doi: 10.1111/j.1743-6109.2008.01056.x.

PMID:
19215620
799.

Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.

Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P.

Eur Urol. 2009 May;55(5):1003-11. doi: 10.1016/j.eururo.2009.01.046. Epub 2009 Feb 4.

PMID:
19211184
800.

Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.

Urology. 2009 May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4.

PMID:
19195695

Radical versus partial nephrectomy: effect on overall and noncancer mortality.

Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI.

Cancer. 2009 Apr 1;115(7):1465-71. doi: 10.1002/cncr.24035.

802.

A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma.

Zini L, Cloutier V, Isbarn H, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Saad F, Arjane P, Duclos A, Lattouf JB, Montorsi F, Karakiewicz PI.

Clin Cancer Res. 2009 Feb 1;15(3):1013-8. doi: 10.1158/1078-0432.CCR-08-1888.

803.

Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies.

Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Van Poppel H.

Eur Urol. 2009 May;55(5):1037-63. doi: 10.1016/j.eururo.2009.01.036. Epub 2009 Jan 25. Review.

PMID:
19185977
804.

Complications of laparoscopic surgery for renal masses: prevention, management, and comparison with the open experience.

Breda A, Finelli A, Janetschek G, Porpiglia F, Montorsi F.

Eur Urol. 2009 Apr;55(4):836-50. doi: 10.1016/j.eururo.2009.01.018. Epub 2009 Jan 20. Review.

PMID:
19168276
805.

Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.

Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG; Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract Urothelial Carcinoma Collaboration.

Cancer. 2009 Mar 15;115(6):1224-33. doi: 10.1002/cncr.24135.

806.

A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses.

Zini L, Perrotte P, Jeldres C, Capitanio U, Duclos A, Jolivet-Tremblay M, Arjane P, Péloquin F, Pharand D, Villers A, Montorsi F, Patard JJ, Karakiewicz PI.

BJU Int. 2009 Apr;103(7):899-904; discussion 904. doi: 10.1111/j.1464-410X.2008.08247.x. Epub 2009 Jan 20.

807.

Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.

Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F.

BJU Int. 2009 May;103(9):1212-7. doi: 10.1111/j.1464-410X.2008.08267.x. Epub 2008 Dec 8. Review. Erratum in: BJU Int. 2011 Apr;107(7):1166.

808.

The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer.

Karl A, Carroll PR, Gschwend JE, Knüchel R, Montorsi F, Stief CG, Studer UE.

Eur Urol. 2009 Apr;55(4):826-35. doi: 10.1016/j.eururo.2009.01.004. Epub 2009 Jan 13. Review.

PMID:
19150582
809.

Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.

Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF.

J Natl Cancer Inst. 2009 Jan 21;101(2):114-9. doi: 10.1093/jnci/djn451. Epub 2009 Jan 13.

PMID:
19141773
810.

Severe vascular complication after implantation of a three-piece inflatable penile prosthesis.

Deho’ F, Henry GD, Marone EM, Sacca’ A, Chiesa R, Rigatti P, Montorsi F.

J Sex Med. 2008 Dec;5(12):2956-9. doi: 10.1111/j.1743-6109.2008.01012.x.

PMID:
19090947
811.

An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction.

Giammusso B, Colpi GM, Cormio L, Ludovico G, Soli M, Ponchietti R, Montorsi F, Panzironi C, Guastella B.

Urol Int. 2008;81(4):409-15. doi: 10.1159/000167838. Epub 2008 Dec 10.

PMID:
19077401
812.

A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study.

Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, Shariat SF, Perrotte P, Antebi E, Patard JJ, Montorsi F, Karakiewicz PI.

BJU Int. 2009 Jun;103(11):1496-500. doi: 10.1111/j.1464-410X.2008.08259.x. Epub 2008 Dec 8.

813.

Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma.

Zini L, Patard JJ, Capitanio U, Crepel M, de La Taille A, Tostain J, Ficarra V, Bernhard JC, Ferrière JM, Pfister C, Villers A, Montorsi F, Karakiewicz PI.

BJU Int. 2009 Apr;103(7):894-8. doi: 10.1111/j.1464-410X.2008.08252.x. Epub 2008 Dec 2.

814.

Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.

Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF.

J Clin Oncol. 2009 Feb 1;27(4):612-8. doi: 10.1200/JCO.2008.17.2361. Epub 2008 Dec 15.

815.

The importance of the extent of pelvic-lymph-node dissection in the diagnosis of lymph-node metastases in prostate cancer.

Briganti A, Rigatti P, Montorsi F.

Lancet Oncol. 2008 Oct;9(10):915-7; author reply 917-8. doi: 10.1016/S1470-2045(08)70242-0. No abstract available.

PMID:
19071244
816.

Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome.

Suardi N, Gallina A, Salonia A, Briganti A, Dehò F, Zanni G, Abdollah F, Naspro R, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Curr Opin Urol. 2009 Jan;19(1):38-43. doi: 10.1097/MOU.0b013e32831a7008. Review.

PMID:
19057214
817.

Thirty-day mortality after nephrectomy: clinical implications for informed consent.

Cloutier V, Capitanio U, Zini L, Perrotte P, Jeldres C, Shariat SF, Arjane P, Patard JJ, Montorsi F, Karakiewicz PI.

Eur Urol. 2009 Dec;56(6):998-1003. doi: 10.1016/j.eururo.2008.11.023. Epub 2008 Nov 25.

PMID:
19054604
818.

Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men.

Capitanio U, Perrotte P, Hutterer GC, Suardi N, Jeldres C, Shariat SF, Duclos A, Arjane P, Montorsi F, Karakiewicz PI.

Int J Urol. 2009 Jan;16(1):91-5. doi: 10.1111/j.1442-2042.2008.02192.x. Epub 2008 Nov 27.

819.

Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.

Zini L, Capitanio U, Perrotte P, Jeldres C, Shariat SF, Arjane P, Widmer H, Montorsi F, Patard JJ, Karakiewicz PI.

Urology. 2009 Feb;73(2):342-6. doi: 10.1016/j.urology.2008.09.022. Epub 2008 Nov 28.

PMID:
19041122
820.

Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.

Salonia A, Briganti A, Gallina A, Karakiewicz P, Shariat S, Freschi M, Zanni G, Capitanio U, Bosi E, Rigatti P, Montorsi F.

Urology. 2009 Apr;73(4):850-5. doi: 10.1016/j.urology.2008.09.026. Epub 2008 Nov 26.

PMID:
19038425
821.

Race affects access to nephrectomy but not survival in renal cell carcinoma.

Zini L, Perrotte P, Capitanio U, Jeldres C, Duclos A, Arjane P, Villers A, Montorsi F, Patard JJ, Karakiewicz PI.

BJU Int. 2009 Apr;103(7):889-93. doi: 10.1111/j.1464-410X.2008.08119.x. Epub 2008 Nov 18.

822.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group.

Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.

PMID:
19013011
823.

External validation of the updated partin tables in a cohort of French and Italian men.

Bhojani N, Salomon L, Capitanio U, Suardi N, Shariat SF, Jeldres C, Zini L, Pharand D, Péloquin F, Arjane P, Abbou CC, De La Taille A, Montorsi F, Karakiewicz PI.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):347-52. doi: 10.1016/j.ijrobp.2008.04.082. Epub 2008 Nov 10.

PMID:
19004573
824.

Critical evaluation of the prostate from cystoprostatectomies for bladder cancer: insights from a complete sampling with the whole mount technique.

Montironi R, Cheng L, Mazzucchelli R, Scarpelli M, Kirkali Z, Montorsi F, Lopez-Beltran A.

Eur Urol. 2009 Jun;55(6):1305-9. doi: 10.1016/j.eururo.2008.10.032. Epub 2008 Oct 28. Review. No abstract available.

PMID:
18995951
825.

Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience.

Suardi N, Strada E, Colombo R, Freschi M, Salonia A, Lania C, Cestari A, Carmignani L, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2009 Jan;103(2):197-200. doi: 10.1111/j.1464-410X.2008.08016.x. Epub 2008 Oct 6.

826.

Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density.

Bolenz C, Shariat SF, Fernández MI, Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Montorsi F, Bensalah K, Wood CG, Roscigno M, Langner C, Koppie TM, Raman JD, Mikami S, Michel MS, Ströbel P.

BJU Int. 2009 Feb;103(3):302-6. doi: 10.1111/j.1464-410X.2008.07988.x. Epub 2008 Oct 16.

827.

Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.

Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, Shariat SF.

BJU Int. 2009 Feb;103(3):307-11. doi: 10.1111/j.1464-410X.2008.08003.x. Epub 2008 Oct 16. Erratum in: BJU Int. 2009 Aug;104(4):574. Karakiewizc, Pierre [corrected to Karakiewicz, Pierre].

828.

Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.

Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP.

Eur Urol. 2009 Feb;55(2):334-47. doi: 10.1016/j.eururo.2008.10.028. Epub 2008 Oct 21. Review.

PMID:
18986755
829.

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.

Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE.

Eur Urol. 2009 Jan;55(1):62-75. doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14. Review.

830.

Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.

Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.

Cancer. 2008 Nov 15;113(10):2695-703. doi: 10.1002/cncr.23885.

831.

Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study.

Fernández MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P.

Urology. 2009 Jan;73(1):142-6. doi: 10.1016/j.urology.2008.07.042. Epub 2008 Oct 8. Erratum in: Urology. 2010 May;75(5):1243. Karakiewizc, Pierre [corrected to Karakiewicz, Pierre].

PMID:
18845322
832.

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.

Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML.

Eur Urol. 2009 Feb;55(2):261-70. doi: 10.1016/j.eururo.2008.09.043. Epub 2008 Oct 1.

PMID:
18838212
833.

Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences.

Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, Montironi R, Montorsi F.

Eur Urol. 2009 Jan;55(1):87-99. doi: 10.1016/j.eururo.2008.09.051. Epub 2008 Oct 1. Review.

PMID:
18838211
834.

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.

Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, Montorsi F.

Prostate Cancer Prostatic Dis. 2009;12(2):152-9. doi: 10.1038/pcan.2008.49. Epub 2008 Sep 23.

PMID:
18813219
835.

The case for postoperative PDE-5 inhibitor drug treatment after radical prostatectomy.

Briganti A, Gallina A, Salonia A, Zanni G, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

J Endourol. 2008 Sep;22(9):2025-7; discussion 2035. doi: 10.1089/end.2008.9752. No abstract available.

PMID:
18811529
836.

Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.

Capitanio U, Zini L, Perrotte P, Shariat SF, Jeldres C, Arjane P, Pharand D, Widmer H, Péloquin F, Montorsi F, Patard JJ, Karakiewicz PI.

Urology. 2008 Nov;72(5):1090-5. doi: 10.1016/j.urology.2008.06.059. Epub 2008 Sep 16.

PMID:
18799207
837.

Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.

Suardi N, Capitanio U, Chun FK, Graefen M, Perrotte P, Schlomm T, Haese A, Huland H, Erbersdobler A, Montorsi F, Karakiewicz PI.

Cancer. 2008 Oct 15;113(8):2068-72. doi: 10.1002/cncr.23827.

838.

Partin Tables cannot accurately predict the pathological stage at radical prostatectomy.

Bhojani N, Ahyai S, Graefen M, Capitanio U, Suardi N, Shariat SF, Jeldres C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Montorsi F, Huland H, Karakiewicz PI.

Eur J Surg Oncol. 2009 Feb;35(2):123-8. doi: 10.1016/j.ejso.2008.07.013. Epub 2008 Sep 10.

PMID:
18786800
839.

The use of partial nephrectomy in European tertiary care centers.

Zini L, Patard JJ, Capitanio U, Mejean A, Villers A, de La Taille A, Ficarra V, Crepel M, Bertini R, Salomon L, Verhoest G, Perrotte P, Bensalah K, Arjane P, Biserte J, Montorsi F, Karakiewicz P.

Eur J Surg Oncol. 2009 Jun;35(6):636-42. doi: 10.1016/j.ejso.2008.07.008. Epub 2008 Sep 4.

PMID:
18775626
840.

Outcomes for patients with pT0 disease after radical nephroureterectomy for upper-tract urothelial carcinoma.

Raman JD, Ng CK, Shariat SF, Margulis V, Montorsi F, Karakiewicz P; Upper-Tract Urothelial Carcinoma Collaboration.

BJU Int. 2009 Jan;103(1):3-4. doi: 10.1111/j.1464-410X.2008.07938.x. Epub 2008 Aug 18. No abstract available.

841.

A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma.

Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, de la Taille A, Tostain J, Mulders PF, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valéri A, Descotes JL, Rambeaud JJ, Méjean A, Montorsi F, Bertini R, Patard JJ.

Eur Urol. 2009 Feb;55(2):287-95. doi: 10.1016/j.eururo.2008.07.037. Epub 2008 Jul 25.

PMID:
18715700
842.

Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma.

Zini L, Perrotte P, Jeldres C, Capitanio U, Pharand D, Arjane P, Lapointe S, Montorsi F, Patard JJ, Karakiewicz PI.

BJU Int. 2008 Dec;102(11):1610-4. doi: 10.1111/j.1464-410X.2008.07917.x. Epub 2008 Aug 14.

843.
844.

A nomogram predicting metastatic progression after radical prostatectomy.

Porter CR, Suardi N, Kodama K, Capitanio U, Gibbons RP, Correa R, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

Int J Urol. 2008 Oct;15(10):889-94. doi: 10.1111/j.1442-2042.2008.02105.x. Epub 2008 Jul 24.

845.

Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.

Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, Giuliano F, Brock G; Study Group.

Int J Impot Res. 2008 Sep-Oct;20(5):479-86. doi: 10.1038/ijir.2008.33. Epub 2008 Jul 24.

PMID:
18650827
846.

Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.

Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C.

Eur Urol. 2008 Oct;54(4):924-31. doi: 10.1016/j.eururo.2008.06.083. Epub 2008 Jul 9.

PMID:
18640769
847.

Re: Orgasm associated incontinence (climacturia) following radical pelvic surgery: rates of occurrence and predictors. J. M. Choi, C. J. Nelson, J. Stasi and J. P. Mulhall. J Urol 2007; 177: 2223-2226.

Abdollah F, Briganti A, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

J Urol. 2008 Sep;180(3):1187; author reply 1187-8. doi: 10.1016/j.juro.2008.05.075. Epub 2008 Jul 18. No abstract available.

PMID:
18639899
848.

Pregnant woman presenting with a gross retroperitoneal mass: surgical treatment with caval replacement.

Bertini R, Suardi N, Marone EM, Roscigno M, Petralia G, Strada E, Cestari A, Arrigoni G, Guazzoni G, Montorsi F, Chiesa R, Rigatti P.

Eur Urol. 2008 Sep;54(3):677-80. doi: 10.1016/j.eururo.2008.06.074. Epub 2008 Jul 2.

PMID:
18614275
849.

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.

Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF.

Eur Urol. 2009 May;55(5):1124-33. doi: 10.1016/j.eururo.2008.06.054. Epub 2008 Jun 23.

PMID:
18585843
850.

Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.

Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI.

Clin Cancer Res. 2008 Jun 15;14(12):3785-91. doi: 10.1158/1078-0432.CCR-07-4969.

851.

Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.

Briganti A, Capitanio U, Chun FK, Gallina A, Suardi N, Salonia A, Da Pozzo LF, Colombo R, Di Girolamo V, Bertini R, Guazzoni G, Karakiewicz PI, Montorsi F, Rigatti P.

Eur Urol. 2008 Oct;54(4):794-802. doi: 10.1016/j.eururo.2008.05.018. Epub 2008 May 21.

PMID:
18514383
852.

Suspected clinical T3 prostate cancer is associated with a high rate of negative extended biopsies: clinical implications.

Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Eur Urol. 2009 Jan;55(1):253-4. doi: 10.1016/j.eururo.2008.05.025. Epub 2008 May 22. No abstract available.

PMID:
18513849
853.

Is node-positive prostate cancer always a systemic disease?

Briganti A, Chun FK, Karakiewicz PI, Rigatti P, Montorsi F.

Eur Urol. 2008 Aug;54(2):243-6. doi: 10.1016/j.eururo.2008.05.026. Epub 2008 May 22. No abstract available.

PMID:
18511184
854.

Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.

Chun FK, Suardi N, Capitanio U, Jeldres C, Ahyai S, Graefen M, Haese A, Steuber T, Erbersdobler A, Montorsi F, Huland H, Karakiewicz PI.

Eur Urol. 2009 Mar;55(3):617-28-6. doi: 10.1016/j.eururo.2008.04.099. Epub 2008 May 15.

PMID:
18499335
855.

Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy–results from a multicenter study.

Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, Shariat SF.

Eur Urol. 2008 Oct;54(4):961-3. doi: 10.1016/j.eururo.2008.04.083. Epub 2008 May 8. No abstract available.

PMID:
18485573
856.

High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer.

Jeldres C, Suardi N, Capitanio U, Montorsi F, Shariat SF, Perrotte P, Peloquin F, Pharand D, Graefen M, Karakiewicz PI.

BJU Int. 2008 Aug;102(4):463-7. doi: 10.1111/j.1464-410X.2008.07705.x. Epub 2008 May 12.

857.

Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.

Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, Shariat SF, Widmer H, Arjane P, Péloquin F, Perrotte P, Karakiewicz PI.

Int J Cancer. 2008 Aug 1;123(3):647-52. doi: 10.1002/ijc.23559.

858.

Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies.

Barbisan F, Mazzucchelli R, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montorsi F, Montironi R.

Eur Urol. 2009 Jul;56(1):105-12. doi: 10.1016/j.eururo.2008.04.043. Epub 2008 Apr 30.

PMID:
18468781
859.

Intraoperative assessment of an implantable electrode array for cavernous nerve stimulation.

Burnett AL, Teloken PE, Briganti A, Whitehurst T, Montorsi F.

J Sex Med. 2008 Aug;5(8):1949-54. doi: 10.1111/j.1743-6109.2008.00865.x. Epub 2008 May 5.

PMID:
18466264
860.

11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.

Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, Franceschelli A, Sanguedolce F, Bertaccini A, Farsad M, Giovacchini G, Fanti S, Grigioni WF, Fazio F, Montorsi F, Rigatti P, Martorana G.

Eur Urol. 2008 Aug;54(2):392-401. doi: 10.1016/j.eururo.2008.04.030. Epub 2008 Apr 18.

PMID:
18456393
861.

Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study.

Cozzarini C, Fiorino C, Di Muzio N, Valdagni R, Salonia A, Alongi F, Broggi S, Guazzoni G, Montorsi F, Rigatti P, Calandrino R, Fazio F.

Radiother Oncol. 2008 Jul;88(1):26-33. doi: 10.1016/j.radonc.2008.03.021. Epub 2008 Apr 30.

PMID:
18455253
862.

Serving the readers of European urology: a platinum honour and privilege.

Montorsi F.

Eur Urol. 2008 Jul;54(1):1-3. doi: 10.1016/j.eururo.2008.04.035. Epub 2008 Apr 22. No abstract available.

PMID:
18448234
863.

Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center prospective randomized trial in patients with obstructive benign prostatic hyperplasia.

Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, Valenti S, Vavassori I, Rigatti P.

J Urol. 2008 May;179(5 Suppl):S87-90. doi: 10.1016/j.juro.2008.03.143.

PMID:
18405765
864.

Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.

Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, Shariat SF, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI.

BJU Int. 2008 Jun;101(12):1513-8. doi: 10.1111/j.1464-410X.2008.07519.x. Epub 2008 Apr 16.

865.

Does educational status affect a patient’s behavior toward erectile dysfunction?

Salonia A, Abdollah F, Gallina A, Pellucchi F, Castillejos Molina RA, Maccagnano C, Rocchini L, Zanni G, Rigatti P, Montorsi F.

J Sex Med. 2008 Aug;5(8):1941-8. doi: 10.1111/j.1743-6109.2008.00810.x. Epub 2008 Apr 8.

PMID:
18399948
866.

Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury.

Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wachs BH; Vardenafil Study Group.

Spine (Phila Pa 1976). 2008 Apr 1;33(7):709-15. doi: 10.1097/BRS.0b013e3181695040.

PMID:
18379396
867.

Menstrual cycle-related changes in circulating androgens in healthy women with self-reported normal sexual function.

Salonia A, Pontillo M, Nappi RE, Zanni G, Fabbri F, Scavini M, Daverio R, Gallina A, Rigatti P, Bosi E, Bonini PA, Montorsi F.

J Sex Med. 2008 Apr;5(4):854-63. doi: 10.1111/j.1743-6109.2008.00791.x.

PMID:
18371044